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Abstract 
Cataract is the opacification of the crystalline lens of the eye. Both childhood and 
later-onset cataracts have been linked with complex genetic factors. Cataracts vary 
in phenotype and exhibit genetic heterogeneity. They can appear as isolated 
abnormalities, or as part of a syndrome. 
During this project, analysis of syndromic and non-syndromic cataract families using 
genetic linkage studies was undertaken in order to identify the genes involved, using 
an autozygosity mapping and positional candidate approach. 
Causative mutations were identified in families with syndromes involving cataracts. 
The finding of a mutation in CYP27A1 in a family with Cerebrotendinous 
Xanthomatosis permitted clinical intervention as this is a treatable disorder. A 
mutation that segregated with disease status in a family with Marinesco Sjogren 
Syndrome was identified in SIL1. In a family with Knobloch Syndrome, a frameshift 
mutation in COL18A1 was detected in all affected individuals. 
Analysis of families with non-syndromic autosomal recessive cataracts was also 
performed, using genome-wide linkage scans to identify homozygous candidate 
regions and to then sequence candidate genes within these regions. The 
identification of a potential putative mutation in one family in CDC25A illustrated the 
challenges of distinguishing between rare benign variants and pathogenic mutations. 
Identification of novel genes involved in cataractogenesis will increase understanding 
of the pathways involved in cataract formation, and benefit affected families through 
genetic counselling, and, potentially personalised management. 
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1. INTRODUCTION 
1.1 Overview 
In this project, work was carried out to find genes responsible for non-syndromic 
cataracts, and some rare autosomal recessive disorders of which cataracts can be a 
feature, and were present in the families studied. The conditions investigated in this 
project were Knobloch Syndrome, Marinesco Sjögren Syndrome, and 
Cerebrotendinous Xanthomatosis. A strategy employing an autozygosity mapping 
with positional candidate gene identification approach was used. For non-syndromic 
cataracts, a locus on chromosome three was investigated, and functional analysis 
was carried out on a putative cataract gene. By identifying genes responsible for 
syndromic and non-syndromic cataracts in families, a greater understanding of the 
processes involved in their formation will be gained. It is important to remember the 
more immediate human benefit of gene identification for the families involved. With 
this knowledge, an accurate diagnosis can be given, along with genetic counselling, 
prenatal diagnosis and treatment, and in the future, tailored therapy. 
1.2 The Eye 
In humans, the eye is a sensory organ which enables light detection. The eye has an 
approximate diameter of 24mm, being roughly spherical in shape. 85% of its 
posterior exterior is encased in the protective sclera, which is white in colour. The 
transparent cornea completes the anterior surface. It is lined by a 7-8μm tear film. 
The ciliary epithelium secretes aqueous humor into the posterior chamber, which 
bathes the posterior surface of the cornea. Light entering the eye travels through the 
cornea and aqueous humor, then reaching the lens (Figure 1.1).  
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Figure 1.1: Anatomy of the eye, from www.gbmc.org. 
 
The biconvex human lens is approximately 5mm thick and its diameter is 
approximately 9mm, although this changes due to accommodation (focusing on 
different objects at varying distances from the viewer) and maturation of the 
individual. It is positioned behind the iris, in the anterior segment of the eye. The lens 
is transparent, and focuses light onto the photoreceptor rich retina. The lens is 
capable of transmitting light of wavelength 390-1200nm, which far surpasses the 
range of visual perception, which only extends to 720nm (Hejtmancik, 2007). The 
mature lens is an avascular structure.  
After the lens, light passes through the vitreous humor, a viscous substance which 
provides structural integrity to the eye, comprising around 90% of the eye‟s volume. 
The retina contains the single largest concentration of the body‟s sensory receptors, 
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where there are around 126 million photoreceptors (rods, cones and ganglion cells), 
accounting for approximately 70% of all receptors. Photoreceptors absorb light and 
convert it into an electrical signal via phototransduction, reaching the photoreceptor 
synapses as an impulse which is conveyed to the ganglion cells, and ultimately the 
brain (Berman, 1991). The retina is actually considered to be part of the brain 
because it develops from part of the forebrain in the embryo. 
1.2.1 Eye Development 
In humans, eye development commences during gastrulation (around day 16 of 
gestation). The anterior neural plate is the central area in the developing brain, and 
this bisects to form the optic vesicles. At this stage, the lens placode is a constituent 
of the surface ectoderm, and it must interact with each optic vesicle. After this, the 
optic cup is created by invagination of the neuroectoderm. The two layers of the optic 
cup become the neural retina and the retinal pigmented epithelium (Graw, 2003). 
1.2.2 Lens Development in Humans 
At approximately day 33 of gestation, in the 4mm embryo (Francis et al, 1999), the 
lens cup forms as the lens placode separates from the surface ectoderm. The lens 
cup develops into the lens vesicle, closing over, which is almost spherical in shape. 
The posterior segment and anterior pole of the lens cup are populated by epithelial 
cells, and at approximately day 44 of gestation, those in the posterior segment 
elongate to fill the lens vesicle‟s central cavity, forming primary lens fibres (Graw, 
2003). At this stage, they lose their nuclei (Francis et al, 1999). 
Secondary lens fibres are formed by the differentiation of mitotically active cells that 
migrate from the central to equatorial part of the lens epithelium. The secondary lens 
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cell fibres surround the primary lens fibres and an onion-like structure begins to form, 
as they lay down in concentric layers. After this differentiation, lens fibre cells no 
longer have mitochondria and nuclei (Graw, 2003).The movement of secondary lens 
fibres from the equatorial region to the outer lens cortex continues for the whole of 
the individual‟s life, but the rate decreases. These successive layers of lamellae 
cause the central fibres to become more compact (Francis et al, 1999).  
The three main components of the adult lens are the lens capsule, lens fibres and 
the lens epithelium. The lens is enclosed by the transparent lens capsule, an elastic 
basement membrane largely made up of sulphated glycosaminoglycans and 
collagen (type IV). Zonular fibres link the capsule to the ciliary body, and when the 
zonular fibres are relaxed, the capsule is under less tension, and this causes the 
lens to become more globular in shape. The lens capsule is not of uniform width, 
being thinnest around the posterior pole, and widest around the equatorial region. 
The lens epithelium lies between the lens capsule and lens fibres in the anterior 
region of the lens. This simple cuboidal epithelium is where the exchange of 
metabolic products, water and ions occurs with the aqueous humor, a homeostatic 
mechanism which ensures that nutrients are available for active processes without 
altering internal lens volume. The lens epithelium differentiates into new transparent 
lens fibres, which comprise the most part of the lens. They are arranged vertically in 
layers, lamellae, stretching between the two poles, and are connected by gap 
junctions. 
1.3 Eye Disease  
The World Health Organisation (WHO) estimates that, globally, more than 161 
million people are visually impaired, with 37 million of these being blind. With a visual 
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acuity of less than 3/60, an individual was considered to be blind. Low vision was 
included in the visual impairment category, and is defined as visual acuity (clarity of 
vision) of less than 6/18, but of equal to or greater than 3/60. (The numerator refers 
to the distance, in feet, of the subject from the Snellen chart. The denominator is the 
distance at which the average eye can read a certain line on the Snellen chart.) The 
WHO 2002 study into visual impairment (Resnikoff et al, 2004), used data from 55 
countries, and found that 90% of visual impairment cases are in  developing 
countries, with the largest age group (over 82%) being those over 50 years of age. 
Gender also appears to be a risk factor, with more females than males affected 
Cataracts are the most common cause of visual impairment in most regions of the 
world, excluding developed countries (Figure 1.2). Other eye diseases causing visual 
impairment are glaucoma, age-related macular degeneration, diabetic retinopathy 
and trachoma (Resnikoff et al, 2004).  
 
Figure 1.2: Global causes of blindness as a percentage of total blindness in 2002. 
From Resnikoff et al (2004).  
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Glaucoma is the second most prevalent cause of blindness, followed by age-related 
macular degeneration (AMD). In those developed countries where cataracts are not 
the main cause of blindness, it is AMD that is the most prevalent cause, and cases 
are increasing, in line with an increasingly weighted ageing population (Resnikoff et 
al, 2004). Trachoma refers to scarring of the cornea, resulting from bacterial infection 
by Chlamydia trachomatis. Onchocerciasis (river blindness) is caused by a host 
immune response to the death of the nematode worm Onchocerca volvulus in 
individuals who were infected through Simulium black fly bites.  
Vitamin A deficiency has long been associated with visual impairment. 
WHO data suggests that 1.4 million children under 15 are blind, and that half of 
these cases involve avoidable blindness. Treatment of cataract can restore vision, if 
corrective measures are initiated at a young age.  
It is the aim of the WHO to eradicate avoidable blindness by 2020, and Vision 2020 
(the Global Initiative for the Elimination of Avoidable Blindness) was set up in 1998 to 
achieve this. 
1.3.1 Hereditary Eye Disease 
1.3.1.1 The Genetics of Eye Development 
A variety of genes play a role in eye development. Normal development relies on a 
complex interaction of signalling molecules and transcription factors which are 
encoded by these genes. Some of those which are the most vital for normal eye 
development are described below. 
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1.3.1.1.1 Paired Box Gene 6 (PAX6) 
The human gene for paired box gene 6 (PAX6) is located on chromosome 11p13, 
and consists of 14 exons. It is a member of a family of genes encoding transcription 
factors which possess both a homeodomain and a paired domain (Graw, 2003).  
When the mouse PAX6 orthologue, Pax6, is expressed ectopically in Drosophila, 
ommatidial eyes are formed, and this was achieved in Drosophila legs, wings and 
antennae (Halder et al, 1995). In another study, Xenopus Pax6 mRNA was injected 
into frogs, resulting in ectopic formation of normal eyes (Chow et al, 1999). 
Homozygous PAX6 mutations result in eye absence, severe brain abnormalities, and 
are lethal (Hanson and Van Heyningen, 1995).  
Most human PAX6 mutations cause aniridia, but they have been associated with 
cataracts. Two PAX6 mutations were identified within the same family (Glaser et al, 
1994). The father had developed bilateral cataracts soon after birth. They 
progressively worsened, and were surgically removed at age 38 and 40. The 
mother‟s ocular anomalies were more severe, including aniridia, but she also 
presented with bilateral cataracts. A TCA (Ser 353) to TGA (stop) mutation in exon 
12 of PAX6 was found in the father, for which he was heterozygous. It is thought that 
this will cause PAX6 truncation in the middle of the PST domain (a region rich in 
proline, serine and threonine). In the mother, a mutation was identified in exon 6 of 
PAX6, for which she was heterozygous. It also involved a premature stop codon, 
with this being substituted for wild type Arg103. It is thought that this renders the 
polypeptide non-functional, since truncation would occur in the C terminal portion of 
the paired domain. Their daughter, the proband, inherited one of each of these 
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mutated alleles (a compound heterozygote) and died eight days after birth (Glaser et 
al, 1994).  
Through experiments with the developing chicken lens, Duncan et al (1998) 
investigated the inverse relationship between Pax-6 and beta-crystallin genes, 
concluding that a likely effect of decreasing Pax-6 levels in lens fibre cells is to 
permit beta-B1 crystallin gene expression. 
1.3.1.1.2 Sonic Hedgehog Gene (SHH) 
The human sonic hedgehog gene, SHH, is a three exon gene which lies on 
chromosome 7q36. It has a role in PAX6 regulation (van Heyningen and Williamson, 
2002), and mutations in humans are most commonly known to manifest 
phenotypically as holoprosencephaly (HPE), with varying degrees of severity. HPE 
occurs when the eye field and forebrain do not separate into the right and left eye, 
and most affected individuals do not make it to term. SHH from the prechordal plate 
probably marks out the area for bisection (Roessler and Muenke, 2003). 
SHH mutations causing HPE and cyclopia have also been observed in mice. 
Targeted SHH gene disruption has widespread effects, causing abnormal spinal 
column, limb and rib development (Chiang et al, 1996). 
1.3.1.1.3 Sine Oculis Homeobox 3 Gene (SIX3) 
The human gene sine oculis homeobox 3, SIX3, is located on chromosome 2p21. Its 
two exons span 4.4kb. In humans, SIX3 mutations have been found to cause 
holoprosencephaly (Wallis et al, 1999). 
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When the mouse gene Six3, which codes for a homeodomain transcription factor, 
was expressed in the ear placode of the medaka fish, a lens developed (Oliver et al, 
1996). This indicates the importance of Six3 in normal eye development.  
When Six3 is overexpressed in chicken embryos, normal lens development is 
prevented. The lens placode does not undergo invagination, and α–crystallin 
expression is lost (Zhu et al, 2002). 
1.3.1.1.4 SRY-Box 2 Gene (SOX2) 
This single exon SRY (sex determining region Y)-box 2 gene, SOX2, on 
chromosome 3q26.3-q27, encodes a 317 amino acid transcription factor. 
Heterozygous SOX2 mutations cause anophthalmia (eyes do not develop) in 
humans, with all of these apparently de novo mutations, inherited in an autosomal 
dominant manner (Fantes et al, 2003). This indicates that SOX2 plays a crucial role 
in eye development.  
1.3.1.1.5 Retina and Anterior Neural Fold Homeobox Gene (RX) 
The human retina and anterior neural fold homeobox gene, RX, is expressed early 
on in eye development, specifically during retinal development. This gene is found 
on chromosome 18q21.31 and encodes a homeodomain transcription factor. 
The first human RX mutations were reported in 2004 (Voronina et al, 2004). DNA 
from 75 individuals with anophthalmia and microphthalmia was obtained, and one of 
these was found to be a compound heterozygote for RX mutations. No mutations 
were found in the remaining 74, or in 55 controls with normal eyes, although 
common polymorphisms were detected. The first mutation identified was a 
premature stop codon instead of a glutamine residue, Gln147X, in exon 2. The 
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second mutation involved a missense substitution of arginine for glutamine, 
Arg192Gln, in exon 3. Both mutations occurred in the protein‟s DNA-binding domain. 
In Rx-deficient mice, anlagen do not form, Pax6 is not expressed in the eye field, and 
eyes do not form (Zhang et al, 2000). 
1.3.1.2 The Genetics of Lens Development 
Lens development is initiated by regulating the formation of the molecular DNA 
binding complex which is composed of PAX6 and SOX2 on lens-specific enhancer 
elements (Kamachi et al, 2001). After this interaction has occurred, other genes and 
their products are necessary for normal lens development. Fibroblast growth factors 
FGF1, FGF2 and FGF3 are involved, as are the transcription factors PAX6, SIX3, 
and PITX3 (Francis et al, 1999). FGF transcripts are expressed in the optic cup and 
vesicle as they develop, and mouse models are suggestive of their essentiality in 
lens fibre differentiation (Robinson et al, 1998). 
FOXE3, MAF, and PITX3 are involved in lens development, and the FOX, MAF and 
PITX gene families contain some more pivotal genes involved in further eye 
development.  
1.3.1.2.1 Forkhead Box E3 Gene (FOXE3) 
FOXE3, forkhead box E3 gene, is found on chromosome 1p21, and comprises one 
exon. It codes for a transcription factor. The FOX genes are a family which share a 
110 amino acid region, which was first noted in Drosophila as a DNA binding 
domain. FOXE3 is expressed in human adult anterior lens epithelium, and mutations 
have been associated with anterior segment ocular dysgenesis and cataracts 
(Semina et al, 2001). A frameshift was identified in two affected individuals, causing 
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the predicted protein to gain 111 amino acids, and possess five abnormal terminal 
amino acids.  
The murine ortholog FoxE3 is located on chromosome 4, showing strong homology. 
In situ hybridisation has been used to demonstrate that FoxE3 is expressed at day 
9.5 in the embryonic development of mice, at lens placode induction. Throughout 
lens placode formation, FoxE3 expression increased, and continued in the lens 
vesicle after detachment from the surface ectoderm. During lens fibre differentiation, 
expression was confined to undifferentiated cells on the anterior lens surface. Peak 
expression was from 9.5-10 days, ceasing after this time (Blixt et al, 2000). 
1.3.1.2.2 V-MAF Avian Musculoaponeurotic Fibrosarcoma Oncogene Homolog 
Gene (MAF) 
The MAF family of genes encode basic region leucine zipper (bZIP) transcription 
factors. The MAF gene, V-MAF avian musculoaponeurotic fibrosarcoma oncogene 
homolog, is located on chromosome 16q22-q23. It was identified via an avian 
retrovirus (AS42) transforming gene, the v-maf oncogene (Nishizawa et al, 2003). 
MAF gene products have a role in regulation of differentiation. Mutations in MAF 
have been implicated in autosomal dominant juvenile cataracts. An arginine to 
proline (Arg288Pro) substitution was found in affected individuals of a family, and it 
was not present in 217 individuals with other ocular anomalies or 496 unaffected 
control chromosomes (Jamieson et al, 2002). This mutation falls in the DNA binding 
domain of MAF, and is suspected to cause aberrant helical conformation. 
1.3.1.2.3 Paired-like Homeodomain Transcription Factor 3 Gene (PITX3) 
The PITX family of genes consists of three genes that encode transcription factors. 
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The paired-like homeodomain transcription factor 3 gene, PITX3, is a four exon gene 
located on chromosome 10q25. PITX3 is expressed in the lens placode and 
developing lens pit. A 17bp insertion in exon 4 of PITX3, causing a frameshift, was 
identified in a patient with anterior segment mesenchymal dysgenesis (ASMD) and 
cataracts (Semina et al, 1998). The same group also identified a missense mutation 
(Ser13Asn) in exon 2 of PITX3 in a family with bilateral congenital cataracts. 
1.3.1.2.4. Crystallins 
There are numerous crystallin genes. There are also numerous pseudogenes, for 
example, CRYBB2P1, CRYGEP, CRYGFP AND CRYZP1. 
Crystallins are either taxon (or enzyme) specific, or ubiquitous. Vertebrate crystallins 
are referred to as ubiquitous, and they make up approximately 95% of human lens 
proteins. They are highly stable and water soluble. Lens transparency is largely due 
to their regular organisation in lens fiber cells.  
There are three categories of mammalian crystallins: alpha, beta and gamma, 
although beta and gamma crystallins are also grouped together as a superfamily. 
This grouping is based on gel exclusion chromatography elution order (Graw, 2009). 
The following crystallins are expressed in mammalian lens tissue: alpha-A, alpha-B, 
beta-B1, beta-B2, beta-B3, beta-A1/A3, beta-A2, beta-A4, gamma-A, gamma-B, 
gamma-C, gamma-D, gamma-E, gamma-F and gamma-S (Bloemendal et al, 2004). 
In human lenses though, the only crystallins detected with high levels of expression 
are gamma-C and gamma-D (Brakenhoff et al, 1990), but alpha-B crystallin has 
strong expression in lens epithelial cells (Bhat and Nagineni, 1989). Crystallin 
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expression is not only limited to the lens, but has been detected in retinal tissue, 
skeletal muscles, heart muscle, skin and other tissues (Bhat and Nagineni, 1989).   
Alpha-crystallin is formed from acidic alpha-A and basic alpha-B crystallin 
polypeptides and plays a key role in preventing abnormal protein interactions, and 
acts as a molecular chaperone (Horwitz, 1992). There is evidence linking alpha-
crystallin to inhibition of apoptosis. Alpha-A crystallin may play an anti-apoptotic role 
(Mehler et al, 1996). Alpha-B crystallin negatively regulates apoptosis (Kamradt et al, 
2005). Overexpression of alpha-A and alpha-B crystallin in cell lines heightens 
tolerance of stress (Andley et al, 2000). They both play a role in cytoskeleton 
maintenance and repair (Liang and McRae, 1997; Vicart et al, 1998). They are 
related to the small heat-shock proteins (Caspers et al, 1995). There is a possibility 
that alpha-crystallins are involved in cell signalling pathways since they undergo in 
vivo phosphorylation and have autokinase activity (Kantorow and Piatigorsky, 1994). 
Little is understood about in vivo alpha-A and alpha-B crystallin substrates. 
Beta-crystallins are composed of around five polypeptides.  
Beta-gamma-crystallins are a protein family with the same general structure of two 
domains with a connecting peptide. The domains are made up of four Greek key 
motifs. These fold into a beta-sandwich structure, with the gamma-crystallins existing 
as monomers and the beta-crystallins forming complexes (Hejtmancik, 2007). 
Expression of beta and gamma crystallins has been detected additionally, in lens 
epithelial cells, and outside the lens (Wang et al, 2004). Beta-B2 crystallin has the 
most extensive expression pattern, and gamma-S crystallin is also expressed 
outside the lens (Andley et al, 2007). Much about the role of gamma and beta-
crystallins in vivo remains to be elucidated.  
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Gamma-crystallin mutations tend to cause nuclear or zonular cataracts, presumably 
based upon when during development the insult exerted its effect. Nuclear cataracts 
suggest that this occurred early on, and zonular cataracts are a result of a later 
developmental insult (Hejtmancik, 2007). There has been a report of a gammaD-
crystallin mutation that causes nuclear and coralliform cataracts (Gu et al, 2006) and 
of another mutation responsible for microcornea (Hansen et al, 2007).  
1.3.1.2.5 Connexins 
Connexins are a family of genes with over twenty members which share a similar 
protein structure consisting of four transmembrane domains, with three intracellular 
regions. These are the N terminus, cytoplasmic loop and C terminus. There are also 
two extracellular loops, E1 and E2 (Yeager and Nicholson, 2000). One connexon is 
composed of six connexins. To form a gap junction channel with a pore diameter of 
10-15 angstroms, the extracellular loops from two contrary connexons must lodge in 
the plasma membrane, and hundreds of these pentalamellar structures localise to 
create gap junctions (Fleishman et al, 2004; Unger et al, 1999). 
Three connexins are known to be structural components of intercellular gap junction 
channels in the lens, essential for transport in the lens. These are alpha-1 
(connexin43 or GJA1), alpha-3 (connexin46 or GJA3) and alpha-8 (connexin50 or 
GJA8) (Gong et al, 2007). This group also demonstrated that alpha-3 connexin is 
required for lens transparency, and alpha-8 connexin is necessary for lens growth 
and transparency. Connexin alpha-1 expression is mostly confined to lens epithelial 
cells (Beyer et al, 1989). Connexin alpha-3 expression is mainly evident in lens fibre 
cells, and connexin alpha-8 expression is found in lens epithelial cells and lens fibre 
cells (Rong et al, 2002). 
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1.3.2 Cataract 
A cataract is said to be present when the crystalline lens of the eye has undergone 
opacification. They show vast genetic heterogeneity and phenotypic variation. 
1.3.2.1 Cataract Classification 
Chronological Classification 
Cataracts are considered to be congenital or infantile when present during the first 
year after birth. Those manifesting during life up to ten years of age are termed 
juvenile cataracts. Presenile cataracts are visible before 45 years of age, and senile 
(age-related) cataracts occur after this time. These are not absolute classification 
boundaries, so a degree of variation is encountered.   
Congenital Cataracts 
Congenital cataracts can occur as isolated anomalies, or they can manifest as a 
feature in a syndrome. A number of genes have been implicated in cataract 
formation, and mutations have been identified. The mode of inheritance can be 
autosomal recessive, autosomal dominant or X-linked. 
Non-Genetic Causes of Cataracts 
A significant proportion of congenital cataracts, estimated to be 8.3%-25% (Francois, 
1982; Merin, 1991), are considered to be genetic in origin. Various environmental 
factors can give rise to the same phenotype. 
1.3.2.2 Types of Cataracts 
An attempt to classify the numerous cataract phenotypes seen in slit-lamp 
examinations of the lens has been made, although there is no standardised 
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nomenclature. Logical classification is hampered because, in the past, many cataract 
phenotypes have been named after the affected family or the ophthalmologist. 
Thefollowing descriptions of opacities are presented as compartmentalised by Reddy 
et al (2004). 
 
Anterior polar cataract: Most anterior polar cataracts are not caused by genetic 
factors, although there are instances where this is the case. Anterior polar cataracts 
affect the anterior pole of the lens, mostly as symmetrical and discrete opacities 
(Figure 1.3A). A study of a four generation family was conducted, where 26 family 
members were examined, and 17 of these presented with cataract. Non-progressive 
cataracts were apparent a few months after birth, and in 16 cases were bilateral. 
Transmission of the defect showed autosomal dominant inheritance. The gene 
responsible is predicted to fall within a 13cM region between markers D17S489 and 
D17S796 on chromosome 17p (Berry et al, 1996). 
Posterior polar cataract: This describes an opacification of the posterior pole of the 
lens (Figure 1.3B). Both progressive and static forms occur. Progressive posterior 
polar cataracts were seen in ten affected individuals of a Japanese family (Yamada 
et al, 2000). The mode of inheritance was autosomal dominant, although there was 
variation in expression. BFSP1, a known cataract gene, falls within the linked region 
(20p12-q12) described by Yamada et al (2000), but no mutations were found in the 
coding exons in the affected members.  
Nuclear: Nuclear cataracts affect the foetal and/or embryonic lens nuclei (Figure 
1.3C). These are phenotypically varied, with pulverulent nuclear cataracts, blue or 
punctuate dots or complete nuclear opacification having been documented. Nuclear 
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cataracts are often described as Coppock or Coppock-like (from the name of the 
family they were first noted in by Nettleship and Ogilvie in 1906), depending on when 
the defect manifests during development, although this practice is becoming less 
common. Coppock-like cataracts refer to those which exist in the nuclear region with 
a diameter of no more than 2.5mm. These are considered to be embryonal because, 
during the second month of gestation, this is the diameter of the nucleus, so the 
cause must have exerted its effect at this stage of development. At this point in lens 
development, the lens vesicle ceases to exist. Coppock cataracts refer to those with 
a nuclear diameter of up to 6mm. At birth, the lens has a diameter of 6mm, so 
cataracts of this type are indicative of a cause that was present during embryonal 
and foetal lens development. The foetal nucleus is said to have formed when 
secondary lens fibres are present. 
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Figure 1.3: Types of cataracts. A: Anterior polar cataract. B: Posterior polar 
cataract. C: Nuclear cataract. D: Lamellar cataract. E: Pulverulent cataract. F: 
Aceuliform-like cataract. G: Cerulean cataract. H: Total cataract. I: Cortical cataract. 
J: Sutural cataract. From Reddy et al (2004). 
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Lamellar: Lamellar cataracts are those occurring in the lamellae (Figure 1.3D). 
Lamellae are formed from secondary lens fibres as they are laid down concentrically 
around the developing embryonal nucleus. The size of the opacity can give an 
indication as to when the cataract arose. 
Pulverulent: These opacities speckle the lens in a scattered pattern, showing 
varying distribution (Figure 1.3E). They can be inherited in an autosomal dominant or 
autosomal recessive manner. Autosomal dominant inheritance of pulverulent 
cataract was demonstrated in a Brazilian family with an intronic donor splice junction 
mutation in betaA1-crystallin, present in all affected members (Bateman et al, 2000). 
Pras et al (2002) identified a mutation responsible for pulverulent cataracts in a 
consanguineous Iraqi Jewish family, which is discussed in more detail under 
1.3.2.3.7.  
Aceuliform: These rare cataracts consist of spiked processes which project from the 
nucleus, through the anterior and posterior cortex (Figure 1.3F). 
Cerulean: Cerulean cataracts are progressive, being absent at birth, but becoming 
apparent during childhood. They consist of cerulean blue and white specks 
distributed across the lens in a scattered pattern, with a greater distribution density in 
the cortex (Figure 1.3G). Cuneiform opacities may be seen in the mid-periphery of 
the cortex as a result of this (Ionides et al, 1999). 
Total: This type of cataract is most common in boys showing X-linked cataract 
inheritance (Reddy et al, 2004). Phenotypically, it is visible as an opacity of the entire 
foetal nucleus at birth and in the cortex in early infancy (Figure 1.3H).  
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Cortical: These are another rare inherited manifestation of cataract. The affected 
area of the lens is the outer part of the cortex, next to the lens capsule (Figure 1.3I). 
It is a less severe form, since it affects new secondary lens fibres in the equatorial 
region, causing minimal visual reduction. 
Sutural: Sutural cataracts (those affecting the anterior and posterior sutures) (Figure 
1.3J) usually present alongside other lenticular anomalies, although they are seen 
without other opacities in Nance-Horan syndrome, in female carriers of X-linked 
cataract (Bixler et al, 1984). 
Polymorphic: This description broadly refers to asymmetric cataracts in the polar 
region of the lens which show great variability amongst affected members, even in 
the same family. This type of cataract was first classified in three unrelated families, 
showing autosomal dominant inheritance, having a phenotypic appearance as a 
bunch of grapes (Rogaev et al, 1996). 
Another review suggests grouping cataracts according to phenotype as follows: total 
(mature, complete, Morganian or disk-like), polar (anterior polar, anterior pyramidal, 
anterior subcapsular, anterior lenticonus, posterior subcapsular, posterior lenticonus, 
or posterior cortical), zonular (lamellar, nuclear oil droplet, cortical, coronary, sutral, 
pulverulent, cerulean, or coralliform), or membranous (capsular) (Huang and He, 
2010). 
1.3.2.3 Genetics of Cataracts 
Different genes are involved in cataract formation, but they fall into subgroups of 
genes, including those encoding crystallins (discussed in 1.3.2.3.2), beaded filament 
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structural proteins, lens intrinsic membrane proteins, heat shock factor proteins, 
glucosaminyl (N-acetyl) transferases and gap junction proteins. 
1.3.2.3.1 Beaded Filament Structural Protein 1 Gene (BFSP1) 
Beaded fiber specific proteins (BFSPs) are intermediate filament proteins, and are 
lens specific (Perng and Quinlan, 2005). They consist of a 12-15nm globular head 
and a 7-9nm filament, with the filament consisting of BFSP1 (115kDa protein, also 
known as filensin or CP115) alone, and the globular head being made up of both 
BFSP1 and BFSP2 (49kDa protein, also known as phakinin and CP49) (Goulielmos 
et al, 1996). It is likely that they play a major role in maintenance of lens opacity in 
humans, since BFSP1 and BFSP2 knock-out mice develop cataracts (Alizadeh et al, 
2002 and 2003). BFSP1 knock-out mice start to develop cataracts at around 2 
months, progressively worsening over time (Alizadeh et al, 2003). 
A study on a consanguineous Indian family by Ramachandran et al (2007) found a 
3343bp deletion (c.736-1384_c.957-66del) in the beaded filament structural protein 1 
gene BFSP1 (located on chromosome 20p12.1) which included exon 6 
(Ramachandran et al, 2007). This was predicted to cause a shift in the open reading 
frame. 19 family members were examined, with 11 of these being affected, and the 
mutation segregated in an autosomal recessive manner. Linkage to a 5.43Mb region 
on chromosome 20p between the markers D20S852 and D20S912 was shown, and 
BFSP1 is located at 20p12.1. The deletion was not found in 50 controls from 
southern India. Most of the affected individuals in this family presented with cataracts 
at five years of age, although in one individual, cataracts were noted at two years.   
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1.3.2.3.2 Crystallins 
Most crystallin genes, when, mutated, play a role in cataractogenesis (Table 1.1).  
1.3.2.3.2.1 Crystallin, Alpha-A (CRYAA) 
Both autosomal dominant and autosomal recessive cataracts can result from 
alphaA-crystallin mutations. A Trp9X substitution in CRYAA in a Persian Jewish 
family caused a chain termination, and cataracts were observed, inherited autosomal 
recessively (Pras et al, 2000). Since the affected individuals had the cataracts 
extracted before three months of age, no cataract phenotype information was 
available. Non–conservative missense mutations in alphaA-crystallin have been 
found in families exhibiting autosomal dominant cataract inheritance. It would appear 
that the surface charge is important for normal functioning, since mutations identified 
tend to involve the substitution of basic arginine to a neutral or hydrophobic amino 
acid (Hejtmancik, 2007). A missense mutation in CRYAA causing Arg116Cys was 
discovered in a family with autosomal dominantly inherited congenital zonular central 
nuclear cataracts (Litt et al, 1998). 
1.3.2.3.2.2 Crystallin, Alpha-B (CRYAB) 
Mutations in CRYAB cause autosomal dominant “discrete” cataracts and desmin-
related myopathy (Vicart et al, 1998) because there is a sharp drop in chaperone 
activation, causing the protein to aggregate and precipitate (Bova et al, 1999). Vicart 
et al (1998) identified Arg120Gln mutations in a French family. In two patients with 
myofibrillar myopathy, mutations in CRYAB were detected: 464delCT and Gln151X 
(Selcen and Engel, 2003). No cataracts were noted with direct ophthalmoscopy. Slit-
lamp investigation was not carried out. 
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1.3.2.3.2.3 Crystallin, Beta-A1 (CRYBA1) 
A 3bp deletion causing delGly91 in CRYBA1 segregated with disease status in a 
Chinese family, where affected members had autosomal dominant congenital 
nuclear cataract (Qi et al, 2004). 
1.3.2.3.2.4 Crystallin, Beta-A4 (CRYBA4) 
CRYBA4 was proven to have a role in cataractogenesis, when mutated, by 
Billingsley et al (2006).A heterozygous c.317T>C genotype was detected in 
members of an Indian family with autosomal dominant congenital lamellar cataract. 
This was predicted to cause Phe94Ser, replacing a hydrophobic amino acid with a 
hydrophilic one, causing protein instability. Leu69Pro was also noted in the index 
case, a de novo mutation, likely to be responsible for the other clinical manifestations 
described in this individual (microphthalmia and enophthalmia). 
1.3.2.3.2.5 Crystallin, Beta-B1 (CRYBB1) 
Both autosomal dominant and autosomal recessive transmission of disease status 
for cataracts linked to mutations in this gene have been reported. 
Gly220X was predicted in a family with autosomal dominant pulverulent cataract, 
where a c.658G>T transversion segregated with disease status (Mackay et al, 2002). 
Pulverulent cataract phenotype has also been associated with mutations in CRYGC 
(Ren et al, 2000). 
Cohen et al (2007) investigated the genetics of autosomal recessive congenital 
nuclear cataract in two apparently unrelated consanguineous Israseli Bedouin 
families. In affected individuals, they identified a single homozygous nucleotide 
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deletion, 168delG which caused a frameshift. This resulted in a missence sequence 
at amino acid 57, and termination of the polypeptide at codon 107. 
1.3.2.3.2.6 Crystallin, Beta-B2 (CRYBB2) 
Litt et al (1997) detected a single base substitution (C475T) in CRYBB2, causing 
Gln155X, and hence, premature termination of beta-b2 crystallin by 51 amino acid 
residues. This was detected in a family where affected individuals presented with 
congenital cerulean cataract. Four affected family members were heterozygous for 
the mutation, and an affected child of a first cousin union was homozygous for the 
change. 
In a four generation Swiss family, Gill et al (2000) identified the same mutation as Litt 
et al (1997), showing autosomal dominant transmission, but in this family, affected 
individuals had Coppock-like cataracts. This finding highlights the variety of cataract 
phenotypes found from mutations within the same gene, and even from the same 
mutation. 
1.3.2.3.2.7 Crystallin, Beta-B3 (CRYBB3) 
A G493C nucleotide substitution was identified in CRYBB3 in two Pakistani families, 
predicted to result in Gly165Arg. The affected family members displayed autosomal 
recessive congenital nuclear cataract (Riazuddin et al, 2005). 
1.3.2.3.2.8 Crystallin, Gamma-C (CRYGC) 
A C502T substitution in CRYGC caused Arg168Trp, resulting in congenital lamellar 
cataract in an affected mother and two affected children in an Indian family (Santhiya 
et al, 2002). Autosomal dominant inheritance was evident even though the family 
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was consanguineous, since affected individuals were found to be heterozygous for 
the mutation.  
Autosomal dominant inheritance for a CRYGC mutation was described by Ren et al 
(2000) in a family where affected individuals had cataracts. This time, the cataract 
phenotype was noted as variable zonular pulverulent, with a range of phenotypes 
including subtle unilateral pulverulent cataract, and bilateral nuclear cataracts. The 
causative mutation is a 5bp deletion in exon 2. 
1.3.2.3.2.9 Crystallin, Gamma-D (CRYGD) 
Héon et al (1999) identified a G411A substitution, predicted to result in Arg58His. 
Individuals heterozygous for this change exhibited aculeiform cataracts in three 
families. One family was from Macedonia, and the other two were from Switzerland 
(Héon et al, 1998). 
There has also been a report of a gammaD-crystallin mutation that causes nuclear 
and coralliform cataracts (Gu et al, 2006) and of another mutation responsible for 
microcornea (Hansen et al, 2007). 
1.3.2.3.2.10 Crystallin, Gamma-S (CRYGS) 
A Gly18Val substitution mutation was detected in exon 2 of CRYGS in a six 
generation Chinese family, with affected individuals displaying progressive 
polymorphic cortical cataracts (Sun et al, 2005). Known loci were excluded with 
microsatellite markers. This was followed by a genome wide scan which identified a 
20.7cM region on chromosome 3 with a maximum lod score of 6.34 (θ=0.0) at 
D3S1602. 
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Gene Location 
Mode of 
Inheritance 
Phenotype of 
Cataracts 
Mutation Reference 
CRYAA 21q22.3 
Autosomal  
recessive 
Not described Trp9X 
Pras et al, 
2000 
Autosomal 
dominant 
Congenital 
zonular nuclear 
Arg116Cys 
Litt et al, 
1998 
Autosomal 
dominant 
Bilateral early 
onset (and iris 
coloboma) 
Arg116Cys 
Beby et al, 
2007 
CRYAB 
11q22.3-
q23.1 
Autosomal 
dominant 
Congenital 
posterior polar 
Frameshift 
at codon 
150 
(450delA) 
Berry et al, 
2001 
CRYBA1 
17q11.2-
q12 
Autosomal 
dominant 
Congenital 
nuclear 
Gly91Del 
Qi et al, 
2004 
CRYBA2 2q34-q36 No association with cataracts reported to date 
CRYBA4 
22q11.2-
q13.1 
Autosomal 
dominant 
Congenital 
lamellar 
Phe94Ser 
Billingsley 
et al, 2006 
CRYBB1 
22q11.2-
q12.1 
Autosomal  
recessive 
Bilateral 
pulverulent 
Gly220X 
Cohen et 
al, 2007 
Autosomal 
dominant 
Congenital 
nuclear 
Frameshift 
at codon 57 
Mackay et 
al, 2002 
CRYBB2 
22q11.2-
q12.1 
Autosomal 
dominant 
Congenital 
cerulean 
Gln155X 
Litt et al, 
1997 
Autosomal 
dominant 
Coppock-like Gln155X 
Gill et al, 
2000 
CRYBB3 
22q11.2-
q12.2 
Autosomal 
recessive 
Congenital 
nuclear 
Gly165Arg 
Riazuddin 
et al, 2005 
CRYGA 2q33-q35 No association with cataracts reported to date 
CRYGB 2q33-q35 No association with cataracts reported to date 
CRYGC 2q33-q35 
Autosomal 
dominant 
Congenital 
lamellar 
Arg168Trp 
Santhiya et 
al, 2002 
Autosomal 
dominant 
Variable zonular 
pulverulent 
5 bp 
insertion in 
exon 2 
Ren et al, 
2000 
CRYGD 2q33-q35 
Autosomal 
dominant 
Aculeiform Arg58His 
Héon et al, 
1999 
CRYGS 3q27 
Autosomal 
dominant 
Progressive 
polymorphic 
cortical 
Gly18Val 
Sun et al, 
2005 
 
Table 1.1: Selected examples of cataract phenotypes resulting from various 
crystallin gene mutations. 
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1.3.2.3.3 Galactokinase 1 (GALK1)  
Galactokinase catalyses the first stage of the galactose metabolic pathway, when 
galactose is phosphorylated, forming galactose-1-phosphate. Okano et al (2001) 
found an Ala198Val mutation in GALK1 (referred to as the Osaka variant) in three 
non-consanguineous Japanese individuals referred to clinic for high galactose levels. 
The three patients were compound heterozygotes, all with one copy of Ala198Val, 
and then c.509-510delGT in patient one, Met1Ile in patient two, but the second 
mutation in the third patient was not described. Based on analysis of DNA from 
infants, they suggested that the Osaka variant had a 4.1% prevalence in the 
Japanese population (24 out of 582 alleles), and a 7.8% frequency (p<0.023) in 
Japanese individuals with bilateral cataract, and that this variant may play a role in 
late onset cataract. 2.8% of Korean individuals screened (8 out of 288 alleles) had 
the Osaka variant, but it was absent in all screened individuals from the USA (188 
alleles in Caucasians, 10 alleles in Blacks).  
Stambolian et al (1995) studied two families and found GALK1 mutations in both. In 
the first family, the female proband had cataracts as the result of homozygous 
Val32Met substitution (which lowers galactokinase activity). Cataracts were absent in 
the heterozygous parents. In the second family, the proband (offspring from a first 
cousin union) developed cataracts and galactosaemia by the age of one. A single 
base substitution was noted (T238G), which produced a nonsense codon (TAG) at 
amino acid 80 (Glu80X). The parents were heterozygous for this substitution and the 
child was homozygous. 
When Ai et al (2000) cloned and disrupted Galk1 in mice, galactose levels increased, 
but cataracts did not develop after six months on a high galactose diet. When these 
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mice were bred with mice expressing human ALDR1, and the resulting transgene 
expressed in Galk1 deficient mice, cataracts were noted in day one postnatal mice. 
1.3.2.3.4 Glucosaminyl (N-acetyl) Transferase 2 Gene (GCNT2) 
This 3 exon glucosaminyl (N-acetyl) transferase 2 gene is located on chromosome 
6p24.2 and there are three known isoforms (GCNT2A, -B and –C). GCNT2 (also 
known as IGNT) has a role in i/I blood group differentiation. The i/I blood group 
classification system refers to the linear i and branched I poly-N-
acetyllactosaminoglycans. The i antigen is found in foetal erythrocytes, and has been 
converted to the I antigen in adult erythrocytes by the enzyme GCNT2 (Bierhuizen et 
al, 1993). Mutations in GCNT2 give rise to structural abnormalities in the enzyme, 
which prevents formation of the branched I antigen. This results in the adult i blood 
group phenotype. It is not problematic unless blood transfusions are received, where 
it has been known to cause severe haemolytic anaemia, due to anti-I antibody 
(Chaplin et al, 1986). 
A study looked at four distantly related Arab families from Israel, whose 13 analysed 
affected members presented with congenital cataract (Pras et al, in 2003). In the 
majority of cases, bilateral leukocoria had been noted before the child was one 
month old. Pras et al (2003) mapped a region of 13.0cM between D6S470 and 
D6S289. A homozygous substitution segregated with cataracts in the families, 
indicating autosomal recessive inheritance. There was a G to A substitution for the 
58th base in exon 2 which resulted in premature stop codon formation: Trp328X for 
GCNT2A, Trp326X for GCNT2B and Trp328X for GCNT2C. 
In humans, the three GCNT2 isoforms have an identical exon 2 and exon 3, but exon 
1 differs. The variants GCNT2-1A and -1C have a coding region of 925bp, and 
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919bp in GCNT2-1B which is the only expressed isoform in human lens-epithelium 
cells (Yu et al, 2003). Mutations in GCNT2-1C alone were not found to be sufficient 
to cause cataracts. 
1.3.2.3.5 Gap Junction Alpha-8 Protein Gene (GJA8) 
The gene for gap junction alpha-8 protein (GJA8) is located on chromosome 1q21.1. 
There are two known GJA8 variants according to Ensemble Release 50 
(http://www.ensembl.org). The first variant has two exons, with exon 1 being non-
coding and the second exon consisting of 1,322 nucleotides, and the second variant 
has one exon with 1,302 coding nucleotides. 
Research was conducted on a three-generation Russian family who had three 
members affected with zonular pulverulent cataract, where DNA was available from 
two affected members (Polyakov et al, 2001). The proband presented with cataracts 
aged three years. Markers D1S2696 and D1S252 were used to confirm linkage to a 
region containing GJA8 which showed a T to G substitution for nucleotide 741. This 
causes isoleucine to be substituted for a methionine residue at position 247, and 
these amino acids are neutral and have non-polar side chains. This change was 
found to segregate in the family in an autosomal recessive manner, and was not 
found in 25 unrelated controls. Mutations in this gene had been previously reported 
to be involved in cataract formation, but the mode of inheritance was autosomal 
dominant (Shiels et al, 1998). 
1.3.2.3.6 Heat Shock Transcription Factor 4 Gene (HSF4) 
Heat shock response genes are activated by heat shock transcription factors in 
response to stresses such as heat and heavy metals. The 15 exon gene encoding 
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heat shock transcription factor 4, HSF4, is located on chromosome 16q21. In 
humans, there are two isoforms, HSF4a and HSF4b. HSF4b has an extra 30 amino 
acids (Smaoui et al, 2004). 
A large consanguineous Tunisian family were studied, with the researchers having 
obtained DNA from 63 family members, with 22 of these being affected with 
congenital total white cataract (Smaoui et al, 2004). Linkage was confirmed to a 
1.8cM (4.8Mb) region flanked by the markers D16S3031 and D16S3095, which 
contains HSF4. A homozygous mutation in the 5‟ splice site of intron 12 
(c.1327+4A>G) was found, which segregated in the family, and causes exon 12 
skipping.  
This study by Smaoui et al (2004) was the first to report an association between 
HSF4 and autosomal recessive cataracts. HSF4 mutations had previously been 
associated with autosomal dominant cataracts, such as Marner cataracts (Bu et al, 
2002). An Arg120Cys substitution, caused by c.36C>T in exon 3 of HSF4, was 
shown to be responsible for autosomal dominant segregation of zonular stellate 
opacity with anterior polar opacity in a Danish family, first reported in 1949 (Marner, 
1949). 
1.3.2.3.7 Lens Intrinsic Membrane Protein 2 Gene (LIM2) 
LIM2 is found on chromosome 19q13.4 and consists of five exons. It codes for a 
protein (lens intrinsic membrane protein 2, LIM2) of 173 amino acids which has an 
approximate molecular mass of 20kDa, containing four intramembrane domains 
(Arneson and Louis, 1998). It is generally considered to be the second most 
abundant lens fibre cell protein.  
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In an inbred Iraqi Jewish family, a homozygous mutation was found to segregate 
with pre-senile cataracts (Pras et al, 2002). A Phe105Val substitution in LIM2 was 
found, caused by a T to G change. The parents in the family were first cousins, and 
their three affected children presented with cataracts between the ages of 20 and 51 
years.  
A Val15Gly mutation in the mouse LIM2 ortholog, Lim2, gives rise to cataracts. This 
was demonstrated in To-3 mice (Steele et al, 1997). The inheritance is 
semidominant, as mice heterozygous and homozygous for this mutation develop 
cataracts.  
1.3.2.3.8 Visual System Homeobox 2 Gene (VSX2) 
The 5 exon visual system homeobox 2 gene, VSX2 is located on chromosome 
14q24.3. It is also known as CHX10, for CEH10 homeodomain-containing homolog, 
with expression in the retina and retinal neuroblasts. It codes for a 361 amino acid 
polypeptide of approximately 39 kDa (Percin et al, 2000). Percin et al (2000) looked 
at a Turkish consanguineous kindred with non-syndromic microphthalmia (OMIM 
251600), cataracts and severe iris abnormalities. Two affected family members were 
studied. Markers were used to show homozygosity in affected members in the 6.3cM 
region flanking VSX2, between D14S77 and D14S61. A G>A substitution caused the 
arginine residue at 200 to be substituted for glutamine (Arg200Gln) in the two 
affected members. This change was not found in 365 mixed ethnicity controls with 
eye defects, or in 110 Turkish control chromosomes. This residue lies within the 
DNA recognition helix of the homeodomain. This study also employed gel mobility 
shift assays to show that Arg200Gln in VSX2 reduces binding to the consensus 
binding site. 
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1.4 Disease Gene Identification 
Identification of disease genes is essential for understanding disease pathogenesis 
and the pathways involved, and hence, potential therapeutic targets, resulting in 
improved patient care. 
Although there are a number of methods that can be employed to identify disease 
genes, they essentially fall into two categories: those techniques identifying a 
disease locus and selecting candidate genes within this region (positional approach), 
and those that proceed in a positionally-independent manner (functional candidate 
gene approach). In practice, most research groups will amalgamate the two and use 
a positional-candidate gene identification approach. 
1.4.1 Functional Candidate Gene Approach 
It is possible to identify disease genes if the pathology of the disease is understood. 
Before genetic mapping information was readily available, this was the most 
frequently used approach to gene identification. Haemophilia A is an X-linked 
recessive disorder caused by mutations in F8 (Xq28), and sufferers bruise easily and 
bleed excessively. F8 was identified as the causative gene via a functional candidate 
approach (Gitschier et al, 1984). The biochemical basis for haemophilia A was 
understood inasmuch as patient serum samples had indicated factor VIII deficiency, 
so gene-specific oligonucleoties were designed to amplify and sequence cleaved 
factor VIII peptides. 
Animal models are a useful tool for the functional approach as they are likely to react 
as a human would, but they are more appropriate for experimentation. Comparisonn 
of the genomes of other species to the human genome can be a useful approach in 
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candidate gene identification. The mouse genome exhibits 99% homology to the 
human genome (Waterson et al, 2002). Even less genetically similar species still 
serve as useful models for researchers. This means that a lot of genetic research is 
carried out in model systems such as Danio rerio (zebrafish), Drosophila 
melanogaster (fruitfly) and Mus musculus (mouse). The Drosophila melanogaster 
genome has been sequenced (Adams et al, 2000). Along with this readily available 
information, this organism is particularly suitable for research because around 75% 
of human disease genes have a fly ortholog (Reiter et al, 2001), it requires little 
space and care in the laboratory, gestation and maturation is relatively rapid and 
development from egg to adult fly can occur in one week, and many distinct 
morphological changes can be seen without the aid of a microscope. Drosophila has 
been used in studies of eye disease, including cataract (Azuma et al, 2000). 
1.4.2 Positional Approach 
With this method, a chromosomal region which contains the disease gene is defined. 
Candidate genes are selected from the region for further analysis, so one of the 
initial aims must be to ensure that the region under scrutiny is as small as possible, 
containing fewer genes for consideration. The Human Genome Project has 
generated large amounts of data with genetic and physical maps indicating the 
position of genes and markers, therefore facilitating this approach.  
The Human Genome Project started in 1990. It aimed to provide the sequence of the 
nucleotide bases in the human genome, and to locate and identify all the genes. The 
human genome was the first vertebrate genome to be sequenced. In parallel to this, 
the mouse genome was also sequenced, with a draft genome released in 2002 
(Waterston et al 2002).  A draft human genome was released in 2001 by the 
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International Human Genome Sequencing Consortium (IHGSC) of 20 groups around 
the world, estimating that the human genome contained 30,000-40,000 protein 
coding genes, but had ~15,000 gaps, including ~10% of the euchromatin in the 
genome (Lander et al 2001).  In 2004, the IHGSC released Build 35 of the human 
genome, with ~99% of the euchromatic genome annotated, consisting of 
2,851,330,913 nucleotides, with approximately 1 error per 100,000 bases, and 341 
gaps, which was a ~475-fold improvement on the draft human genome sequence 
(International Human Genome Sequencing Consortium, 2004). 
There are still heterochromatic areas of the human genome which have not been 
sequenced, and these were not investigated by the human genome project. 
Online databases (Ensembl, NCBI and UCSC Genome Browser, for example) serve 
as repositories for all this information. Linkage analysis is most often used to map 
Mendelian disorders to a specific locus. Once this region is defined, candidate genes 
can be chosen from within the chromosomal region, usually selected on the basis of 
expression data, phenotypes in animal models resulting from disruption of orthologs, 
gene function and homology. 
1.4.2.1 Genetic Mapping  
Genetic and physical maps have been created, and are invaluable to scientists 
engaged in mapping disease loci and identifying genes involved. There are many 
examples of these, and over time, more accurate maps have been constructed. The 
Généthon Map was constructed on the basis of 814 polymporphic (CA)n repeats in 
three generations of eight families, covering about 90% of the estimated human 
genome (Weissenbach et al, 1992). The Marshfield Map was created using 
information on almost one million genotypes in eight Centre d‟Etude du 
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Polymorphisme Human (CEPH) families, using over 8,000 short tandem-repeat 
polymorphisms (Broman et al, 1998). The Icelandic deCODE Map was constructed 
with information from 5,136 microsatellite markers in 146 families, totaling 1, 257 
meiotic events, making it immensely more accurate than previous maps (Kong et al, 
2002). Linkage is the most common tool used for mapping, but some groups have 
used cytogenetics, such as in identifying rare translocations in Duchene Muscular 
Dystrophy (Worton and Thompson, 1988). Others have used association studies, for 
example, for haemochromatosis (Feder et al, 1996). 
By mapping, researchers, aim to identify a small region of a chromosome that 
contains the gene of interest. Genome browsers such as Ensembl, NCBI and UCSC 
show the location of markers and genes along the chromosome. Genes within the 
region of interest can be selected as candidate genes for further investigation, 
considering known functions, paralogs, orthologs, and expression data. 
In human genetic mapping, researchers discover how frequently loci are separated 
by recombination during meiosis, and the location of a locus in relation to another. 
The proportion of offspring who are recombinant (R), as opposed to non recombinant 
(NR) is represented by θ, the recombination fraction, calculated as follows: 
   
 
       
 
An allele is one form of a DNA segment or gene, at a defined chromosomal locus. 
Say that an individual is heterozygous at both loci of interest, with allele 
combinations G-1 G-2, H-1 H-2. If the individual‟s offspring inherit either combination 
of G-1 H-1 or G-2 H-2, then that child is non-recombinant, but those inheriting G-1 H-
2 or G-2 H-1 are recombinant. The recombination fraction is a measure of the 
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proportion of recombinant offspring between the two loci, in this case, G and H, and 
never exceeds 0.5. If θ is 0.5, the loci are not linked. The closer two loci are, the less 
likely it is that there will be recombination to separate them, so θ decreases. When 
loci coincide, θ=0. 
Loci on different chromosomes exhibit independent segregation. Loci on the same 
chromosome are said to be syntenic, and ignoring crossovers during prophase of 
meiosis I, would segregate together. In this family scenario, if sperm has allele G-1, 
there is 50% chance it will also have allele H-1 and 50% chance of also having allele 
H-2 instead, meaning that the average expected outcome would be for 50% of 
offspring to be recombinant and 50% of offspring to be non-recombinant.  
Meiotic recombination happens less often when two loci are located in close 
proximity on a chromosome. More recombination is seen when loci are on separate 
chromosomes or far apart on the same chromosome (Morgan, 1911). Alleles in close 
proximity which tend to be inherited together are termed haplotypes. Two loci are 
said to be linked if recombination occurs in fewer than 50% of events. The distance 
between two loci can be measured by their genetic distance or their physical 
distance. If recombination between two loci occurs in 1% of meiosis events, they are 
said to be 1 centimorgan (cM) apart. 
Single recombination events create two recombinant and two non-recombinant 
chromatids. Even though double recombination events can occur between two, three 
of four chromatids, the net result will still never exceed a recombination fraction of 
0.5. It is not possible to arrive at the recombination fraction across a section of a 
genetic map, over multiple loci, by simple addition. This is achieved by employing 
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mapping functions. Haldene‟s function is used when crossovers happen randomly 
without exerting an influence on each other. 
Haldene‟s function:  w= -½ln (1 - 2θ) or θ= ½ [1 – exp (-2w)]  
map distance = w    θ = recombination fraction 
ln = logarithm to the base e exp = e to the power of 
Crossovers are never entirely random events due to interference, as when 
chiasmata are formed between chromosomes the formation of another chiasma 
close by is prevented. Kosambi‟s function is one mapping function which allows for 
interference. 
Kosambi‟s function: w= ¼ln [(1 + 2θ) / (1 - 2θ)] or θ= ½ [exp(4w) – 1] / [exp(4w) + 1] 
Genetic distances and physical distances do not correspond to one another since 
the physical distance is a measure of the number of bases, often measured in 
megabases (Mb). Recombination occurs more frequently in females, and more often 
near the telomere. Other areas in the genome, such as repetitive sequences, are 
more prone to recombination too, and hence are known as recombination hot-spots. 
Centromeric regions tend to see fewer recombination events.  
1.4.2.2 Linkage Analysis 
Linkage refers to the tendency of particular loci to be inherited together. The closer 
that two loci lie on a chromosome, the greater the likelihood that they will be 
inherited together during meiosis and escape recombination events which would 
cause them to be located in different daughter cells. With increasing distance 
between two loci on a chromosome, recombination events become more likely, and 
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hence, it is more likely that these loci will not be inherited together. Linkage occurs 
when recombination happens in less than 50% of events. This principle is used to 
conduct linkage analysis studies. Quantitatively, linkage analysis is a measure of 
whether or not θ (the recombination fraction) is significant; that is to say, if it differs 
significantly from 0.5. If θ=0.5,the two loci are not linked.   
Linkage analysis only works well for Mendelian disorders with a single causative 
gene at one locus. In complex disorders with multiple risk alleles, it loses its power. 
There must be information on the marker status for at least one of the parents (who 
will be heterozygous) in order for the marker to be informative in the offspring. The 
mean heterozygosity (H) is usually sufficient to indicate marker informativeness, 
calculated by subtracting the sum of the square of each allele frequency from 1. 
        
 
 
 
It is important to note that members of consanguineous families are more likely to 
carry homozygous alleles, so heterozygosity (H) is decreased. The inbreeding 
coefficient (F) is introduced, taking into account the proportion of genes which are 
identical by descent, giving (1-F)H. 
The polymorphism information content (PIC) also gives information about marker 
informity, and incorporates the significant proportion of children (0.5) who will be 
heterozygous offspring of parents who are heterozygous for the same allele 
combination, pi being the frequency of the ith allele (Strachan and Read, 2001).  
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1.4.2.3 LOD Scores and Critical Values 
LOD scores, Z(θ) are a measure of the probability of linkage, and are required to test 
if θ is significant (Morton, 1955). It is the logarithm of the ratio between two 
assumptions: the loci are linked, H1 (recombination factor = θ), and the loci are not 
linked, H0 (θ = 0.5). In some cases, θ can be calculated by counting the 
recombinations, but only if the parental phase is known. 
Z(θ) = log10 [L(H1)/L(H0) 
Z(θ) = log10 [L(θ)/L(θ=0.5)] 
θ is calculated at a range of values for each pedigree, and the most likely value for θ 
is the highest LOD score. LOD scores from multiple families can be combined by 
addition. 
The likelihood ratio can be calculated when information on the phase of the parents 
is available, where a=those with known meiosis phase, b=non-recombinants and 
c=recombinants. 
(1 - θ)b x θc / (1/2)a  
For autosomal loci, linkage is accepted when the LOD score is Zmax ≥3, and linkage 
is rejected when Zmax<-2 (Morton, 1955). If Z falls between 3 and -2, it is 
inconclusive.  For linkage to be accepted with X linked loci, Zmax must be ≥2.The 
corresponding significance values must not exceed 0.001 (Zmax ≥3) and 0.01 (Zmax<-
2). It has been estimated that only once in fifty random selections will two loci be 
linked purely by chance. 
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1.4.2.4 Two-Point and Multi-Point Linkage Analysis 
LOD scores can be calculated by two-point and multi-point analysis, providing proof 
of linkage. Two-point linkage analysis is used to discern if one marker and one locus 
are linked, and is regarded as a way to gauge the location of the locus under 
investigation. Multi-point linkage analysis maps the disease locus in relation to a 
number of markers, and provides much more information than two-point analysis, 
gives a more accurate estimation of the disease locus, and yields higher LOD 
scores. 
1.4.2.5 Markers 
A haplotype is a set of linked alleles on a chromosome, and they can be used in 
mapping. A locus is the defined position of a particular DNA segment on a 
chromosome. The locus of a disease gene can be pinpointed using markers. 
Markers are tracked through pedigrees to elucidate inheritance of the markers within 
the family. For a marker to be informative, it must be polymorphic. The most suitable 
markers are those which are highly polymorphic in the population, so most people 
will be heterozygous. As part of the Human Genome Project, over 10,000 markers 
were overlaid on maps of the human genome (Broman et al, 1998). When looking at 
markers transmitted through the pedigree, they are informative if it is possible to 
discern whether or not recombination has occurred.  
1.4.2.5.1 Restriction Fragment Length Polymorphisms (RFLPs) 
RFLPs were the first markers to be developed and used in genetic studies 
(Grodzicker et al, 1974). These refer to different fragment sizes that result from the 
presence or absence of restriction sites, which cause differing polymorphic lengths of 
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homologous DNA. Temperature sensitive adenovirus mutations were correlated with 
differences in restriction fragment lengths and this information was used to place the 
mutations on a physical map. This technique was developed further to allow 
mapping of traits to loci without knowing the gene responsible. Restriction enzymes 
are used to digest DNA into fragments of known sizes which are then detected by 
hybridising them to radioactive probes using Southern blotting (Botstein et al, 1980). 
This approach is time consuming compared to other available methods, and often a 
particular locus is uninformative because the restriction enzymes are only able to 
recognise a specific variant. 
1.4.2.5.2 Microsatellites 
Microsatellites are used as genetic markers. They are short tandem repeat 
polymorphisms of a DNA sequence of 1-4 base pairs in length, with the longest 
extending up to approximately 0.1kb in total length. Tetranucleotide repeats are 
rarer, but preferable, as they tend to yield more definitive results, whereas 
dinucleotide repeats are more inclined to yield less robust results. They can be 
amplified by PCR with specific primers, using a fluorescently labelled forward primer, 
and the dye is detected during analysis. Many studies have been successful in 
identifying genes responsible for disorders using microsatellite markers to genotype 
DNA from affected individuals and family members. Genotyping with microsatellite 
markers (in combination with results from SNP arrays) was used to identify FLVCR2 
as the gene harbouring mutations responsible for Fowler Syndrome (Meyer et al, 
2010). 
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1.4.2.5.3 Single Nucleotide Polymorphisms (SNPs) 
SNPs are polymorphic variations at a specific nucleotide base. The aim of two 
projects, HapMap and 1000 genome project, has been to assemble a catalogue of 
variation within the human genome which will be made available to the global 
scientific community as it is generated.  
The International HapMap Project (http://www.hapmap.org) began in 2002, aiming to 
find a minimum of one SNP per 5kb of the human genome, using 270 samples from 
four different populations: Yoruba of Nigeria, European ancestry in Utah, Han 
Chinese in Beijing, and Japanese in Tokyo (The International HapMap Consortium, 
2007). The Human Genome Project had made sequence information available, and 
information about many SNPs had been deposited in online databases such as 
Ensembl and UCSC. By the end of the first phase of the project, ~1.3 million SNPs 
had been genotyped (The International HapMap Consortium, 2005). 
The second phase of the project characterised 2.1 million more SNPs in the same 
samples, generating a HapMap with 1.14 SNP per kb average, meaning an average 
of 875bp between SNPs (The International HapMap Consortium, 2007). 
A significant strength of the International HapMap project is that it provides high 
density information on SNPs in the individuals analysed (Collins and Tapper, 2011). 
The 1000 genome project commenced in 2008. Itinvolves a consortium composed of 
the Wellcome Trust Sanger Instiute (Hinxton, UK), Beijing Genomics Institute (BGI) 
in Shenzen, China and National Human Genome Research Institute (NHGRI) in 
Maryland, USA, amongst others.  It aims to describe >95% of the variation within the 
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genome with an allele frequency ≥1%, in the regions that can be analysed by 
existing sequencing technology (The 1000 Genomes Project Consortium, 2010).  
The populations studied include Yoruba from Nigeria, Han Chinese in Beijing, 
European ancestry in Utah, Japanese in Tokyo, Chinese in Denver, British from 
England and Scotland, and Luhye in Kenya. 
For the main project, approximately 2500 samples will be sequenced with 4X 
coverage. As more data from the 1000 Genomes Project becomes available, 
researchers will be able to make comparisons with data generated by their own 
genome-wide association studies to determine, computationally, the likely genotypes 
of their samples, without physically genotyping them. This will reduce the overall cost 
of genotyping. In the long run, this data will pave the way for clinical advances linked 
to individual susceptibility to disease and drug response (Via et al 2010). 
Even though SNPs are biallelic, their density across the (human) genome makes 
them invaluable in genetic mapping studies, SNPs can be used for analysis by 
arrays, allowing large numbers to be included at the same time. SNPs have 
successfully been used in studies linking polymorphisms with disease risk. SNPs in 
TNC (coding for an extracellular matrix protein) have been associated with 
atherosclerosis and coronary artery disease (Minear et al, 2011). 
Genome wide scans, to investigate Mendelian disorders, complex disorders and 
copy number variants (CNV), can be conducted using SNP arrays. The first of these 
to be developed was the Affymetrix Genechip® 10K Xba Array (Affymetrix Inc, Santa 
Clara, CA, USA), which contained 11,555 SNPs, and it is still used by many 
laboratories today to conduct mapping studies (Hattersley et al, 2010). Arrays with 
greater SNP density have now been developed. The Affymetrix Genome-Wide 
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Human SNP Array 6.0 contains over 906,600 SNPs and over 946,000 probes for 
CNV detection. 
1.4.2.6 Autozygosity Mapping 
Autozygosity mapping refers to genetic mapping of consanguineous families that 
have an autozygous region inherited from a common ancestor, hence homozygous 
by descent. The power of homozygosity was recognized by Smith (1953), since if 
consanguineous families are used, fewer families are usually required to provide 
proof of linkage. If nuclear families were to be used, large numbers would be 
required, with many affected siblings, but with rare disorders, it is often the case that 
a large enough study group cannot be found (Wong et al, 1986). This is an extremely 
useful approach for investigation of the genetic cause of autosomal recessive 
disorders nowadays, due to the increasing availability of information on the human 
genome and advances in molecular biology. Once genetic maps had been 
constructed, this methodology could be utilized, first of all with RFLPs (Lander and 
Botstein, 1987). Many genes involved in autosomal recessive disorders have now 
been identified using autozygosity mapping (for example, White et al, 2007). 
1.4.2.6.1 Consanguinity 
The coefficient of inbreeding (F) is the probability an individual will be homozygous 
by descent at any particular loucs (Wright, 1922). Consanguinity is generally 
regarded to be a union between second cousins, or more closely related individuals, 
giving a coefficient of inbreeding (F) of ≥0.156 in their offspring.  
The coefficient of relationship (R) is the proportion of genes that a consanguineous 
couple expect to share by descent from a common ancestor. 
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Parental relationship 
Coefficient of 
relationship (R) 
Coefficient of 
inbreeding (F) 
Siblings 1/2 1/4 
Uncle-niece/ aunt-
nephew/ double first 
cousin 
1/4 1/8 
First cousins 1/8 1/16 
Double second 
cousins 
1/16 1/32 
Second cousins 1/32 1/64 
 
Table 1.2: Coefficients of relationship (R) and inbreeding (F).  
 
In some populations, there is a high incidence of consanguinity, which can usually be 
explained by perceived sociocultural benefits, including strengthening family ties. 
Economic considerations are sometimes a factor, as smaller dowries are usually 
required. It is usually the parents who make the choice of partner for their children. 
Religious tradition was not often given as a reason to enter into a consanguineous 
union. Women involved in consanguineous unions often feel that the marriages allow 
them to be manipulated, reinforcing the hierarchy within the family (Hussain, 1999). 
There is a high incidence of autosomal recessive disorders amongst populations 
where consanguineous unions are prevalent, and this problem has been 
exacerbated in recent years since health care is improving, and more people survive 
to childbearing age, and pass on the allele associated with the autosomal recessive 
disorder. 
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A five year study was carried out in Birmingham to examine the effects of 
consanguinity (Bundey and Alam, 1993). 4934 children born in 1986 and 1987 were 
enrolled, with ~20% of these being of Pakistani origin. 7.9% of the genetic disorders 
encountered were those in the Pakistani populations, compared to 4.3% in the 
population of European descent. Only 0.4% of marriages between individuals of 
European descent were found to be consanguineous. 69% of British Pakistanis in 
the study were related, and 57% were first cousins. 
1.4.2.6.2 Principles of Autozygosity Mapping 
Figure 1.4 shows a pedigree of a consanguineous family, in which there are 
members affected with an autosomal recessive condition (IV:1 and IV:2). These are 
children from a union between first cousins, III:1 and III:2. They have both received 
two copies of the mutation from their common ancestor, I:2, which has been passed 
down through the generations, making them homozygous by descent for the disease 
gene. The region flanking the disease gene, indicated in black, is also homozygous 
in IV:1 and IV:2. In successive generations, the size of the autozygous region will 
decrease due to meiotic recombination. In consanguineous families, most autosomal 
recessive disease mutations are located within a homozygous region, and these can 
be identified using markers spaced along the genome (such as microsatellite 
markers and SNP arrays). When a homozygous segment in affected individuals is 
identified, candidate genes can be selected and sequenced. 
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Figure 1.4: The principle of autozygosity mapping. The red bar indicates a gene 
harbouring a mutation. Generation IV are products of a first cousin consanguineous 
union, and demonstrate how a mutation passed on from a common ancestor can 
cause disease affected status. 
 
1.4.2.6.3 Mathematical Principles of Autozygosity Mapping 
For a child from a consanguineous union, the probability of being homozygous by 
descent (Fq) is equal to the disease allele frequency (q), multiplied by the coefficient 
of inbreeding (F), assuming the disease is in Hardy Weinberg equilibrium (Lander 
and Botstein, 1987). The probability of the child not being homozygous due to two 
randomly meeting disease alleles is: 
(1-F)q2  
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If the disease gene is in Hardy Weinberg equilibrium in the population, the proportion 
of affected individuals who are homozygous by descent (α) is: 
   
  
          
 
Assuming disease allele frequency (q) is small in comparison to the coefficient of 
inbreeding (F), α is more likely to be approximately equal to 1. This equation 
therefore shows the validity of assumption that for a rare recessive disorder, the 
disease gene will lie within a homozygous region.  
This also explains why children with recessive disorders are likely to have parents 
who are closely related.The proportion of affected individuals with related parents will 
be: 
  
           
  
1.4.2.6.4 The Power of Autozygosity Mapping 
By using α and F, a LOD score can be generated. The probability of the region 
flanking a disease gene being homozygous by descent is α. The rest of the genome 
will be unlinked, and the probability of homozygosity by descent is represented by F. 
The ratio α:F is the odds in favour of linkage, if genotyping is fully informative. In an 
individual with an inbreeding coefficient (F) of 1/16 (offspring from a first cousin union 
or equivalent), with a region that is homozygous by descent, the odds ratio will be 
1:16 in favour of linkage, corresponding to a LOD score of 1.204. A significant LOD 
score of 3.61 would be generated by detecting a shared homozygous region in just 
three separate first cousin unions, each having one affected child with a shared 
phenotype, assuming the marker is fully informative and α is approximately 1.  
1. Introduction   49 
 
If more distantly related families are used in mapping (inbreeding coefficient 
decreases), the power to detect linkage increases, as does the maximum LOD 
score. A maximum LOD score of 2.41 can be obtained from an affected child from a 
second cousin union. In this case though, the region, homozygous by descent, will 
be smaller due to meiotic recombinations, so this necessitates more closely spaced 
markers (Lander and Botstein, 1987).   
1.4.2.6.5 Pitfalls of Autozygosity Mapping   
There are some considerations that researchers must bear in mind when using 
autozygosity mapping in disease gene identification.  
Some mutations will only be present in one particular isolated community, so it may 
be impossible to find other families who have the same mutation, or even a mutation 
in the same gene. This is particularly problematic in the search for new cataract 
genes since one particular mutation may cause a variety of cataract phenotypes, and 
also, the same cataract phenotype may be the result of a mutation in one of a 
number of genes (locus heterogeneity). In these instances, it is more of a challenge 
for researchers to provide convincing proof of pathogenesis. If possible, a large 
consanguineous kindred with affected individuals should be obtained, investigated 
for regions of homozygosity, and then compared with regions of homozygosity in 
smaller families with the same phenotype. Functional studies are required to confirm 
this with putative mutations. Autosomal recessive diseases are rare, and it can prove 
difficult to find enough patients with a matching phenotype. Depending on the 
population group studied, it may be difficult to find families with more than one 
affected child due to small overall family sizes (Mueller and Bishop, 1983). In an 
attempt to surmount this obstacle, international collaborations are often set up.  
1. Introduction   50 
 
Not all diseases in consanguineous kindreds are caused by homozygous mutations. 
Occasionally, disease may arise as a result of compound heterozygous mutations. A 
genome-wide scan which identifies homozygous regions in the genome will fail to 
find the causative mutations, as they will not lie in a homozygous region. This was 
the case in a consanguineous Jordanian Arab family with two boys affected with 
Karak Syndrome (pantothenate kinase associated neurodegeneration with early 
onset cerebellar ataxia), where inheritance appeared to be autosomal recessive or X 
linked, based on the pedigree, but no linkage to PNAK2 was found (Mubaidin et al, 
2003). Morgan et al (2006) found compound heterozygous mutations in PLA2G6 in 
the two boys, selected for analysis because of phenotypic similarities to neuroaxonal 
dystrophies. The parents had different heterozygous alleles.  
In a consanguineous kindred, it is still possible for allelic heterogeneity to occur, so 
that linkage will not be detected with markers when searching for homozygous 
regions. An example of this was highlighted in a study of enhanced S-cone 
syndrome (Miano et al, 2000).There were four affected individuals in the kindred, 
with homozygous mutations, but one of them was a compound heterozygote, so this 
was missed as the locus due to pooling. Also, autozygosity was detected which had 
no connection with the disease. The extent of inbreeding was also underestimated, 
resulting in a higher LOD score, making false-positive linkage more likely. 
1.4.3 Exome Sequencing 
Until exome sequencing was developed, there had been little progress in identifying 
Mendelian disease genes, in comparison to the progress made in the understanding 
of complex disorders, achieved via genome-wide association studies. Linkage 
studies are useful, but they are not always successful at identifying pathogenic 
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alleles. High-throughput sequence capture and next-generation sequencing 
advances have now made exome sequencing more accessible to researchers (Ku et 
al, 2010). 
The causative gene for Kabuki syndrome, MLL2, was identified using exome 
sequencing (Ng et al, 2010). Massively parallel sequencing was undertaken for ten 
affected patients, each from a different family, and less stringent criteria were set, so 
that genetic heterogeneity could be identified. In MLL2, seven of the patients 
harboured nonsense of frameshift mutations, and two of the remaining patients were 
found to have mutations in MLL2. 
Exome sequencing involves enrichment and sequencing of the exome (coding 
regions of the genome), Approximately 1% (30Mb) of the human genome consists of 
protein coding regions, dispersed in ~180,000 exons (Ng et al, 2009). Therefore, 
exome sequencing has some drawbacks. Non-coding sequences cannot be 
investigated, and also, not all exons are captured, Whole genome sequencing is 
currently too expensive for this approach to be used routinely when identifying 
disease genes. 
1.4.4 Progress in Gene Identification 
According to OMIM, in June 2011, the molecular basis for 2725 autosomal 
Mendelian phenotypes are known, along with 236 for X-linked disorders, 4 for Y-
linked, and 28 for mitochondrial disorders. 
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2. MATERIALS AND METHODS 
This chapter details the reagents and techniques used. Primer sequences are given 
in the relevant chapters, and further information can be found in the Appendix. 
2.1 Materials 
2.1.1 Chemicals 
10X TBE (1X TBE dilution used)           Geneflow  
Acetamide                   Sigma 
Acrylamide                   Geneflow 
Agarose (molecular grade)             Bioline 
Albumin from bovine serum, minimum 98%       Sigma-Aldrich 
Ammonium Persulphate (APS)            Sigma 
Ampicillin                    Sigma 
β-mercaptoethanol                Sigma  
BigDye Terminator Cycle Sequencing Kit version 3.1    Applied Biosystems 
BioMixTM Red                  Bioline 
Bio-x-act                    Bioline 
ColorPlus Prestained Protein Ladder P7711S      New England Biolabs 
Competent cells, JM109              Promega 
Complete Mini Protease Inhibitor Tablets        Roche 
2. Materials and Methods   54 
 
DC Protein Assay Reagents A, B and S         Bio-Rad 
dNTPs (working dilution of 2mM)           Bioline 
DMSO                     Sigma  
ECL Plus Western Blotting Detection System, Amersham TM GE Healthcare 
EDTA                     Fisher Scientific 
Eagle‟s Minimum Essential Medium (EMEM)       LGC Standards 
EcoRI                     New England Biolabs 
Ethanol                     Sigma  
Ethidium Bromide                 Sigma 
ExoSAP-IT                   Amersham Pharmacia 
FastStart Taq DNA polymerase GCRich        Roche Diagnostics 
Genescan-500 LIZ size standard           Applied Biosystems 
Hi-Di Formamide                 Applied Biosystems 
Hi-Spec Additive                 Bioline 
Hyperladder I                  Bioline  
IMAGE Clone CDC25A               Source Bioscience 
JM109 Competent Cells (high efficiency)        Promega 
Kanamycin                   Sigma  
KpnI                      New England Biolabs  
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LB Broth Medium Powder              Sigma 
L-Glutamine                   Invitrogen 
LipofectamineTM 2000               Invitrogen 
Magnesium Chloride (MgCl2)             Roche  
Methanol                    Fisher 
Micro CLEAN                  Web Scientific 
Milk (powdered)                 Marvel 
Mouse monoclonal anti-HA clone (HA-7)        Sigma-Aldritch 
OptiBuffer                    Bioline 
PVDF Membrane                 GE Healthcare  
Paraformaldehyde (4%, in PBS)           Sigma 
Phosphate buffered saline tablets (Dulbecco A) (PBS    OXOID 
Polyclonal rabbit anti-mouse immunoglobulin HRP (P0161  DakoCytomation  
Prestained Protein Broad Range Protein Ladder     New England Biolabs 
Primers                     Sigma-Genosys 
ProLong® Gold Antifade Reagent           Invitrogen 
Propidium iodide                 Sigma 
Protein Standard BSA (2mg/ml)            Sigma 
QIA Prep Spin Mini Prep Kit             Qiagen 
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Quiagen-tip 500 columns             Qiagen 
QIAQuick® Gel Extraction Kit           Qiagen 
Quik Change® Lightning Site Directed Mutagenesis Kit   Agilent Technologies 
ResGen v10 Mapping Set             ResGen 
RNase A                   Fermentas 
Saran wrap                  Dow 
SDS (10%)                  Fisher 
SDS PAGE Tank Buffer (10X) Tris Glycine SDS (B9-0032) Geneflow 
Silver Effieciency Competent Cells          Bioline 
SOC Medium                 Invitrogen 
T4-DNA Ligase                 Promega 
TEMED                   Fisher 
TOPRO®-3 iodide                Invitrogen 
Tris Glycine Electroblotting Buffer (B9-0056)      Geneflow 
TRIS powder (1.5M and 0.5M used)         Fisher 
Triton X100 (0.1% in PBS)             Sigma 
Tween-20                   Sigma 
Water, distilled (dH2O) DNAse, RNAse free      Gibco Invitrogen 
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2.2 Methods 
2.2.1 DNA 
Genomic DNA used in this project was already extracted from blood or buccal swabs 
when received. Most extractions were carried out by West Midlands Regional 
Genetics Molecular Genetics Laboratory, using Gentra System‟s Puregene DNA 
Purification System, which involves salting-out precipitation.Cells are lysed, then 
protein is precipitated, followed by precipitation of DNA. DNA is washed with ethanol 
and then hydrated. In this state, DNA can be put into long term storage at -80°C. 
2.2.2 Polymerase Chain Reaction (PCR) 
A number of PCRs were carried out during the course of this study, with varying 
conditions. Specific primer details are contained within the appropriate chapters. 
PCR allows specific DNA sequences to be amplified, employing a thermostable DNA 
polymerase, Taq polymerase. Taq polymerase was originally isolated from the 
organism Thermus aquaticus, a bacterium which is found in hot springs (Chien et al, 
1976), although it was not until the 1980s that Kary Mullis developed PCR as a 
viable research technique for use in molecular biology.  
For PCR, the following reagents are required: sample DNA (to act as a template), 
buffer, deoxyribonuclease triphosphates (dNTPs), a DNA polymerase (usually Taq 
polymerase), MgCl2 and primers. The concentrations of these can be adjusted to 
achieve optimum conditions. Similarly, the cycling conditions may be altered to 
obtain required amplification. 
Specific oligonucleotide primers are designed on opposite DNA strands, flanking the 
region of interest. Primer design is only possible with data on the nucleotide 
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sequence of the target DNA segment. It is assumed that there is a remote chance 
that this sequence occurs elsewhere in the genome, even for only one primer, and 
that there is even less possibility that the other primer‟s sequence will, by chance, 
occur nearby. This assumption is always tested using BLAST.  
There are three main stages to PCR: denaturation, annealing, and elongation (or 
extension). Heat is used to denature the template duplexes, breaking the hydrogen 
bonds that hold the two strands of the double helix together, and giving rise to single 
strands. A temperature of around 95°C is employed. The temperature is then 
decreased to allow annealing of complementary primers to the single strands of 
DNA. The optimum temperature for this annealing step usually falls within the range 
of 50-65°C. Next, primer extension occurs along the single strands of the double 
helix, with dNTPs added in a 5‟ to 3‟ direction to the nascent strand. This is usually 
carried out at 72°C, close to the optimum temperature of the Taq polymerase. The 
steps are repeated numerous times, and the newly formed segments are used as 
templates in subsequent stages of the PCR. This is how the exponential increase in 
copies of sequence of interest is achieved. A final extension step is usually carried 
out at 72°C to allow complete extension of any remaining single strands. 
PCR is an incredibly sensitive technique. To maintain accuracy, it is therefore 
necessary to ensure that there is no contamination of samples and reagents with 
foreign DNA, so a negative control is always included, which experiences the same 
conditions as the experimental PCR, and contains all the same reaction components 
apart from experimental DNA.  
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2.2.2.1 PCR Conditions 
Although it was sometimes necessary to alter the standard procedure, the following 
general conditions were generally used to achieve satisfactory amplification.  
The reactions used BioMix Red, which enables faster set-up since it already includes 
the polymerase enzyme BIOTAQ DNA polymerase, dNTPs, buffer and 1.5mM 
MgCl2. A final reaction mixture of 25μl was made including: 
2X BioMix Red      12.5μl 
forward primer (5.0pmol)    0.5μl 
reverse primer (5.0pmol)    0.5μl 
dH20            6.5μl 
DNA (20ng/μl)        5.0μl 
PCR was carried out on a Tetrad Thermal Cycler using the following conditions: 
1. 95°C for 5 minutes 
2. 95°C for 30 seconds 
3. 57°C for 1 minute 
4. 72°C for 1 minute 
5. Stages 2-4 carried out 35 times 
6. 72°C for 5 minutes 
A heated lid condition was programmed to avoid evaporation of reagents.  
If these conditions did not yield required product, the annealing temperature and the 
concentration of MgCl2 could be altered. If there was non-specific priming, 5% [w/v] 
acetamide or GC rich solution was added to reactions to optimize results. Reactions 
could also be supplemented with DMSO to inhibit non-specific priming.  
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2.2.2.2 Primer Design 
Primers for this project were on the whole designed using the program Primer3 
version 0.4.4 at http://frodo.wi.mit.edu/. The sequence of the exon (or partial exon) of 
interest was copied from Ensembl (http://www.ensembl.org/index.html) and pasted 
into the Primer3 programme. Occasionally, it was necessary to design some primers 
by eye where the regions flanking the target sequence were inconducive to 
automatic primer design, being highly GC rich. Primers were designed to 18-26bp in 
length. An annealing temperature between 55-65°C was required, and could be 
predicted with the following formula: 
Annealing temperature = 59.9 + 0.41 x (%GC) – 600/length 
Primers were designed to amplify coding exons of genes of interest, including intron-
exon boundaries, and were positioned so that the segments amplified were not much 
over 600bp in length, but were ideally 500bp. Any larger exons were covered with 
more than one pair of oligonucleotide primers, ensuring that overlap occurred.  
2.2.3 Agarose Gel Electrophoresis 
After PCR, DNA was separated based on product size by agarose gel 
electrophoresis. Phosphate groups in DNA are negatively charged, so DNA migrates 
through the gel medium towards the positive anode. This movement occurs at a 
slower rate with larger molecules, but is not always entirely dependent on this. 
Secondary structure can also affect the rate of migration.  
1% (w/v) Agarose gels were made with 1.5g agarose powder and 150ml 1X TBE. 
These were melted in a 600W microwave, then left to cool to approximately 40°C. 
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Ethidium bromide was then added (3μl). It is an intercalating agent, and interacts 
with DNA, fluorescing with UV light. In this way, DNA can be visualized.   
The gel was cast in a gel casting tray and wells were ensured by the positioning of 
well combs as the gel solidified, taking approximately 30-60 minutes. Gels were then 
placed in an electrophoresis tank so that samples could be loaded. No additional 
loading buffer was required due to the presence of BioMix Red. 5μl of product was 
loaded in the wells, and 3μl of Hyperladder I was added to the first well to allow size 
comparison. Hyperladder I features 14 fragments varying in size from 200 to 
10,000bp. 
The gels were run at 180V for 10-15 minutes. This depended on the size of the gel 
and the size of the fragment of interest. The gel was viewed on a UV 
transilluminator, using a wavelength of 260nm. It was photographed with a 
connected camera.  
2.2.4 DNA Purification 
PCR products of interest needed to be further purified in order for it to be suitable for 
sequencing reactions. This was achieved either by using ExoSAP or MicroCLEAN. 
Primers had to be removed so that only the forward or reverse primer was amplified 
in subsequent reactions. 
2.2.4.1 ExoSAP-IT 
ExoSAP-IT was used to clean up the PCR/DNA amplification product.  For 5μl PCR 
product, 2μl ExoSAP-IT and 2μl dH2O were added. This mixture was incubated at 
30°C for 15 minutes, and then inactivated by heating at 80°C for 15 minutes. After 
this inactivation, sequencing was initiated within 30 minutes. 
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 ExoSAP-IT is a combination of hydrolytic enzymes Exonuclease I and shrimp 
alkaline phosphatase. Exonuclease I degrades single stranded DNA (primers and 
superfluous PCR products), and shrimp alkaline phosphatase is responsible for 
hyrdolysing excess dNTPs. 
2.2.4.2 MicroCLEAN 
MicroCLEAN is another reagent designed for PCR/DNA clean up, and it was used 
independently of ExoSAP-IT clean up reactions. An equal volume of MicroCLEAN 
was added to PCR product (typically 2.5μl of each per forward or reverse primer). 
This mixture was then centrifuged for 40 minutes at 4000rpm, the supernatant 
removed, and the pellet re-suspended in dH2O (5μl per primer reaction) to rehydrate 
the DNA. 
2.2.5 Linkage Studies 
During this project, two approaches were used to conduct linkage studies: 
microsatellite marker analysis, and SNP arrays. 
2.2.5.1 Microsatellite Marker Analysis 
Linkage analysis, using microsatellite markers was, carried out during the course of 
this study, with varying conditions, detailed within the appropriate chapters. 
Microsatellites are tandem repeats of 1-4bp of DNA, usually running for less than 
0.1kb, and are markers with a known genomic location. Linkage analysis was 
performed using fluorescently labelled microsatellite markers and an ABI PRISM 
3730 DNA sequencer. The microsatellite markers were part of ResGen v10 mapping 
set or ABI panels, labelled with dyes FAM (blue), HEX (yellow) and TET (green). The 
ResGen v10 mapping set consists of 405 microsatellite markers, with approximate 
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spacing of 9cM between markers. Novel microsatellite markers were also designed 
using microsatellite data on UCSC (GRCh37/hg19) (RepeatMasker; Variations and 
Repeats; Microsatellites), and Primer3.The forward primer was labelled with FAM. 
This was necessary when no known or in-laboratory markers for the region of 
interest were available. Stock primers for novel markers were made up with dH2O 
according to the manufacturer‟s recommendation, and working dilutions were made 
up with 20μl forward primer 20μl reverse primer and 160 μl dH20. A reaction mix of 
10μl was prepared including: 
2X BioMix Red       5.0μl 
Forward primers (2.0pmol)  0.2μl 
Reverse primers (2.0pmol)  0.2μl 
dH20           3.6μl 
DNA (20ng/μl)       1.0μl 
The PCR conditions were an initial denaturing step for 5 minutes at 95°C, followed 
by 30 cycles (95°C for 30 seconds, 55°C for 30 seconds, 72°C for 30 seconds), then 
72°C for 5 minutes. PCR products were diluted 1:5 to 1:15 with dH20 and 10μl of a 
HiDi and LIZ mixture (1000 μl HiDi with 4 μl LIZ) was added to 1μl of the diluted PCR 
product. After centrifugation, the plate was run through a denaturing cyle (95°C for 5 
minutes), and afterwards, was immediately placed on ice. Once cool, the plate was 
taken to be put on the ABI PRISM 3730 Sequencer. A negative control, using dH20 
instead of DNA, was included for each pair of primers to detect contamination. The 
ABI PRISM 3730 uses LIZ as a size standard.  
Gene Mapper Software was used to analyse the data gathered from the computer 
attached to the sequencer. Genescan (Applied Biosystems) was used to identify the 
size of the products.  
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2.2.5.2 SNP Chip 
SNP chip genome-wide linkage scans were performed by Louise Tee or Fatimah 
Rahman, using the GeneChip® Human Mapping 250K SNP Array. These 
microarrays permit analysis of 238,304 SNPs of an individual‟s DNA. Genotyping 
with these SNP chips was carried out as per the manufacturer‟s instructions. 250ng 
DNA was digested with StyI restriction enzymes (New England Biolabs), then ligated 
to StyI adaptors with T4 DNA Ligase (New England Biolabs). For each DNA sample, 
three PCR reactions were carried out, with primer 002 (Affymetrix) and Titanium 
DNA Amplification Kit (Clontech). A 1.5% agarose gel was used to run PCR products 
(200-1,100bp). A DNA Amplification clean-up kit (Clontech) was then used. DNA was 
then fragmented to yield products no larger than 200bp, labelled, and hybridised to 
the 250K SNP chip. A fluidics station was used to wash and stain the chips. An 
Affymetrix GeneChip Scanner 3000 with GCOS 1.3 software was used to scan the 
chips, and GTYPE 4.1 software was consequently employed to identify genotypes at 
the SNPs and chromosomal location. 
Microsoft Office Excel 2007 was used to manipulated the generated data, and to 
identify regions of homozygosity ≥2Mb. Each chromosome‟s data was given a 
separate Excel sheet. The cells with heterozygous calls were filled with pale shading, 
and the homozygous calls were given two different darker shades. „No calls‟ could 
not be discounted as representative of continuing homozygosity, so they were also 
shaded, lightly. By eye, the data was scanned (with magnification reduced to 15%), 
and regions of homozygosity ≥2Mb were noted and used to commence linkage 
analysis studies. 
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2.2.6 Sequencing 
If a sequence of DNA is known, it can be detected using Direct Sequencing. One 
type of Direct Sequencing is Sanger Dideoxy sequencing, which uses 
dideoxynucleotides. Dideoxynucleotides have hydrogen at the 3‟ prime carbon where 
the hydroxyl group is in deoxynucleotides. This prevents phosphodisester bond 
formation between the dideoxynucleotides and nucleotide, terminating amplification. 
Each of the four dideoxynucleotides can be labelled with a different fluorophore, and 
therefore can be identified. Sequencing was carried out on an ABI 3730. 
A 10μl reaction mix is made up with the following quantities: 
Big Dye Reaction Mix       0.5μl 
5X Sequencing buffer       2.0μl 
Forward or reverse primer (4.0pmol)  2.0μl 
dH20          1.0μl 
Purified DNA product   4.5μl 
The cycling conditions were an initial denaturing step for 3 minutes at 96°C, followed 
by 30 cycles (96°C for 30 seconds, 50°C for 15 seconds, 60°C for 4 minutes). 
Precipitation steps are then carried out, with centrifugation after each addition. 1μl 
250mM EDTA is added to sequencing reaction, spun briefly, and then 30μl 100% 
ethanol is added. This is centrifuged for 20 minutes at 2000rpm. The plate is then 
inverted and spun gently onto absorbent paper. 90μl of freshly made 70% ethanol is 
then added to sequencing reaction, and this is centrifuged for 10 minutes at 
2000rpm. After this, the plate is again inverted and centrifuged at low speed onto 
absorbent paper. 10μl of HIDI is added to every well and it is denatured for five 
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minutes. The plate is then put onto ice immediately to stop the products reannealing. 
At this point the plate can be taken to the ABI 3730 automated sequencer. 
Chromas Software is used to view the sequencing results after the plate has been 
run on the ABI 3730. 
2.2.7 Next Generation Sequencing 
Next generation sequencing is used to identify DNA sequences, and is often referred 
to as massively parallel sequencing. The genome is fragmented, and the fragments 
of DNA are ligated to adapters, in order to be read randomly during DNA synthesis 
(Zhang et al, 2011). Current next generation sequencing methods only produce short 
read lengths of 50-500bp, so adequate coverage is essential for accuracy. Coverage 
refers to the number of overlapping short reads for a specific section of the genome. 
For next generation sequencing, samples were sent to Dr Michael Simpson at Guy‟s 
Hospital in London. DNA from individuals with cataracts was fragmented and Agilent 
SureSelect Whole Exome hybrid capture was used to enrich these fragments for 
exomic sequences. Biotinylated RNA probes of 120bp were used to cleave off DNA 
from the array, transcribe DNA and incorporate it. 3μg DNA yields a fragment of 
150bp which is introduced into a Covaris sample processing tube, with ultra high 
frequency sound waves. The ends of the strands are repaired (adenine overhangs) 
with ligation and universal sequence adapters. This is then mixed with probes and 
left at 65°C overnight, then passed through magnetic beads which hold onto the 
biotin. DNA is bound to the probes, and eluted. This resulting library is sequenced 
with 76bp paired end reads across two lanes of the Illumina GaIIx flowcell (v2 
chemistry) (Ostergaard et al, 2011). Reference genome hg18 was used for 
alignment. Optical and clonality duplicates were identified and not included in further 
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analysis. The SamTools software package was used to sort through SNPs and small 
insertion deletions, and sequence variations were compared with data from the 1000 
Genomes Project and dbSNP131 to see if any variants detected by exome 
sequencing were novel, and hence, potentially pathogenic mutations (Ostergaard et 
al, 2011). At this point, the generated data was received, and novel variants in genes 
known to be expressed in the eye were selected for further analysis. 
2.2.8 Cloning of PCR Products 
Cloning was used in this project to obtain the sequence of a gene, CDC25A, in 
isolation, amplify it, and introduce it into cell lines for further investigation, and to 
allow manipulation of the gene from wild type to a specific mutant form. 
2.2.8.1 IMAGE Clone 
An IMAGE (integrated molecular analysis of genomes and their expression) clone of 
full length cDNA for CDC25A was obtained, in a pOTB7 vector, with resistance to 
chloramphenicol. 
An incubator was set to 37°C, and an agar plate infused with chloramphenicol was 
inverted, and placed inside. A sterile inoculation loop was swiped across the top of 
the agar in the cryovial containing the IMAGE clone. This loop was then traced lightly 
across the surface of the agar in a zigzag pattern. The inverted plate was incubated 
overnight. During the morning of the following day, the agar plates were examined 
for growth of colonies. 
20ml falcons were set up with 5ml LB medium and 6.25μl 20mg/ml chloramphenicol. 
A single, individual colony was removed from the agar plate with a pipette tip and 
transferred to one of the falcons. The falcons were placed in the incubator and the 
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rotor was switched on to160rpm. This was left to incubate overnight. A mini-prep 
(see 2.2.8.4.1) was carried out, followed by gel extraction (see 2.2.8.5). 
The required section of DNA was obtained by PCR. A 1X reaction mix with plasmid 
preps of the IMAGE clone was set up: 
Optibuffer         20.0μl 
MgCl2 (50mM)       10.0μl 
dNTPs            4.0μl 
Bio-x-act           8.0μl 
Hi-spec additive      40.0μl 
Forward primer (2.0pmol)     4.0μl 
Reverse primer (2.0pmol)     4.0μl 
dH2O           94.0μl 
Plasmid prep of IMAGE clone   2.0μl 
The products were loaded onto 1% agarose gel and run for two hours at 80V. The 
required band was then excised from the gel in a dark room, and gel extraction (see 
2.2.8.5) was carried out. 
2.2.8.2 Vectors 
Vectors are cloning vehicles consisting of DNA, which are used to contain a DNA 
sequence of interest (the target sequence). DNA sequences for entire genes, or 
DNA segments, can be inserted via recombinant DNA methods. Plasmid vectors 
contain double-stranded, circular DNA. This can be cleaved with specific 
endonucleases. Vectors typically contain many unique restriction sites. Directional 
cloning is made possible due to the presence of multiple cloning sites. The same two 
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restriction endonucleases are used to cleave both the target sequence and the 
vector, and these particular enzymes are chosen based on the sticky ends that will 
result, ensuring that target DNA can be inserted in the vector in the correct 
orientation. In order to insert the DNA sequence of interest, the ends are joined with 
DNA ligase to form a circular DNA loop again. The vectors consisting of recombinant 
DNA are introduced into cells, to transform them. Vectors have a replicon with an 
origin of replication, so they can replicate independently of the host cell‟s 
chromosomes when the host cell replicates. Progeny cells will contain a copy of the 
vector. One or more genes in the vector give them a detectable phenotype (usually 
resistance to a specific antibiotic). This allows individual colonies to be selected 
when transformed cells are plated out on a solid medium, such as agar, infused with 
a particular antibiotic. The amount of cells can then be scaled up in liquid culture, 
and the recombinant DNA harvested. 
The CDC25A IMAGE clone was supplied with CDC25A located within a pOTB7 
vector, with resistance to chloramphenicol. During this project, CDC25A was ligated 
into pCMV-HA and/or pEGFPC2 vectors. 
2.2.8.3 Antibiotic Plates and LB Medium 
16g powdered agar was added to 500ml dH2O in glass conical flasks. Lids were 
loosely fastened with autoclave tape, and the bottles and contents were autoclaved. 
This was allowed to cool but not set. The bottle was infused with 500μl of 100mg/ml 
ampicillin or kanamycin, and this was aliquoted in 25ml volumes into plates. These 
were left to set at room temperature with lids ajar, and stored at 4°C long term. 
LB medium (luria broth) was prepared in autoclaved flasks. 500ml distilled water and 
10g LB broth medium powder were used per flask. 
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2.2.8.4 Plasmid DNA Purification 
2.2.8.4.1 Miniprep of Plasmids 
The LB medium was supplied with the CDC25A IMAGE clone, and incubated at 
37°C. It was then checked to see if it had become cloudy overnight, indicating 
growth. 1.6ml medium was transferred (2x 800μl) into eppendorfs and centrifuged at 
6.800g for three minutes, lysing the E. coli bacterial cultures containing the sequence 
of interest. To purify plasmid DNA, the Qiagen QIA Prep Spin Miniprep Kit was used, 
following the manufacturer‟s instructions. Rounds of centrifugation follow. In the spin 
column, the silica gel membrane permits adsorption of DNA. Impurities are removed 
as flow-through. Finally, a sample of purified DNA in water is eluted. 
2.2.8.4.2 Maxiprep of Plasmids 
In order to obtain sufficient amounts of plasmid DNA for transfection, 1ml bacterial 
culture was introduced to 500ml LB medium. A Qiagen Maxiprep was carried out as 
per the manufacturer‟s instructions, with Qiagen-tip 500 columns, capable of yielding 
up to 500μg DNA. 
2.2.8.5 Gel Extraction 
Gel extraction is necessary to obtain clean DNA, so that it can be used for further 
investigation. Gel extraction was carried out with a Qiagen QIAquick® Gel Extraction 
Kit. Bands of DNA are excised from an agarose gel under UV light, dissolved in high-
salt buffer, adsorbed to the spin column membrane and subjected to rounds of 
centrifugation in spin columns, using washing to remove impurities, binding again, 
and elution of DNA in a low-salt buffer. This step is carried out after restriction 
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enzyme digests (see 2.2.8.6) are used to cut the plasmid, and the products are 
separated on an agarose gel. 
2.2.8.6 Restriction Enzyme Digests 
Restriction enzyme digests rely on the ability of restriction endonucleases to cut DNA 
when they recognise specific sites. This principle works well when attempting to 
distinguish between wild type and mutant sequences. It is also useful for cloning as it 
makes ligation possible and ensures that the gene of interest is cloned in the plasmid 
in the right direction. Both the gene fragment and plasmid must be cut. Restriction 
endonucleases recognise small sequences of 4-8bp, usually not falling on the axis of 
symmetry, resulting in DNA with sticky ends. When the recognition site falls on the 
axis of symmetry, blunt ends are produced. In many cases, two different restriction 
endonucleases will be used to cleave the vector so a segment of DNA between two 
sites is removed, and the vector cannot rejoin as the ends are not complementary. 
A 1X master mix (30μl) was set up for the first restriction endonuclease, EcoRI, 
consisting of: 
Buffer H        3.0μl 
BSA          0.3μl 
EcoRI         1.0μl 
dH2O         0.7μl 
Gel extraction of gene or plasmid   25.0μl 
These were left on a heating block set to 37°C for 90 minutes.  
A KpnI master mix (20μl) was set up, 1X consisting of: 
Buffer J      5.0μl 
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BSA       0.5μl 
KpnI       1.0μl 
dH2O    13.5μl 
and this was added to the 30μl EcoRI digest. These were left on the heating blocks, 
still at 37°C, for 90 minutes. 
Total volumes were loaded on 1% agarose gels, loading 3μl hyperladder I in one 
lane, and run at 120V for two hours. In a dark room, the bands were excised from 
the gel and gel extraction (see 2.2.8.5) was carried out.  
2.2.8.7 Ligation 
DNA ligase is required to form a circular DNA loop again. Vectors and inserts were 
ligated in the following way. 10μl reactions were set up: 
Rapid ligation buffer   5.0μl 
T4-DNA ligase     1.0μl 
Insert        3.0μl 
Vector        1.0μl 
Ligation was allowed to occur at room temperature for 10 minutes. In the meantime, 
polypropylene tubes were chilled on ice, and either JM109 Competent Cells or Silver 
Efficiency Competent Cells were thawed on ice. The cells were mixed by flicking 
them, and 100μl transferred to each chilled tube. The ligation reaction mixtures were 
then added to the appropriate labelled, chilled tube, and mixed by flicking. These 
were left on ice for 10 minutes. The chilled tubes were taken to a water bath which 
had been pre-heated to 42°C, and heat-shocked by immersion for 45 seconds taking 
extreme care not to shake the tubes. Immediately after this, the tubes were placed 
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on ice for 2 minutes. 900μl chilled SOC medium was added to each tube, and these 
were then incubated at 37°C in a shaker for one hour. 300μl of incubation was added 
to an appropriate antibiotic agar plate. When pEGFPC2 vector is used, kanamycin 
plates are required, and ampicillin plates for pCMV-HA vector. Sterile spreaders are 
used to plate out the mixture. The plates were returned to 37°C, first with the lids ajar 
for 20 minutes so that the plates would dry. The lids were then replaced and the 
plates were inverted and incubated at 37°C overnight. Single, individual colonies 
were selected from the agar‟s surface, and grown in LB medium. After this, 
minipreps (see 2.2.8.4.1) and maxipreps (see 2.2.8.4.2) were carried out. 
2.2.8.8 Site-Directed Mutagenesis 
The cloned wild type sequence of CDC25A must be expressed in a cell line. In order 
to compare phenotypes of the CDC25A wild type and mutant sequences, the mutant 
must be created as a construct within a plasmid, and expressed in a cell line. This is 
achieved via site-directed mutagenesis. This can be achieved using Agilent‟s 
QuikChange Lightning Site-Directed Mutagenesis Kit. Site-directed mutagenesis 
involves synthesis of the mutant strand via PCR. The DNA template is denatured, 
and the mutagenic primers are annealed (possessing the desired mutant sequence), 
extended, and incorporated with Pfu-based DNA polymerase. Dpn I is used to digest 
the template DNA, and then the resulting mutant construct is transformed into 
competent cells.  
2.2.8.8.1 PCR of Site-Directed Mutagenesis 
The volume of dH2O to be added to stock primers (from Thermo Scientific) was 
calculated, and these stocks were run through a Nanodrop ND-100UV to confirm 
concentrations and to enable working dilutions of 25ng/μl to be made. A 
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QuikChange® Lightning Site-Directed Mutagenesis Kit (stored at -20°C), was used, 
and the manufacturer‟s instructions were followed. After addition of 1μl QuikChange 
Lightning Enzyme, PCR conditions were: 
1. 2 minutes at 95°C 
2. 20 seconds at 95°C 
3. 10 seconds at 60°C 
4. 3 minutes at 68°C 
5. Stages 2-4 cycled 17 more times 
6. 5 minutes at 68°C 
2.2.8.8.2 Digest and Transformation 
2μl DpnI enzyme was added to the amplification reaction, mixed by pipetting, and 
incubated at 37°C for 5 minutes. XL-10 Gold Ultracompetent Cells were taken from -
80°C and thawed on ice. Polypropylene tubes were chilled on ice. 45μl thawed cells 
were transferred to each chilled polypropylene tube. 2μl β-mercaptoethanol was 
added to each, incubated on ice for 2 minutes, then 2μl DpnI-treated DNA was 
added. These were incubated on ice for 30 minutes. SOC medium was warmed by 
holding the bottle in a water bath heated to 42°C for 90 seconds. The tubes 
containing cells were pulse-heated in the water bath for 30 seconds. The tubes were 
then incubated on ice for 2 minutes. 500ml pre-warmed SOC medium was added, 
and the tubes incubated on a shaker set to 225-250rpm for one hour at 37°C. 250μl 
was transferred to each appropriate antibiotic-infused agar plate and spread with a 
sterile spreader. The plates were returned to the 37°C incubator with the lids ajar for 
30 minutes, and the lids were then replaced, the plates inverted, incubated 
overnight. The following day, a single, individual colony was selected, and grown in 
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LB medium (see 2.2.8.3). Then a miniprep (see 2.2.8.4.1) and maxiprep (see 
2.2.8.4.2) were carried out, followed by transfection (see 2.2.9.1.2). 
2.2.9 Functional Work 
2.2.9.1 Cell Culture 
Cell culture experiments were carried out in a Class 2 biological safety cabinet, using 
plasticware from Starstedt.  
Cells were cultured in EMEM, supplemented with10% fetal bovine serum (50ml 
aliquots stored at -20°C until required), 2% penicillin/streptomycin, and 2% L-
glutamine, in an incubator maintained at 37°C with 5% CO2. 
CRL-11421 cell line was selected for functional work because it was derived from 
human lens cells. The cells came from a lens that was surgically removed from child 
under 1 year of age, who was undergoing surgery for retinopathy of prematurity. The 
cells were then transformed with an adenovirus 12 – SV40 virus hybrid, and then this 
cell line was made commercially available. CRL-11421 is an adherent cell line which 
grows in a monolayer. 
2.2.9.1.1 Cell Storage and Thawing 
To store lower passage numbers of cell lines, a T75 flask of cells was trypsinised, 
and then transferred to a falcon using aseptic technique. The falcons were 
centrifuged at 750g for 5 minutes. The cells were resuspended in 3.6ml EMEM and 
0.4ml DMSO. 1ml volumes were transferred to cryovials, and the cells were frozen 
slowly in a vaporization chamber. They were then kept at -80°C overnight and then 
transferred to liquid nitrogen for long term storage.  
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In order to bring up a viable cell line from storage, cells were thawed inside their 
cryovials, suspending these in a 37°C waterbath. Cells were then centrifuged at 
750g for 5 minutes. The supernatant was removed, EMEM added, and the cells were 
again centrifuged at 750g for 5 minutes. This supernatant was removed. New EMEM 
was added, the cells resuspended, and transferred to a T25 flask containing 5ml 
EMEM, and incubated at 37°C. 
2.2.9.1.2 Transfection 
Transfection is a nonviral mediated method used for gene transfer. It can be used to 
introduce vectors into cells, and there are a variety of ways that this can be 
achieved. Electroporation, calcium phosphate and artificial lipid vesicles are 
commonly used. In this project, lipofectamineTM 2000 was used to transfect plasmid 
DNA into cell lines. Cells were grown to approximately 90% confluency in six well 
plates in EMEM, and then provided with glass cover slips, the medium changed to 
2ml opti-MEM, and incubated at 37°C over night. A ratio of 1:3 for DNA to 
lipofectamine concentration was calculated for wild type DNA sequence, mutant 
DNA sequence, and empty vector, so that 12μl lipofectamine would be used per well 
with 4μg DNA. Lipofectamine was incubated at room temperature with opti-MEM 
(1.5ml opti-MEM and 72μl lipofectamine for a six well plate) for 5 minutes in 
eppendorfs prior to addition of DNA. DNA (4μg in 250μl opti-MEM for each well) and 
lipofectamine/opti-MEM (1:3, made up to 250μl for each well) were combined, mixed 
by inverting several times, and incubated for 20 minutes. 500μl of the resulting 
complexes were added to each appropriate well, and incubated at 37°C for 18 hours. 
 
 
2. Materials and Methods   77 
 
2.2.9.1.3 Cell Lysis  
Cell lysis is a method which destroys the cell membrane in order to obtain the cell‟s 
contents. In this way, it is possible to acquire the protein of interest for analysis. 
Six-well plates were used to grow cells to approximately 90% confluency. The media 
was removed and cells were washed briefly with PBS, using 0.5ml per well, tilting the 
plate to allow addition via the wells‟ walls. After removal of the PBS, 50μl RIPA buffer 
(5ml 1M Tris pH8.0; 3ml 3M sodium chloride; 1ml SDS; 200μl 0.5M EDTA; 5ml 10% 
deoxycolate; 10ml 10% igepal; all made up to 100ml with H20; then 10ml transferred 
to a universal adding one tablet Complete Mini Protease Inhibitor) was added. Cells 
were removed from the bottom of the wells using a plastic cell scraper and the 
resulting suspension was transferred to relevant, labelled, 1.5ml eppendorfs for 
untransfected, wild-type transfected, mutant transfected, and empty vector 
transfected. The eppendorfs were closed and left on ice for 15 minutes to allow the 
buffer to work. These were centrifuged at 14,000rpm at 4°C for 20 minutes. The 
supernatant was transferred to new, labelled eppendorfs. This was stored at -20°C, 
or kept on ice if protein determination (see 2.2.9.2) was to be carried out immediately 
afterwards. 
2.2.9.2 Protein Determination 
This was carried out to quantify the protein content of the lysed cell samples. Serial 
dilutions of BSA protein standard in lysis buffer were set up along with lysed cell 
samples and RIPA buffer, using 5μl total volume per well. The standards were 
diluted as follows: 
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Concentration 
(mg/ml) 
BSA, 2mg/ml 
(μl) 
Lysis Buffer 
(μl) 
0.4 4.0 16.0 
0.8 8.0 12.0 
1.2 12.0 8.0 
1.6 16.0 4.0 
2.0 20.0 0.0 
Table 2.1: Protein determination results. 
These dilutions were set up in duplicate, and lysed cells samples were analysed in 
triplicate. 1ml Bio-Rad DC Protein Assay Reagent A was combined with 20μl Bio-
Rad DC Protein Assay Reagent S, and 25μl was added to each well in use, followed 
by 200μl Bio-Rad DC Protein Assay Reagent B, and this was left for 15 minutes 
before reading absorbances with Perkin Elmer Workout 2.5 Software on Perkin 
Elmer 2030 Multi Label Reader Victor x3 spectrophotometer at A690. This generated 
a standard curve of standards‟ absorbances against BSA absorbance, and used to 
determine protein concentration in lysed cell samples. 
2.2.9.3 Western Blotting 
Western blotting (or immunoblotting) is used to separate proteins in a polyacrylamide 
gel, based on size. Detergent is used to solubilise cells and the resulting lysate is 
separated with SDS-PAGE gel electrophoresis, keeping the proteins denatured. 
When current is applied, smaller proteins migrate more quickly. After transfer by 
electroblotting to a nitrocellulose or PVDF (polyvinylidene difluoride) membrane, 
antibody probes are used to detect the protein of interest. These primary antibodies 
must be able to react with SDS-solubilised proteins. Non-specific binding to the 
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membrane is prevented by blocking with proteins (such as non-fat milk in PBST). 
Labelled anti-immunoglobulin antibodies (labelled with an enzyme, usually 
horseradish peroxidise, or radioisotope), known as the secondary antibody, are then 
bound to these antibodies. This cleaves a chemiluminescent molecule, therefore 
causing luminescence, which is used to detect the protein of interest, and the signal 
strength is an indicator of protein concentration. 
Due to protein concentrations obtained during the course of this project, gels in 
Western blotting were made up to accommodate 1.5mm 10 well combs. The proteins 
in the samples, obtained from cell lysis (see 2.2.9.1.3) were separated using gel 
electrophoresis and 10% denaturing SDS polyacrylamide gel in BioRad Mini-Protean 
II Electrophoresis Units.  
The resolving gel was made up first in a 50ml falcon: 
water        4.13ml 
30% acrylamide    3.16ml 
TRIS (1.5M, pH8.8)   2.50ml 
10%SDS         100μl 
TEMED             6μl 
10% APS         100μl 
APS and TEMED cause the gel to set between two glass plates. 
The stacking gel was made up in a 50ml falcon: 
water        2.94ml 
30% acrylamide      660μl 
TRIS (0.5M, pH6.8)   1.26ml 
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X% SDS           60μl 
TEMED           10μl 
10% APS           80μl 
After the resolving gel had set, the stacking gel was poured on top, placing the comb 
carefully in the unset stacking gel between the glass plates.  
Calculations were carried out with results from protein determination to decide the 
volumes of protein sample and dye to use per well, loading 5μg protein per well. 5X 
dye was used consisting of bromophenol blue (5mg/ml) and β-mercaptoethanol in a 
ratio of 1:2. Samples combined with dye were denatured at 100°C for five minutes on 
a heating block. Alongside the samples, one well was also loaded with 3μl 
Prestained Protein Broad Range Protein Ladder. The tank was filled with 1X running 
buffer, and gels were run for one hour at 150V.  
The gel was prised from the glass plate and placed onto a piece of PDVF membrane 
(previously soaked in methanol, briefly, just before use). A sandwich for the transfer 
was set up in a tray of 1% transfer buffer (transfer buffer consisting of 150ml ethanol, 
100ml 10X transfer buffer, 750ml water) as follows: sponge, two pieces of 3mm filter 
paper, PVDF membrane (cut diagonally at one corner to facilitate recognition of 
membrane direction), gel, two pieces of filter paper, sponge. Any air bubbles were 
squeezed out. This sandwich was lifted from the tray, kept in that orientation, and 
placed onto the clear side of the cassette, and closed. The black side of the cassette 
was slotted next to the black side of the running tank. An ice pack was also placed in 
the running tank, and the tank was filled with 1% transfer buffer. The transfer was 
carried out at 100V for 75 minutes. When the transfer had taken place the 
membrane was removed from the sandwich and blocked in 5% milk (0.75g milk 
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powder and 15 ml PBST mixed thoroughly first by vortexing) for at least one hour at 
room temperature, although this could be done at 4°C overnight.  
The PVDF membrane was probed with primary antibodies specific to the protein of 
interest, diluting the antibody in 5% milk according to the required concentration. The 
membrane was incubated in primary antibody in a falcon on a tube roller for one 
hour. The membrane was washed three times, each for 5 minutes in PBST. The 
secondary antibody was made up to the required concentration (again diluted in 5% 
milk), and the membrane was incubated in this on a tube roller for one hour. The 
membrane was washed three times 5 minutes in PBST, and placed on saran wrap 
with the protein side facing up. ECL Plus Western Blotting Detection System Solution 
A (1ml) and Solution B (25μl) were mixed and used immediately, dripping the 
resulting solution onto the membrane. After 1 minute, excess ECL solution was 
dripped off, and the membrane was trapped in a new sheet of folded-over saran 
wrap. This was taped down in a hypercassette and taken to a dark room, where 
exposures of varying time intervals were taken using a SX-101A Developer, 
exploiting the chemiluminescence of the horseradish peroxidase (conjugated to the 
secondary antibody), activated by the ECL. 
If the membrane was to be reprobed, it was first stripped by boiling it in a beaker of 
water for 10 minutes, and then stored in a falcon of PBST at 4°C until required, for 
reprobing with primary antibody. 
2.2.9.4 Protein Densitometry 
Protein densitometry allows measurement of the intensity of protein staining, and 
can give a measure of how stable proteins are.  
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The PVDF membrane was stripped and reprobed using mouse monoclonal anti-HA 
clone (HA-7) 1:1000 as the primary antibody, and polyclonal rabbit anti mouse 
immunoglobulin HRP 1:2000 as the secondary antibody. 
Pictures of the membranes probed for HA were taken in the dark room, and then 
again for the same membrane when probed for actin. The images were scanned and 
the bands of staining were selected on Gene Tools software (Syngene) for spot blot 
analysis. Each band was compared to the background to discern the intensity of 
staining. The staining was normalised by dividing the value of the HA staining for the 
band by the actin staining for the band and multiplying this value by 100, and a graph 
was generated. 
2.2.9.5 Immunofluorescent Staining 
Immunofluorescent staining is the prelude to immulofluorescence microscopy. It is 
process where a protein of interest is stained with an appropriate fluorescent dye so 
that its subcellular location can be detected with a microscope. During this project, 
immunofluorescent staining was carried out after transfection of CRL-11421 cells, 
but cells were not lysed as they were for Western blotting. 
The slide mountant, ProLong Gold Antifade Reagent was removed from -20°C at the 
start of the procedure. Cells on glass coverslips in six-well plates were washed 
briefly three times in PBS, taking care to ensure that cells did not dry out, and gently 
so that the cells were not removed from the coverslips. Cells were fixed in 4% 
paraformaldehyde in PBS for 20 minutes. Cells were washed three times 5 minutes 
in PBS on a shaker. Permeabilisation of cells was achieved by immersing them in 
0.5ml 0.1% Triton X100 in PBS for 3 minutes. After this, cells were again washed 
three times 5 minutes in PBS. 1% bovine serum albumin in PBS (PBS-BSA) was 
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used to block the cells, by submersing them in this solution for 30 minutes. The glass 
cover slips were removed from the plates with forceps and transferred onto a sheet 
of hydrophobic wax and incubated with 100μl primary antibody for one hour. The 
required dilution of primary antibody was achieved by diluting stock solutions with 
PBS-BSA, as per the manufacturers‟ recommendations. The incubation was covered 
over to minimise light exposure. Coverslips were transferred to new wells and 
washed three times 5 minutes with PBS-BSA. During the washes, the required 
dilution of secondary antibody was prepared according to the manufacturers‟ 
instructions. PBS-BSA was used to block the cells, by submersing them in this 
solution for 30 minutes. The glass coverslips were removed from the plate wells with 
forceps and transferred onto a sheet of hydrophobic wax and incubated with 90μl 
secondary antibody for 45 minutes, covering them for the duration of the incubation. 
Coverslips were washed three times 5 minutes with PBS in new wells, covered with 
tin foil to exclude light. TOPRO®-3 iodide was diluted 1:1000 in PBS, and the 
coverslips were incubated with this for 2 minutes, and were then immediately 
washed three times 5 minutes with PBS, always excluding light whenever possible. 
2.5μl ProLong Gold Antifade Reagent (molecular probe) was applied to glass 
microscope slides (pipette tips were slant-cut due to the reagent‟s viscosity), towards 
the centre. The coverslips were inverted, using forceps, and mounted, avoiding 
bubbles and movement once placed in the mountant. Slides could be left overnight, 
at room temperature, in the dark, until viewed with a confocal microscope.  
2.2.9.5.1 Confocal Microscopy 
A Leica Confocal Scanning Light Microscope SP2 AOBS (Leica, Germany), with lens 
63 N/A 1.3, optical zoom 4, was used to visualise cells on the slides, and various 
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pictures of untransfected, wild-type transfected, mutant transfected, and empty 
vector transfected were taken. 
2.2.9.6 Fluorescence Activated Cell Sorting (FACS) 
Flow cytometry is used to analyse certain characteristics of microscopic particles, in 
particular, cells and chromosomes. FACS is a particular flow cytometry method used 
to separate cells labelled with fluorophores, based on their ability to scatter light and 
fluoresce. Initially, the cells pass through a fluorescence detector where the intensity 
is measured. Cells are introduced in a stream of droplets, with vibration adjusted to 
avoid more than one cell per droplet. An electrical charge can be assigned to each of 
these at this point (via a charging collar). As the droplets pass through the electrical 
deflection plates, they are sorted into separate containers, depending on whether 
they are charged or uncharged. 
Cells in six well plates, transfected at least 18 hours before (see 2.2.9.1.2) were 
taken from 37°C incubation. The trypsin-EMEM media was removed, and the cells 
were washed with PBS. 200μl trypsin was added and the plate was returned to 37°C 
for 2 minutes. After this, 2ml media was added to inactivate the trypsin. The 
transfected cells were removed from the wells with plastic scrapers and transferred 
to appropriately labelled falcons. Centrifugation was carried out at 1250rpm for 5 
minutes at 4°C. The supernatant was removed and discarded. 1ml PBS was added 
to each tube. The cells were resuspended by pipetting, and centrifuged again. The 
supernatant was removed again, taking care not to disturb the pellet. 1ml cold 70% 
ethanol was added drop by drop, whilst vortexing, to each falcon. The tubes were left 
on ice for 30 minutes. These were then centrifuged at 6000rpm for 5 minutes. The 
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supernatant was removed, 1ml PBS added, the cells resuspended, and centrifuged 
again. 
30μl PI and 30μl RNase A were added to 3ml PBS. 500μl of this was added to half of 
the tubes. To the other half, 500μl of 30μl RNase A in 3ml PBS was added. The 
tubes were left at room temperature in the dark for 30 minutes. They were then 
processed on the Flow Cytometer, and results were analysed with FlowJo software 
to produce histograms. Gates were put on FSC (forward scatter) and SSC (side 
scatter) to separate debris from the selection. FSC corresponds to cell volume, and 
SSC corresponds to aspects of cell structure. Gates were put on FL3-H vs FL2-A to 
remove doublets. 
  
 
 
 
 
 
 
 
Chapter 3 
SYNDROMIC CATARACT FAMILIES 
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3. SYNDROMIC CATARACT FAMILIES 
3.1 CEREBROTENDINOUS XANTHOMATOSIS (CTX) 
3.1.1 Introduction 
Cerebrotendinous Xanthomatosis (CTX; MIM 213700) is a disorder resulting from 
defective lipid-storage metabolism. It is rare, and inherited in an autosomal recessive 
manner. The clinical features include juvenile cataracts, tendon xanthomatosis and 
premature atherosclerosis. Abnormally large cholesterol and cholestanol deposits 
are found in most tissues during autopsy. Cerebellar ataxia usually manifests as the 
first stage of the progressive neurological degeneration that is a characteristic of 
CTX. There is a pseudobulbar stage, foreshadowing imminent death. CTX is 
clinically heterogeneous. It is often the case that characteristic features such as 
cataracts may not be present before neurological degeneration becomes apparent. 
The first report of CTX was made in 1937, when affected cousins in their 30s were 
found to have cataracts, tendon xanthoma, xanthelasmata, and mental degeneration 
(Van Bogaert et al, 1937). Symptoms became apparent at ages 12-13. When 
autopsies were performed, the cousins were found to have deposits in the 
cerebellum‟s white matter and the cerebral peduncles.  
Mutations in the gene cytochrome P450, family 27, subfamily A, polypeptide 1, 
CYP27A1, on chromosome 2q35, are responsible for CTX (Cali et al, 1991b). It is 
expressed in the brain, lung, liver, skin, small intestine, and numerous other tissues. 
CYP27A1 is a nine exon gene, with parts of exon 1 and exon 9 being non-coding, 
giving a translation length of 531 amino acid residues. Cali‟s group identified a 
cysteine residue instead of the wild type arginine at position 446, and at position 362, 
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in two unrelated CTX patients. CYP27A1 encodes sterol 27-hydroxylase (CYP27), a 
mitochondrial cytochrome P-450 enzyme. It is an integral component of the bile acid 
synthesis pathway. CYP27 converts cholesterol to cholic acid and chenodeoxycholic 
acid, which is the initial stage in side chain oxidation of sterol intermediates (Cali et 
al, 1991a). Cholic acid and chenodeoxycholic acid form part of a feedback loop, 
inhibiting cholesterol production, so in individuals with homozygous CYP27A1 
mutations, this leads to increased serum cholestanol levels. This is one 
characteristic tested for, diagnostically, along with a urine test. Individuals with CTX 
have higher levels of bile acids in their urine. A diagnosis can be made by showing 
evidence of elevated serum cholestanol and tendon xanthoma. 
Early identification of CTX is vital, since disease progression can be slowed or halted 
by treatment with bile acids (Salen et al, 1975). 
Aims: To identify the gene and pathogenic mutation responsible for cataracts 
in this family. 
3.1.2 Patient DNA 
A consanguineous family from Bangladesh presented with cataracts and learning 
difficulties (Figure 3.1). Since learning difficulties are often seen within the general 
population, the cataracts were initially classed as a non-syndromic anomaly. During 
this project, a mutation which segregated with disease phenotype was found in 
CYP27A1. This led to further clinical investigation, so that a diagnosis of CTX could 
be made for affected individuals.  
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Figure 3.1: Pedigree of the Bangladeshi family that presented with cataracts and 
learning difficulties. 
 
An incomplete medical history was made available. There was no information on the 
father (I:1). The mother (I:2) had questionable developmental delay, due to not 
having learnt Bengali or English until she was 3, but this could be due to changing 
country of residence. She had no cataracts. Affected child II:1 had developmental 
delay and bilateral pulverulent cataracts. He received lens implants at age 15 (right 
eye) and age 16 (left eye). His sister II:2 had developmental delay and learning 
difficulties. She presented with bilateral pulverulent cataracts, and received lens 
implants at age 14 (right eye) and age 15 (left eye). Affected child II:4 had bilateral 
pulverulent cataracts and learning difficulties. Visual acuity of 6/18 was noted in the 
right eye, and 6/9 in the left eye. An orthoptic examination of unaffected sibling II:7 
revealed a visual acuity of 6/6 and was reported to have learning difficulties. The 
youngest sibling, II:8, had global developmental delay, microcephaly, hypotonia, 
hyperextensibility of the joints, and possibly had learning difficulties. There was no 
noted evidence of cataracts. The eldest child (not shown on the pedigree) died from 
gastroenteritis in Bangladesh, aged 1 year. There were three siblings (II:3, II:5 and 
II:6) without pathological findings. At this stage, it was uncertain if the cataracts and 
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developmental delay were a single condition with variable expression or if they were 
the result of different conditions.  
3.1.3 Previous Work 
DNA was available for all members of the family who were shown in the pedigree. 
Genome wide linkage analysis was carried out using 250K Affymetrix SNP 
Microarray, by Fatimah Rahman. Three continuous homozygous regions were found, 
as listed in the Table 3.1. 
Chromosome Location Size(Mb) 
((M(Mb) 
2 218,994,785-222,589,683 3.6 
6 107,406,110-127,463,213 20.0 
16 31,511,273-47,017,059 (including centromere) 15.5 
Table 3.1: Homozygous regions detected in the Bangladeshi family. 
 
Linkage analysis was performed by Dr Esther Meyer using microsatellite markers 
located within regions of apparent homozygosity.  
The 3.6Mb region on chromosome 2 from 218,994,785 to 222,589,683 contained the 
crystallin gene, crystallin beta A2, CRYBA2 (219,556,371-219,563,156). Since many 
other crystallin genes are known to be involved in cataractogeneis when mutated, 
CRYBA2 was prioritized as a candidate gene. It was amplified using the primers 
listed in Table 3.2, and then sequenced. No mutations were found. 
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3.1.4 Molecular Genetic Methods 
Genes in the region on chromosome 2 were prioritised for sequencing if they were 
known to be expressed in the eye and/or lens, and if they had previously been 
reported to have a role in cataract formation. After primer optimisation with control 
DNA, DNA from the unaffected father (I:1) and affected child (II:1) was sequenced in 
order to identify any pathogenic changes.  
3.1.4.1 Prioritised Candidate Genes 
3.1.4.1.1 Indian Hedgehog (IHH) 
IHH (Indian hedgehog homolog) is a three exon gene, the third of which is partially 
non-coding, giving a translation length of 411 residues. It is found on chromosome 
2q33-35, and is expressed in the eye and lens, as well as the colon. It is also 
expressed in the kidney and liver (Marigo et al, 1995). There are no reports of IHH 
mutations causing cataracts, but there have been reports of involvement in 
brachydactyly (Gao et al, 2001) and acrocapitofemoral dysplasia (Hellemans et al, 
2003). IHH has a role in cartilage differentiation, acts in the hedgehog signalling 
pathway, cholesterol binding, cell-cell signalling and cellular maturation. 
Primers were designed and optimised for all three exons (Table 6.2), but were not 
sequenced due to results obtained when sequencing CYP27A1 (discussed below).  
3.1.4.1.2 Inhibin Alpha (INHA) 
INHA (inhibin, alpha) is a two exon gene on chromosome 2q33-q36, with non-coding 
sections of both, having a translation length of 366 amino acids. It is expressed in 
the eye, brain and other tissues. There is no known association between cataracts 
and INHA. This gene has been demonstrated to play a role in tumour suppression in 
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poorly differentiated prostate tumours. INHA promoter hypermethylation and loss of 
heterozygosity in 42% of prostrate carcinomas implicates this gene in tumours 
(Schmitt et al, 2002). 
Primer (Tabe 6.3) optimisation was carried out with control DNA, but family DNA was 
not sequenced due to CYP27A1 results. 
3.1.4.1.3 Tubulin Alpha 4a (TUBA4A) 
The tubulin alpha-4A gene, TUBA4A, is located on chromosome 2q36.1, spanning 
2853kb of DNA. There are three transcripts, all sharing a 223bp second exon and 
149bp third exon, with a non-coding first exon. Two transcripts have 4 exons, and 
the other has five, containing the same sequence, but split over two exons, with a 4 
bp intron. It is expressed in the eye, as well as the brain, testis and tonsils. There is a 
pseudogene, TUBA4B, on 2q36. 
The tubulins are a family of genes, mostly comprised of pseudogenes. They make 
up microtubules, which are then involved in movement and mitosis (Lewis and 
Cowan, 1990). 
All exons were amplified with control DNA, using the primers and conditions listed in 
Table 6.4. 
3.1.4.1.4 Wingless-type MMTV Integration Site Family Member 10A (WNT10A) 
The wingless-type MMTV (mouse mammary tumour virus) integration site family, 
member 10A gene, WNT10A, is located on chromosome 2q35, consisting of four 
exons. Expression has been noted in the lens, eye, prostate and placenta.  
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WNT gene family products are signalling proteins, many of which are said to be 
oncogenes. WNT10A overexpression has been noted in human carcinoma lines, for 
example in HL-60, derived from promyelocytic leukaemia (Kirikoshi et al, 2001). 
A WNT10A mutation has also been associated with odono-onycho-dermal dysplasia. 
A premature stop codon (Glu233X) was detected in affected members from three 
families, causing the protein to consist of 232 amino acids instead of 417 (Adaimy et 
al, 2007). 
The first exon could not be amplified using the primer pair WNT10A-1F and 1R. All 
other exons were amplified with control DNA (Table 6.5). 
3.1.4.1.5 Cytochrome P450 Family 27 Subfamily A Polypeptide 1 (CYP27A1) 
This gene lies within the region identified through linkage analysis on chromosome 2. 
It was selected as a suitable candidate gene due to its known involvement in CTX, 
and hence cataractogenesis, when mutations are present. This gene was amplified 
by the primers listed in Table 3.7. 
 
3.1.5 Results 
CYP27A1 was considered to be the best candidate gene, due to its known 
involvement in cataractogenesis in CTX. Since a mutation, which segregated with 
cataract status, was identified, sequencing of the remaining candidate genes was not 
necessary. Direct sequencing of CYP27A1 revealed a substitution of a guanine to an 
adenine at the first base in intron 6 (c.1184+1G>A, NM_000784.3; Figure 3.2). The 
mutation was predicted to affect a splice site and therefore the precise consequence 
of this change on protein level is difficult to establish.  
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  A. Father (I:1)     B. Affected child (II:1)        C. Control 
Figure 3.2: Sequencing results illustrating the splice site mutation in intron 6 of 
CYP27A1.A. The father (I:1) is heterozygous A/G. B.The affected child (II:1) is 
homozygous G/G for the mutation. C. The sequence for the control is G/G. 
 
The other family members were then sequenced and the results are shown in Table 
3.2.  
Family Member Cataracts Genotype 
I:1 (father) no A/G 
I:2 (mother) no A/G 
II:1 yes A/A 
II:2 yes A/A 
II:3 no G/G 
II:4 yes A/A 
II:5 no A/G 
II:6 no G/G 
II:7 no G/G 
II:8 no A/G 
Table 3.2: Results of sequencing of CYP27A1 gene in Bangladeshi family. 
 
The mutation was not detected in 454 ethnically matched control chromosomes, 
which all showed wild type G at the intronic splice site.  
3.1.6 Discussion 
A family was referred for analysis, described as a non-syndromic cataract family. 
Cholestanol tests had not been done on the family by clinicians at this time. 
Molecular genetic analysis results indicated that a diagnosis of CTX may be 
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accurate. Cholestanol testing was carried out for some of the family members, with 
the results summarised in Table 3.3, confirming a diagnosis of CTX for affected 
members. 
Family Member Cataracts Genotype Cholestanol Level 
II:1 yes A/A 129 
II:2 yes A/A 62 
II:4 yes A/A 79 
II:5 no A/G 6 
II:6 no G/G 6 
Table 3.3: Cholestanol test results. 
 
The results for affected children II:1, II:2, and II:4 are classed as high, whereas the 
results for unaffected children II:5 and II:6 are normal cholestanol levels.  
A possible effect of the mutation c.1184+1G>A is the insertion of intron 6 or the 
splicing out of exon 6, therefore leading to a change in protein sequence.  
Due to the absence of alleles with genotype A in the first base in intron 6 of 
CYP27A1 in all 454 ethnically matched control chromosomes, it is even more likely 
that the change is pathogenic, and causes CTX within this family. 
A number of other mutations in CYP27A1, associated with CTX, have been 
described, including substitution, deletion, and splice site mutations. Shiga et al 
(1999) identified a splice site mutation in a Japanese family with CTX. The 39 year 
old male proband with first cousin parents presented with tendon xanthomas, ataxia, 
and mental retardation. His serum cholestanol level was 37.5μg/ml. A sequence 
change from G to A at the first nucleotide in intron 7 was detected, causing skipping 
of exon 7. This was observed in patient cDNA, where exon 8 directly followed exon 
6. The proband was homozygous for this mutation, whereas all other family 
members were heterozygous. Transcripts from blood leukocytes were analysed, 
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revealing truncated transcripts alone in the patient, while the unaffected silblings had 
normal and truncated transcripts. 
It has been noted that the first two nucleotides at splice donor sites (GT) are highly 
conserved amongst many eukaryotes (Padgett et al, 1986), and mutations at this 
location can disrupt splicing, since the 5' GT sequence facilitates cleavage and 3' 
splice site exon joining (Aebi et al, 1986). 
The Bangladeshi family is an important clinical case because it was referred as a 
non-syndromic cataract family, but has been shown to be CTX, of which, cataracts 
are a feature. CTX manifests with variable phenotype, so clinicians should test for 
mutations in this gene to confirm or exclude CTX diagnosis in individuals that 
present with congenital and juvenile cataracts, especially those who also have 
learning difficulties. It highlights the importance of evaluating if CTX is an appropriate 
diagnosis since the condition can be treated if identified before irreversible brain 
damage. This finding shows the validity of autozygosity mapping and positional 
candidate gene identification to find causative mutations, even when the aetiology of 
the condition and diagnosis are uncertain.  
 
3.2 MARINESCO-SJÖGREN SYNDROME (MSS) 
3.2.1 Introduction 
3.2.1.1 Marinesco-Sjögren Syndrome (MSS) 
Marinesco-Sjögren Syndrome (MSS; OMIM #248800) is a rare autosomal recessive 
condition. It is of particular relevance to this study, as sufferers present with 
congenital bilateral cataracts. A diagnosis is made based on clinical symptoms and 
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brain MRI. Its mandatory features include cerebellar ataxia as a result of cerebellar 
atrophy, demonstrating decreased numbers of Purkinje fibres and granular cells. 
Muscle is gradually replaced by fat and connective tissue. Fibre size varies. There 
are atrophic and necrotic myofibres, rimmed vacuoles, and autophagic vacuoles with 
membranous whirls (Anttonen et al, 2005). Most MSS sufferers have dysarthia, short 
stature, developmental delay and mental retardation. Other symptoms include 
skeletal abnormalities, such as pigeon chest, and hypergonadotropic hypogonadism. 
Serum creatine kinase levels are often elevated.  
Under the electron microscope, lysosomes can be seen to have whorled lamellar or 
amorphous inclusion bodies (Walker et al, 1985).This was observed in four affected 
individuals, from two nonconsanguineous families, one of Sicilian and Irish descent, 
and a family consisting of a “nonconsanguineous black couple” and their offspring. 
When conjunctival biopsies were conducted, elevated numbers of lysosomes in 
fibroblasts were found in six patients displaying typical MSS symptoms of congenital 
cataracts, mental retardation, delayed motor development and cerebellar ataxia 
(Zimmer et al, 1992). Vacuolar degeneration and abnormal mitochondria were also 
noted.  
MSS has been linked to mutations in the gene SIL1 homolog endoplasmic reticulum 
chaperone, SIL1, on chromosome 5q31. Using DNA from a Finnish family with 
individuals with MSS, a 3.52Mb region on chromosome 5 was identified, which was 
then narrowed down to a 1.98Mb region between D5S500 and D5S2116 when 
haplotype analysis was conducted with two Swedish affected individuals (Anttonen 
et al 2005). This group identified a homozygous four-nucleotide duplication 
(c.506_509dupAAGA) in exon 6 of SIL1 in the Finnish individuals, and the Swedish 
individuals were found to be compound heterozygotes, having the duplication found 
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in the Finnish individuals, and an intron 6 donor splice site mutation (c.645+2T>C). 
RT-PCR showed the duplication transcript to be of the expected 461 residues, but 
there were two shorter transcripts as a result of the splice site mutation. The shortest 
demonstrated higher expression, and a 64 amino acid in-frame deletion. The 
duplication was again detected as a homozygous mutation in a Norwegian family by 
this group, segregating with disease phenotype. In 96 Finnish controls, one carrier of 
the duplication mutation was detected. The group noted that exon 6 of SIL1 is 
serine-rich, and that this could be an indication of encoded phosphorylation sites 
(Anttonen et al, 2005). 
3.2.1.2 SIL1 
The protein coded for by SIL1 is a 54kD ER glycoprotein nucleotide exchange factor 
for HSP70 chaperone HSPA5. SIL1 (SIL1 homolog, endoplasmic reticulum 
chaperone (S. cerevisiae) gene), located on 5q31, spans 346.83kb. It is ubiquitously 
expressed (Senderek et al, 2005). SIL1 was cloned via yeast two-hybrid screening of 
a liver cDNA library and database screening, and found to contain an N-terminal ER 
targeting sequence, two putative N-glycosylation sites, and a C-terminal ER retention 
signal (Chung et al, 2002). 
Not all individuals diagnosed with MSS are found to have a SIL1 mutation, perhaps 
demonstrating its genetic heterogeneity, although non-coding mutations could be 
causative.    
 
 
3. Syndromic Cataract Families  99 
3.2.1.3 Cataract, Congenital, with Facial Dysmorphism and Neuropathy 
(CCFDN) 
CCFDN is considered to be distinct from MSS, even though there are many common 
features. Merlini‟s group looked at two members of a consanguineous Italian Gypsy 
kindred with MSS (Merlini et al, 2002). They had congenital cataracts, delayed motor 
development, ataxia. One patient also had acute recurrent myoglobinuria. This report 
argued that MSS with myoglobinuria, peripheral neuropathy, and CCFDN result from 
a common founder mutation. Using haplotype analysis with the Italian Gypsy kindred 
and a German family with MSS described elsewhere (Muller-Felber et al, 1998), 
Merlini‟s group showed segregation of MSS with demyelating neuropathy and 
myoglobinuria with the CCFDN region. 
CCFDN causative mutations have been found in the CTDP1 gene (C-terminal 
domain of RNA polymerase II subunit A, a phosphatase of, subunit 1) on 
chromosome 18q23. It codes for FCP1, a protein phosphatase, which is a vital part 
of eukaryotic transcription machinery. A C>T substitution in intron 6 of CTDP1 
caused aberrant splicing so that an Alu insertion was present in processed mRNA, 
and the T allele segregated with disease phenotype in 52 families with 85 affected 
members (Varon et al, 2003). 
3.2.2 Patient DNA 
DNA was available from two families with MSS.  
Family 1 is a consanguineous Pakistani family (Figure 3.3). The two identical twin 
daughters, II:1 and II:2, have cerebellar hypoplasia, and developed cataracts in the 
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fourth year of life. Their sister II:3 is unaffected, and the youngest brother II:4 
presented with cerebellar hypoplasia, but is yet to develop cataracts. 
 
Figure 3.3: Pedigree of Pakistani family 1 with MSS. 
 
Family 2 is of Pakistani origin (Figure 3.4). The proband, the eldest daughter II:1 
presented at Birmingham Women‟s Hospital at eight months of age, and was found 
to have a structural brain anomaly, Dandy Walker variant, after MRI. She had 
bilateral cataracts, hypoplasia of the cerebellum, hypoplastic cerebellar vermis, 
global developmental delay, learning difficulties, convergent squint and nystagmus. 
The cataracts were described as “rapidly progressing intumescent cataracts”. The 
right lens was removed and replaced with an intraocular implant, and a dense white 
cataract was observed in the left eye. Ultrasound was used to determine that there 
was no retinal detachment.  
The brother, II:3, presented with hypoplasia of the cerebellum and hypoplastic 
cerebellar vermis. His lenses were clear but a sub-clinical lens change was noted. 
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He had hypermetrophic astigmatism, gross motor delay, nystagmus and a flattened 
occiput. In the brain, there was evidence of atrophy of the posterior fossa contents.  
Due to these clinical observations, a “likely” diagnosis of MSS was given. 
 
Figure 3.4: Pedigree of Pakistani family 2 with MSS. 
 
3.2.4 Molecular Genetics Methods 
Since SIL1 mutations are associated with MSS, this gene was selected for initial 
molecular genetic analysis of DNA from all members of family 1 and family 2. Table 
3.10 lists primers which were designed, and the PCR conditions used to amplify the 
coding exons of SIL1 in Families 1 and 2. Sequencing was then carried out, as 
detailed in Chapter 2.  
3.2.5 Results 
Previous work carried out in the Birmingham Laboratory did not demonstrate linkage 
to the region on 5q31 in family 1, using microsatellite markers. In this project, the 
coding exons were amplified, but no mutations were found in the coding regions of 
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SIL1 in Family 1, highlighting the genetic heterogeneity of MSS. SIL1 interacts with 
HSPA5 (Anttonen et al, 2005), so markers flanking HSPA5 on chromosome 9 were 
chosen, from 126,928,403 to 136,324,922. No common homozygous regions for 
affected individuals were found (Figure 3.5). It is unlikely that mutations in HSPA5 
are responsible for the apparent MSS symptoms in this family.  
 
Figure 3.5: Linkage analysis for microsatellite markers flanking HSPA5 on 
chromosome 9 
 
Since mutations in CTDP1 (18:77,439,801-77,514,510 on GRCh37) have been 
implicated in CCFDN, a syndrome where symptoms are very similar to those of 
MSS, in-lab microsatellite markers near CTDP1 were analysed, from 75,615,199 to 
75,615,267. D18S1095 (at 75,319,246) and RH55591 (at 75,538,273) could not be 
optimised, and other markers selected for analysis were non-informative (Figure 
3.6). 
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Figure 3.6: Linkage analysis for microsatellite markers in the vicinity of CTDP1 on 
chromosome 18. 
 
In Family 2, a mutation was found when sequencing exon 11 of SIL1. There was a 
C>T substitution (c.1126C>T, NM_001037633.1; Figure 3.7), causing glutamine to 
be substituted for a stop codon (p.Gln376X), predicted to result in the loss of 86 
amino acids.  
                                   
Figure 3.7: c.1126C>T in exon 11 of SIL1. On the left, is the sequencing result for 
the mother of the family, showing that she is heterozygous for both the T and C 
allele. On the right is the sequencing result for the eldest affected daughter, showing 
that she is homozygous for the mutant T allele. 
 
Controls were not sequenced for this change in this family because mutations in 
SIL1 are known to be responsible for MSS, and this is a nonsense mutation.  
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3.2.6 Discussion 
A mutation in SIL1 was identified in Family 2. Since the stop codon will cause the 
loss of 86 amino acids, it is likely that this is the mutation responsible for the MSS in 
affected individuals. Other nonsense mutations in SIL1 have been described. 
Arg111Ter has been noted in an Iranian family and a Turkish family (Senderek et al, 
2005) . This mutation was also found in another Turkish family with MSS, where 
affected individuals had cataracts from 4 years of age (Anttonen et al, 2005). 
In a Japanese family with  three members affected with MSS, Takahata et al (2010) 
identified two novel mutations. One mutation was a 5bp homozygous deletion, 
del598-602(GAAGA), in exon 6 of all affected individuals. The father demonstrated 
heterozygosity for this mutation, but sequencing of the mother's DNA reveal this 
mutation. A ~58kb deletion in exon 6 was detected in the mother and the three 
affected individuals by array comparative genomic hybridisation and quantitative 
PCR. The mother was hemizygous for this deletion. All three affected individuals had 
both deletion mutations. With this in mind, some cases of MSS with unclear genetic 
basis after sequencing coding regions of SIL1 might not be explained by locus 
heterogeneity. Instead, deletions may be responsible. 
Intronic substitutions have been associated with MSS, but so far, only alterations 
within the splice site have been found. The substitution c.1029+1G>A causes exon 9 
skipping in affected members of a Bosnian family, and c.645+1G>A causes exon 6 
skipping in a Turkish family (Senderek et al, 2005).  
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It is possible that a dominant intronic mutation is responsible for MSS in Family 1, 
even though to date there are no reports of dominant causative mutations, and 
extensive analysis with PCR and sequencing would be required to confirm or 
exclude this possibility. 
 
 
3.3 KNOBLOCH SYNDROME 
3.3.1 Introduction 
This syndrome was first described in 1971 (Knobloch and Layer, 1971). It is a rare 
autosomal recessive disorder showing clinical heterogeneity, characterized by high 
myopia, vitreoretinal degeneration with retinal detachment, and occipital 
encephalocele. Other features accompanying the syndrome can include cataracts, 
subluxation of the lens, atypical palmar creasing, scalp defect, lung hypoplasia, 
flattened nasal bridge, joint hyperextensibility, unilateral duplicated renal collecting 
system and cardiac dextroversion (Cook et al, 1982, Czeizel et al, 1992, Passos-
Bueno et al, 1994, Suzuki et al, 2002). Affected individuals experience progressive 
and irreversible loss of vision. Intelligence is normal.  
Knobloch Syndrome was first noted in a family with 5 affected siblings (Knobloch and 
Layer, 1971). Although encephalocele is considered a characteristic feature of the 
syndrome, in some cases, congenital occipital scalp defects can be seen (Seaver et 
al, 1993). 
Homozygosity mapping in a Brazilian family allowed a locus for Knobloch Syndrome 
to be mapped to a 4.3cM region on chromosome 21q22.3 (Sertie et al, 1993). A 
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splice site mutation was identified in the gene collagen type XVIII alpha 1, COL18A1, 
in this Brazilian family and in families from Hungary (Menzel et al, 2004). In the 
Hungarian families, one mutation was a 1bp insertion leading to a frameshift and 
premature stop codon, and the second was an amino acid substitution (Asp104Asn) 
of a conserved aspartic acid residue. Mutations in the COL18A1 gene giving rise to 
Knobloch Syndrome are said to cause Knobloch Syndrome Type 1 (KNO1). At 
present, 17 different COL18A1 mutations have been described in 19 families.  
A second locus for Knobloch Syndrome was reported for a family from New Zealand 
who presented with features of the syndrome, but did not show linkage to COL18A1 
(Menzel et al, 2004). This unidentified locus has been designated KNO2.  
Aims: To prioritise genes in the region between D17S1532 and D17S798 for 
sequencing, in order to identify any pathogenic mutations.  
3.3.2 Patient DNA 
A consanguineous Pakistani family shown in the pedigree presented with features 
associated with Knobloch Syndrome, at the Al-Shifa Trust Eye Hospital, Rawalpindi, 
Pakistan (Figure 3.9). Peripheral blood samples were obtained, after informed 
consent, from all family members. The standard phenol chloroform extraction 
procedure was used to obtain genomic DNA. A childhood history was obtained from 
parents of affected children. Affected individuals displayed high myopia with severe 
nystagmus, vitreoretinal degeneration and occipital scalp defect (Khaliq et al, 2007). 
At birth, the scalp defect was described as a swollen purple-red hairless area, and 
over time, this decreased in size and became firmer. Nightblindness became 
apparent between ages 2 to 4 years, degenerating to total blindness between 17 to 
18 years. Three patients (V:1, V:7 and V:8) did not show occipital encephalocele on 
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brain imaging scans. There was mild attenuation of the retinal vasculature. Choroidal 
sclerosis with chorioretinal atrophy was observed. Cataract, lens subluxation, 
glaucoma and phthisis bulbi were also noted. Unlike classic Knobloch Syndrome, no 
retinal detachment was noted in this family, and the scalp defect was the only 
extraocular anomaly observed. 
 
Figure 3.8: Pedigree of family, with * indicating family members for whom DNA was 
available. 
 
D08.23732 is an additional “singleton”, from a Caucasian family, who presented with 
Knobloch Syndrome. A DNA sample was obtained, but no other clinical information 
was available for this individual. 
3.3.3 Previous Work 
Initial mapping was carried out in Pakistan, in Professor Qasim Mehdi‟s laboratory. 
Linkage analysis to 17q11.2 was confirmed in the Medical and Molecular Genetics 
laboratory in Birmingham by Dominic White, with a maximum lod score of 3.40 
(θ=0.00) at markers D17S1307 and D17S1166. A minimum candidate region of 
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2.82cM (2.606Mb) was detected between markers D171532 and D 17S798. It 
contained 43 genes, and this was thought to include the putative KNO3 locus. 
Dominic White undertook sequencing of candidate genes MYO1D and RAB11-FIP4, 
and Professor Mehdi‟s laboratory sequenced UNC119 but no putative mutations 
were identified. 
3.3.4 Molecular Genetic Methods 
Genes were prioritised for sequencing depending on expression data available at the 
databases AceView (http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/) and 
Genatlas (http://www.dsi.univ-paris5.fr/genatlas/). Those with evidence of expression 
in the lens and/or eye were chosen. Genes were sequenced as described in the 
Materials and Methods chapter. Both forward and reverse primers were designed for 
coding exons of the genes C17orf42, RNF135, OMG, EVI2A and EVI2B, ensuring 
that they were within the introns, or outside the gene. DNA from family members IV:4 
and V:8 was used initially for genotyping. If the mother, IV:4, was found to be 
heterozygous, and the affected child, V:8, homozygous for an atypical sequence, the 
other family members were sequenced to see if the homozygous mutant allele 
segregated with disease phenotype. PCR products were sequenced in both the 
forward and the reverse direction.  
3.3.5 Results 
The region on 17q11.2 contains 26 known genes, according to UCSC 
(http://genome.ucsc.edu/).  
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3.3.5.1 Chromosome 17 Open Reading Frame 42 (C17orf42) 
This gene, chromosome 17 open reading frame 42 (C17orf42) is expressed in the 
eye, as well as in the small intestine, brain and lung. Its function is unknown. 
C17orf42 consists of four exons, and 360 translated residues.  
A known SNP (rs28539246) was identified in exon 3 of C17orf42. This fragment was 
sequenced in all family members for whom DNA was available (Table 3.4). 
Family Member 
mEMMememMe
mber 
Status Genotype 
IV:1 Unaffected T/T 
IV:2 Unaffected T/A 
V:1 Affected T/A 
V:2 Unaffected T/T 
IV:3 Unaffected T/T 
IV:4 Unaffected T/A 
V:5 Unaffected T/A 
V:7 Affected T/T 
V:8 Affected T/T 
Table 3:4:  rs28539246 segregation in Pakistani family with Knobloch syndrome. 
 
If this region segregated with disease status, it would be expected that affected 
individuals would have the same homozygous genotype. 
3.3.5.2 Oligodendrocyte Myelin Glycoprotein (OMG) 
OMG, the oligodendrocyte myelin glycoprotein gene, consists of two exons, the first 
of which is non-coding. The translation length is 44 residues. It lies within the first 
exon of NF1, but is transcribed from the opposite strand. It is expressed in the lens 
and eye, as well as in the brain and lung. The protein product plays a role in CNS 
myelination, potentiating neurite outgrowth inhibition (it is a NOGO- neurite 
outgrowth inhibitor- receptor ligand) and in axonal regeneration after brain injury.  
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A non-pathogenic change was found, rs11655238, where IV:4 was heterozygous 
T/C and the affected child V:8 was homozygous T/T. This is a SNP and does not 
disprove linkage. 
3.3.5.3 Ecotropic Viral Integration Site 2A (EVI2A) 
EVI2A, ectropic viral integration site 2A, is thought to be an oncogene in retrovirus-
induced myeloid tumours. There are three different transcripts, only one of which 
contains an initial non-coding exon. It is located within intron 1 of NF1, but is 
transcribed on the opposite strand. There is evidence of expression in the eye, as 
well as in the brain, lung, spleen, kidney and uterus.  
No sequence alterations were detected in I:4 and II:5. 
3.3.5.4 Ecotropic Viral Integration Site 2B (EVI2B) 
EVI2B, ectropic viral integration site 2B is a two exon gene, the first of which is non-
coding. It is thought to have a role in melanocyte and keratinocyte differentiation. 
The protein product is thought to be proline rich and consist of 448 amino acids. 
Again, it lies within intron 1 of NF1, but is transcribed from the opposite strand. It is 
expressed in the eye, along with the brain, lung, spleen, kidney and uterus.  
Two sequence variations were identified in exon 2 of EVI2B. The first was a coding 
SNP, rs12942186, where IV:4 was heterozygous G/A, and V:8 was homozygous 
G/G. The second was a 15bp deletion (del_TTTTAAAAAAAGTTA) in the non-coding 
region of the exon that the mother, I:4 was heterozygous for. The deletion was not 
evident in the sequencing results from II:5, the affected child.  
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3.3.5.5 Ring Finger Protein 135 (RNF135) 
RNF135, the ring finger protein 135 gene, is expressed in the eye, as well as the 
lung, brain, prostate, kidney and placenta. It falls within the region of NF1 commonly 
deleted in neurofibromatosis. The protein product has a role in ubiquitin ligase 
activity, and possibly in protein-protein interactions. There are two transcripts for this 
gene. The first consists of five exons, the first and fifth being partially non-coding. 
The transcript contains 432 amino acid residues. The second transcript consists of 
four exons, lacking the third 163bp coding exon found in the first transcript. The first 
and fourth exons are partially non-coding, and the transcript has a length of 210 
amino acids. Mutations in this gene have been associated with Overgrowth 
Syndrome, where symptoms include macrophthalmia, myopia, learning disabilities, 
facial dysmorphism and hearing loss (Douglas et al, 2007).  
A previously unreported change, c.299A>G (NG_011701.1), was found in this gene 
at amino acid position 100, causing a histidine residue to be substituted for an 
arginine residue. Initially, only DNA from IV:4 and V:8 was sequenced, and the 
change was found to be “possibly damaging” when using Polyphen 
(http://genetics.bwh.harvard.edu/pph/). The other family members were then 
sequenced, but the change did not segregate with disease phenotype (Table 3.5). 
Family Member Status Genotype 
IV:1 Unaffected A/G 
IV:2 Unaffected A/G 
V:1 Affected A/G 
V:2 Unaffected A/A 
IV:3 Unaffected A/G 
IV:4 Unaffected A/G 
V:5 Unaffected A/A 
V:7 Affected G/G 
V:8 Affected G/G 
Table 3.5: Results of sequencing the novel change in RNF135. 
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In V:8, heterozygous missense substitutions were also noted in RNF135, 
g.[39C>T;40C>A], c.[-13C>T;-12C>A] . 
In light of the identification of SNPs rs28539246 at 26,250,127 in C17orf42, and of  
c.299A>G in RNF135, which did not segregate with disease phenotype, it seemed 
unlikely that the gene causing the Knobloch-like Syndrome will be found in this 
segment of the region. This narrowed down the candidate region identified by 
previous efforts, so the remaining region spanned from 26,351,053 to 28,292,780 on 
chromosome 17, a region of around 1.9Mb (according to March 2006 Build, 
NCBI36/hg18). 
It was possible that a good candidate region was missed when the initial genome 
wide scan was undertaken, so affected individuals V:1, V:7 and V:8 were analysed 
by Louise Tee, using Affymetrix GeneChip Human Mapping 250K SNP Sty1 Array to 
see if a better candidate region can be identified. It was possible that a better 
candidate region was missed because the initial linkage study was conducted using 
a genome wide scan and microsatellite markers at 10-20cM intervals. The SNP Chip 
has been developed since this time, offering a more accurate picture due to its 
higher resolution. Homozygous regions in the three affected individuals were 
identified, including one that contained COL18A1 (NM_130445.2), the original gene 
cited as being involved in Knobloch Syndrome. This region spanned 2.4Mb on 
chromosome 21 from 44,548,483 to 46,902,240 (March 2006 Build, NCBI36/hg18). 
Primers were designed to flank all  coding exons in all versions of the gene. The 
Table 3.6 summarises the results of this analysis. Included in the Table is the result 
of sequence analysis of a Caucasian individual, D08.23732, who presented with 
Knobloch Syndrome, apparently a compound heterozygote. 
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In the Knobloch family from Pakistan, a 2bp deletion (CT) was detected in exon 40 
(Ensembl transcript ID ENST00000400347), predicted to cause a frameshift 
mutation, NM_130445.2:c.3514_3515del, NP_569712.2:p.Leu1172Valfs*72 (Figure 
3.9). In family member IV:4, this was a heterozygous change. The deletion was 
homozygous in V:8. The mutation segregated with disease status when available 
DNA from the other family members (IV:1, IV:2, IV:3, IV:4, IV:6, IV:7, V:2, V:4) was 
analysed. The three affected individuals tested were all homozygous for the 
mutation. Eight of nine unaffected individuals were heterozygous for the mutation, 
and one was homozygous wild type, and none were homozygous for the mutation. 
Using Superlink Online (http://bioinfo.cs.technion.ac.il/superlink-online/), the LOD 
score at recombination θ=0.00 was calculated as 2.24. 213 Asian controls (426 
chromosomes) were sequenced using PCR product generated using primers 
flanking exon 40, and none demonstrate this change.  
 
          
 Wild type              Heterozygous deletion             Homozygous deletion  
Figure 3.9: Electropherograms showing c.3617_3618delCT status. 
 
In exon 38, IV:4 was found to be heterozygous G/A for SNPrs12483761, and V:8 
was found to be homozygous A. 
The affected Caucasian individual may be a compound heterozygote. In exon 1 
(Ensembl transcript ID ENST00000359759), a heterozygous C/T SNP (rs8133886) 
was detected, along with a heterozygous previously unreported amino acid change, 
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p.Leu392Pro, which was found in 5 of 103 Caucasian control samples (all 
heterozygous for this change) so is likely to be an unreported SNP. In exon 8 
(Ensembl transcript ID ENST00000342220), a previously unreported heterozygous 
cytosine insertion was found, but was detected in 5 out of 98 Caucasian controls as 
a heterozygous insertion. In exon 6 (Ensembl transcript ID ENST00000400347) 
heterozygous SNPs rs2230687 and rs2230688 were detected. Other heterozygous 
SNPs were found in ENST00000400347, in intron 10 (rs9979845) in exon 18 
(rs11702425), and in intron 24 (rs35423701). A previously unreported sequence 
variation was found in exon 38, where cytosine was substituted for adenine, 
c.3239C>A, causing p.Pro1080Gln according to Ensembl, and P1077 according to 
NCBI and UCSC. This change was not found in 33 Caucasian controls. There is a 
previously unreported heterozygous cysteine to tyrosine substitution in exon 42 
(ENST00000400347) which Polyphen predicts to be “probably damaging”, 
p.Cys1288Tyr, caused by c.3912G>A. This sequence variation was not found in 398 
control Caucasian chromosomes.  
3.3.6 Discussion 
During the course of investigation, five candidate genes (C17orf42, RNF135, OMG, 
EVI2A and EVI2B) were excluded as Knobloch Sydrome candidates. KNO3, a novel 
Knobloch Syndrome locus was mapped to 17q11.2 (Khaliq et al, 2007) but the 
identification of a germline mutation in COL18A1 (21q22.3) in the same family now 
permits rejection of the KNO3 locus for the Knobloch Syndrome described in the 
Asian family (Joyce et al, 2010). The frameshift mutation identified (c.3514_3515del), 
predicted to cause p.Leu1175delinsValfsX71, is the likely culprit. It is perhaps of note 
that initially the family was described in clinic as having Knobloch-Like Syndrome, 
since affected members did not exhibit occipital encephalocele or cardiopulmonary 
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defects that are usually seen with Knobloch syndrome, even though most COL18A1 
mutations in Knobloch Syndrome are found in and after exon 30. It is possible that 
additional genetic factors, or environmental effects, are responsible for the atypical 
phenotype (Suzuki et al, 2009). 
This finding demonstrates that high-density SNP arrays are more reliable aids in 
candidate gene mapping than the microsatellite markers and autozygosity mapping 
approach. Initially, mapping did not highlight the 2.4Mb autozygous region, which 
contains COL18A1, because it lies inside a 6.7Mb interval between flanking markers 
D21S2055 and D21S1446. In consanguineous kindreds, the gene harbouring the 
autosomal recessive mutation usually resides in a large homozygous region. Woods 
et al (2006) found the mean homozygous segment length to be 26 cM (range 5-70 
cM. Hence, small intervals may be found in some families. 
 Primer Sequence 
Product 
size (bp) 
Annealing 
Temp. 
(°C) 
Additional D08.23732 IV:4 V:8 
COL18A1-
203pr1A-F 
CCACCTCCAGGCACAGAG 
559 64 acetamide 
Ensembl rs914230. T 
allele. (ancestral=C) 
Ensembl rs914230. T 
allele. (ancestral=C) 
Ensembl rs914230. T allele 
(ancestral=C) COL18A1-
203pr1A-R 
AGAGTGGTCCCATTCTCCTG 
COL18A1-
203pr1B-F 
AGGAGAACATTGCCGGTGT 
593 64 acetamide wt wt wt 
COL18A1-
203pr1B-R 
GCTGTCCCTGGTTAAAGTGG 
COL18A1-
203pr1C-F 
ACTTCTGCACCCCCTGGT 
478 64 acetamide 
1) Htz CT SNP 
rs8133886. 2) 
Leu392Pro "possibly 
damaging" in 5/103 
Caucasian Cs 
wt wt 
COL18A1-
203pr1C-R 
GCTCCAACACGCATCCTG 
COL18A1-
203pr1D-F 
CCTTCCTCGCCTGGTTCT 
291 57   wt wt wt 
COL18A1-
203pr1D-R 
ACCTGTACCAGGCTCACGTC 
COL18A1-
205pr8-F 
CCAGCCTGGGACTCTGGA 
407 60.4   
Htz C ins. Caucasian 
controls: 93/98=wt 
5/98=htz C ins 
wt wt 
COL18A1-
205pr8-R 
AGCTCAGCTCACTCCCATGT 
COL18A1-
205pr14-F 
CCAAGCTTCCACGTTGGTTA 
174 60   wt wt wt 
COL18A1-
205pr14-R 
CTCAGTCCAAAGCAGTGCAG 
COL18A1-
205pr15-F 
TTTGCAGGGTTTAGAAAGCA 
300 57   wt wt wt 
COL18A1-
205pr15-R 
GTAGTAGGGCTGGGGCAAC 
COL18A1-
205pr17-F 
GATGGGCCACAGGTAGTGTT 
203 57   wt wt wt 
COL18A1-
205pr17-R 
GTTCAATGAAGGGGCATCTC 
COL18A1-
204pr1+2-F 
ACCGCGGCGGAGGAGGCAGCAT 
varies 64 DMSO wt 
Insertion in intron 1: 
CTGCGGGG. 
Heterozygous 
Insertion in intron 1: 
CTGCGGGG. Homozygous COL18A1-
204pr1+2-R 
TGGGCAGGGCCGGGGCTGAA 
 
 Primer Sequence 
Product 
size (bp) 
Annealing 
Temp. 
(°C) 
Additional D08.23732 IV:4 V:8 
COL18A1-
204pr3A-F 
GCCCTCCCAGACTCAGTTTC 
499 57   wt wt wt 
COL18A1-
204pr3A-R 
GTCCACTGGCCGACGAAG 
COL18A1-
204pr3B-F 
CAGGCCATGGTCTTGCTG 
394 64 acetamide wt wt wt 
COL18A1-
204pr3B-R 
CACAGCTCCGTCCCTGTC 
COL18A1-
204pr4-F 
ATCTGGAGCTCAAGCAGCAC 
241 57   wt wt wt 
COL18A1-
204pr4-R 
GTCATAGACCTTGGCCCTGA 
COL18A1-
204pr5-F 
AGAGCAGCGTCCTTTGCTT 
226 60.4   wt wt wt 
COL18A1-
204pr5-R 
ACATGTGTCACCCCACTGC 
COL18A1-
204pr6-F 
TCACAAACCAAGCAAGTCTCC 
278 60   
Heterozygous 
rs2230687 (C=WT, 
G=var), rs2230688 
(G=WT, C=var) 
wt wt 
COL18A1-
204pr6-R 
CACCATCACACAAACACACG 
COL18A1-204-
7new-F 
CAGGACTGAAAGCGTTTGG 
277 64   wt wt wt 
COL18A1-204-
7new-R 
ACAGAGGGGCTTCATCAGG 
COL18A1-
204pr9-F 
TGGGGTGCATTTCCATGTAG 
207 57   wt wt wt 
COL18A1-
204pr9-R 
CTGGGTCGCGTTTAAAAAGA 
COL18A1-
204pr10+11-F 
GGGGAGGAGCACTGAGAGT 
393 57   
Intron 10 a/g 
rs9979845 
wt wt 
COL18A1-
204pr10+11-R 
CAGTGCCTGCTTTTGAGGAG 
COL18A1-
204pr12-F 
CGTGGTTTCTCAGCTCCTTG 
250 57   wt wt wt 
COL18A1-
204pr12-R 
CTGAATCTTGGGGGTCCAT 
 
 Primer Sequence 
Product 
size (bp) 
Annealing 
Temp. 
(°C) 
Additional D08.23732 IV:4 V:8 
COL18A1-
204pr13-F 
GTGGTGGTCATCCCTGGT 
284 57   wt wt wt 
COL18A1-
204pr13-R 
ggtgttcacccctcactcc 
COL18A1-
204pr14-F 
aaatcgttttagtggccgaat 
228 57   wt wt wt 
COL18A1-
204pr14-R 
gggctattcctggcatttc 
COL18A1-
204pr15-F 
ttcctctgtccactgtgctg 
233 57   wt wt wt 
COL18A1-
204pr15-R 
gatggacagatggcaggagt 
COL18A1-
204pr17-F 
gaggggtccttccctaagaa 
202 57   wt wt wt 
COL18A1-
204pr17-R 
tggctctcagggacactctc 
COL18A1-
204pr18-F 
tactagcgggcttttcttgc 
247 57    rs11702425 (T/C) wt wt 
COL18A1-
204pr18-R 
gcaaacttcccaggatgaat 
COL18A1-
204pr19-F 
aactcacccttcccttcacc 
244 64   wt wt wt 
COL18A1-
204pr19-R 
aaacaaagcagtggcaggaa 
COL18A1-
204pr20-F 
agagaagtccaggccatcg 
241 57   wt wt wt 
COL18A1-
204pr20-R 
atagtcccttcagggctcca 
COL18A1-
204pr21-F 
cggtcgggaaataaagaacc 
206 57   wt wt wt 
COL18A1-
204pr21-R 
gccaaaccttctgggatgt 
COL18A1-
204pr22-F 
gtggactctggggtcctg 
262 60   wt 
Apparent unseen 
heterozygous 
frameshift in intron 21 
wt 
COL18A1-
204pr22-R 
gtcctgacctgggggatgt 
 
 Primer Sequence 
Product 
size (bp) 
Annealing 
Temp. 
(°C) 
Additional D08.23732 IV:4 V:8 
COL18A1-
204pr23+24-F 
aagtcgctcgagtccagttg 
321 57   
rs35423701 in intron 
24 
wt wt 
COL18A1-
204pr23+24-R 
ctgctctgtgctaccaggtg 
COL18A1-
204pr25-F 
ctgtcgggggagatggag 
226 57   wt wt wt 
COL18A1-
204pr25-R 
cctcccaacagtggtcatct 
COL18A1-
204pr26-F 
gtgaggctttgtggggaag 
222 60   wt wt wt 
COL18A1-
204pr26-R 
agccagaccctcaggaagac 
COL18A1-
204pr27-F 
ctcagagaggctgccaggt 
183 60   wt wt wt 
COL18A1-
204pr27-R 
cacagcacaagctcagcag 
COL18A1-
204pr28-F 
cccaactcgtggtcaagg 
209 64   wt wt wt 
COL18A1-
204pr28-R 
actcccctctgggcatgt 
COL18A1-
204pr29-F 
cgggaaggtgtctggtaatc 
239 57   wt wt wt 
COL18A1-
204pr29-R 
ataagtggcctctgggagga 
COL18A1-
204pr30-F 
tgcctggtcaggtttctgat 
232 56 GC rich wt wt wt 
COL18A1-
204pr30-R 
ggctctgtgtgacagccaag 
COL18A1-
204pr31-F 
atacaggggctggtgcttct 
244 57   wt wt wt 
COL18A1-
204pr31-R 
ccactgggggagtctcact 
COL18A1-
204pr32-F 
ccaggcactagggcatttc 
249 57   wt wt wt 
COL18A1-
204pr32-R 
ccaggacctgcttgtggt 
 
 Primer Sequence 
Product 
size (bp) 
Annealing 
Temp. 
(°C) 
Additional D08.23732 IV:4 V:8 
COL18A1-
204pr33-F 
ctaccgcgaaatggctagaa 
216 57   wt wt wt 
COL18A1-
204pr33-R 
ccagcgggatgtacaggac 
COL18A1-
204pr34-F 
gctccggaagcttctgact 
393 57   wt wt wt 
COL18A1-
204pr34-R 
acacggggacagggacat 
COL18A1-
204pr35+36-F 
gtgggggtttctcaggctat 
547 57   wt wt wt 
COL18A1-
204pr35+36-R 
ggtccgtgggagagtgtct 
COL18A1-
204pr37-F 
ctgaaacgggcattccttc 
290 57   wt wt wt 
COL18A1-
204pr37-R 
gagcctctcgccttcctta 
COL18A1-
204pr38-F 
gagggagaggtgggtgct 
450 56 acetamide 
Hetz unknown SNP 
23rd base, C to A. 
P1080Q Ensembl. 
P1077 NCBI/UCSC. 
Not in 33 Caucasian 
controls  
wt (heterozygous GA 
for rs12483761) 
wt (homozygous A  rs12483761) 
COL18A1-
204pr38-R 
aggaccacgtgttgttcctc 
COL18A1-
204pr39-F 
ctgcttgccagttcagagc 
430 57   wt wt wt 
COL18A1-
204pr39-R 
ctgggccctcttctgctg 
COL18A1-
204pr40-F 
cccctcagtgtgtcacttgc 
410 64   wt 
Htz 
NM_130445.2:c.3514
_3515del, 
NP_569712.2:p.Leu1
172Valfs*72. Not in 
213 Asian controls 
Hmz  
NM_130445.2:c.3514_3515del, 
NP_569712.2:p.Leu1172Valfs*7
2.. Not in 213 Asian controls 
COL18A1-
204pr40-R 
ggagttcaccccagaggtc 
COL18A1-
204pr41-F 
cacatccacaccccacatc 
296 57   wt wt wt 
COL18A1-
204pr41-R 
ggggaaactgcagataggag 
 
 Primer Sequence 
Product 
size (bp) 
Annealing 
Temp. (°C) 
Additional D08.23732 IV:4 V:8 
COL18A1-
204pr42-F 
agcggcctctgccctaag 
386 66 acetamide 
Hetz Cys1291Tyr 
(Ensembl), 
Cys1288Tyr 
(NCBI/UCSC), 
Polyphen: probably 
damaging. Not in 199 
Caucasian controls 
wt wt 
COL18A1-
204pr42-R 
GAAAGTATGGCAGCCAGGTC 
 
Table 3.7: Details of primer and conditions used in molecular genetic analysis of COL18A1 in the kindred, and the singleton case 
D08.23732, and results of this analysis. Key: wt=wild type, htz=heterozygous, hmz=homozygous. 
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4. NON-SYNDROMIC CATARACT FAMILIES 
4.1 General Introduction 
Isolated cataracts can occur as an inherited condition, without any other detectable 
characteristics to suggest an underlying syndrome diagnosis. Non-syndromic 
cataracts may manifest as a result of autosomal dominant, autosomal recessive or 
X-linked recessive inheritance.  
Careful consideration was given to the grouping of the families with non-syndromic 
cataracts studied during this project. The families could not be grouped by cataract 
phenotype, because in many cases, this was not available in the clinical information 
supplied. Some affected individuals had cataract surgery abroad, before their genetic 
predisposition was noted in clinics in the UK. In some cases, cataract phenotype was 
simply not noted or provided. Additionally, as discussed in 1.3.2.3.2.6, mutations in 
the same gene can sometimes cause a variety of cataract phenotypes. Grouping by 
ethnic origin was also considered as in some cases a founder mutation can be 
detected in apparently unrelated families with a common ethnic origin. However, 
equally, there are examples of families with shared ethnicity and location who prove 
to have different mutations (or genes) despite a shared phenotype. Hence it was 
decided not to make unsupported assumptions about underlying locus heterogeneity 
but to re-evaluate various hypotheses as results were accrued.  
All positions referred to in this chapter are based on the February 2009 
GRCh37/hg19 build of the human genome, unless otherwise stated. 
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4.2 Cataract Family 1 and CDC25A  
Aim: To map the locus for a gene causing cataracts in a Turkish family and 
then to investigate the involvement of CDC25A as a candidate gene. 
4.2.1 Patient DNA 
DNA was extracted from blood samples. DNA was available from all family 
members, consisting of unaffected parents I:1 and I:2, and the three affected 
children II:1, II:2 and II:3 (Figure 4.1).  
 
Figure 4.1: Pedigree of Cataract Family 1 (of Turkish origin). 
 
4.2.2 Molecular Genetic Methods 
Experimental procedures were carried out as detailed in Chapter 2. 
4.2.2.1 Genome-Wide Scan 
To identify shared regions of homozygosity between the affected individuals, a 
genome-wide scan was carried out with the Affymetrix 10K SNP microarray. 
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4.2.2.2 Microsatellite Markers 
Regions of homozygosity >2Mb were probed with microsatellite markers. Family 
DNA was amplified by PCR, and then genotyped with an ABI 3730 Genetic Analyser. 
Data obtained here was analysed with the GeneMapper programme.  
4.2.2.3 Primer Design and Sequencing 
Candidate genes were selected for analysis. Dr Esther Meyer had previously 
investigated GPX1 as a candidate. Mutation analysis was carried out for RHOA, 
LAMB2, TREX1, CSPG5, CCDC12, TMIE and CDC25A.  
4.2.2.4 Functional Work 
To investigate the effect of a putative mutation in CDC25A, wild type and mutant 
constructs were cloned using specific plasmid primers (Table 4.8) and introduced 
into the CRL-11421 cell line. Changes at the protein level were analysed by Western 
blotting, FACS and immunofluorescent staining. 
4.2.3 Results 
4.2.3.1 Genome-Wide Scan 
The genome-wide scan was performed for individuals II:1, II:2, and II:3. One 
potential region of extended homozygosity was detected on chromosome 3 between 
rs2056321 (45,083,133) and rs1444185 (58,686,977). These SNPs define the extent 
of the homozygous region, because at least one of the affected individuals is 
heterozygous at this position.  
 
4. Non-syndromic Cataract Families  126 
4.2.3.2 Microsatellite Markers 
This region of interest was investigated further by Dr Esther Meyer to confirm 
presence or absence of homozygosity at various polymorphic microsatellite markers. 
Linkage to the region on chromosome 3 was confirmed.  
4.2.3.3 Candidate Genes 
The linked region on chromosome 3 from rs2056321 (45,083,133) to rs1444185 
(58,686,977) overlapped with a previously reported region for three Arab families 
with autosomal recessive cataracts from D3S1768 (34,624,330) to D3S2409 
(49,418,084) (Pras et al, 2001). The search for the causative gene was therefore 
focussed on the overlap region from 49,418,084 to 58,686,977, which contains 169 
genes. 
Candidate genes were selected based on evidence of expression in the eye and/or 
lens. Previously, GPX1 was investigated, and no pathogenic exonic mutations were 
identified. RHOA, LAMB2, TREX1, CSPG5, CCDC12, TMIE and CDC25A were 
chosen for mutation analysis. Analysis of coding exons of RHOA, LAMB2, TREX1, 
CSPG5, CCDC12, and TMIE revealed no potential mutations but a previously 
unreported variant was detected in CDC25A. 
 
4.2.3.3.1 CDC25A 
A putative mutation, c.137_139del (referring to NM_001789.2; Figure 4.2), was 
detected in exon 1 of CDC25A, this was predicted to cause the deletion of two amino 
acids and the insertion of a new amino acid (p.Thr46_Val47delinsIle) in the gene 
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product. This variant segregated with disease status. Affected individuals II:1, II:2 
and II:3 were all homozygous for the 3bp deletion, whereas the unaffected parents 
I:1 and I:2 were heterozygous. Analysis of DNA from ethnically matched control 
chromosomes (316 Asian, 26 Caucasian, and 450 Turkish) did not reveal this 
deletion. 
A 
  
 
 
B 
 
C 
 
Figure 4.2: Electropherograms showing homozygosity and heterozygosity for 
p.Thr46_Val47delinsIle, and wild type sequences. A=control sample showing wild 
type sequence. B=parent DNA showing heterozygosity for p.Thr46_Val47delinsIle. 
C= affected child, homozygous for p.Thr46_Val47delinsIle. 
 
A sequence alignment was carried out, which showed these bases to be highly 
conserved in mammals, but not in chickens (Figure 4.3). 
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Figure 4.3:Sequence conservation of the T and V nucleotide (highlighted) involved 
in p.Thr46_Val47delinsIle across species. 
 
DNA from an affected individual from the pedigrees published by Pras et al (2001) 
was obtained, but mutation analysis revealed no putative mutations in the coding 
regions of CDC25A.  
 
Figure 4.4:  Pedigree for cataract family 2. Affected members presented with non-
syndromic cataracts. 
 
Another cataract family (Cataract family 2) which was of Turkish ethnicity was 
ascertained (Figure 4.4). PCR and sequencing of exon 1 of CDC25A was performed 
in family 2 but did not reveal the c.137_139del variant. Mutation analysis was then 
undertaken for the remaining exons of the gene, and in intron 5, III:11 was found to 
be heterozygous for rs3731507, thus excluding this gene in this family. Furthermore, 
coding exons of CRYBB3, CRYBB1, CRYBB2 and CRYBA4 were sequenced for 
II:10 and III:10 (see Tables 6.21-6.24). No sequence changes were detected for 
CRYBB3. 
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In exon 6 of CRYBB1 (NM_001887.3), II:10 was heterozygous for c.755A>G, and 
III:10 was homozygous for c.755A>G (see Table 4.1). This exon was analysed for 
the remaining family members for whom DNA was available and all affected family 
members were homozygous G/G for c.755A>G. An unexpected genotype of A/A was 
detected for II:7, since the affected child III:3 was G/G and possible explanations for 
the apparent non-maternity would include mistyping or sample mixup or rare 
occurrences such as uniparental disomy. Though the c.755A>G variant segregated 
with disease status it was unclear if the variant was pathogenic as the predicted 
amino acid change p.252Lys>Arg was considered to be likely to be benign change 
by the Polyphen prediction program. This is a conservative change since both lysine 
and arginine are basic, hydrophilic amino acids with positively charged side chains. 
This sequence change has not been previously reported as a SNP. This residue is 
conserved in chimpanzee, dog, cow and mouse, but not in chicken or zebrafish. 
Family member Status Genotype  
II:1 Unaffected A/G 
II:2 Unaffected A/G 
II:7 Unaffected A/A 
II:10 Unaffected A/G 
II:11 Unaffected A/G 
III:1 Affected G/G 
III:2 Affected G/G 
III:3 Affected G/G 
III:8 Unaffected A/G 
III:9 Unaffected A/A 
III:10 Affected G/G 
III:11 Affected G/G 
Table 4.1: Genotypes for cataract family 2 and c.755A>G in CRYBB1. 
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Gene Individual SNP Genotype 
CRYBB1 II:10 rs576564656 C/G 
CRYBB1 III:10 rs576564656 G/G 
CRYBB2 II:10 c.306+67T>A A/T 
CRYBB2 III:10 c.306+67T>A T/T 
CRYBB2 II:10 rs4049504 C/T 
CRYBB2 III:10 rs4049504 C/T 
CRYBA4 II:10 rs16982454 C/A 
CRYBA4 III:10 rs16982454 A/A 
CRYBA4 II:10 rs7609505 T/C 
CRYBA4 III:10 rs7609505 T/T 
Table 4.2: Genotypes for SNPs detected in CRYBB1, CRYBB2 and CRYBA4.  
In summary, no definite mutations were detected in the candidate genes tested in 
cataract family 2. 
4.2.3.4 Functional Work 
To further evaluate the significance of the c.137_139del mutation in CDC25A, 
functional work was carried out with the cell line CRL-11421, which was first derived 
from human lens, grown in EMEM, supplemented with10% fetal bovine serum. 
4.2.3.4.1 Western Blotting 
CRL-11421 cells were grown on glass cover slips to ~80% confluency and 
transfected with plasmid DNA (pCMVHA+CDC25A and pCMHVA+CDC25A 
p.Thr46_Val47delinsIle and pCMVHA empty vector as a control) using 
Lipofectamine, in a ratio of 1μg DNA: 3μl Lipofectamine. After 16 hours, cells were 
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lysed with RIPA buffer. Protein determination was carried out with Bio-Rad DC 
Protein Assay, using Perkin Elmer Workout 2.5 Software on Perkin Elmer 2030 Multi 
Label Reader Victor X3, measuring absorbance at A690. Calculations were 
performed too so that 5μg could be loaded per well in the polyacrylamide-SDS gel 
(see 2.2.9.3). Sigma-Aldrich monoclonal anti-HA clone HA-7 (mouse) was diluted 
1:1000 in PBST to detect HA antigen. Primary antibodies were detected with 
polyclonal rabbit anti-mouse immunoglobulin HRP, diluted 1:2000 in PBST. 
Enhanced chemiluminescence was used to detect the secondary antibody. Pictures 
of the chemiluminesence were taken. CDC25A is a 56kD protein. Then the 
membrane was stripped and reprobed for actin (42kD). The primary antibody, Sigma 
mαβ-actin was diluted 1:15,000 in PBST, and the secondary antibody, polyclonal 
rabbit anti-mouse from Dako Cytomation was diluted 1:20,000 in PBST. Enhanced 
chemiluminesence was used to detect the secondary antibody. All experiments were 
carried out in triplicate. 
Protein Densitometry was carried out to show protein stability levels. 
4.2.3.2.1.1 Western Blotting Results 
Although by eye there appeared to be a reduction in intensity for the mutant vs the 
wild type construct, it was necessary to reprobe for actin to confirm this and to check 
for equal well loading, and this was checked with protein densitometry (see 
4.2.3.4.1.2). 
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Figure 4.5: A=protein ladder. B=pCMVHA-CDC25A. C=pCMVHA-CDC25A 
p.Thr46_Val47delinsIle mutant. D=pCMVHA (untransfected). E=pCMVHA (empty 
vector). 
 
Figure 4.6: Probing for actin, A=pCMVHA-CDC25A. B=pCMVHA-CDC25A 
p.Thr46_Val47delinsIle mutant. C=pCMVHA untransfected). D=pCMVHA (empty 
vector). 
 
4.2.3.2.1.2 Protein Densitometry Results 
Normalised results still clearly show a reduction in protein stability from wild type to 
mutant. This was carried out as an average for three blots (Table 4.3).  
 
Intensity per 
volume: 
CDC25A 
CDC25A - 
blank 
Intensity 
per 
volume: 
actin 
Actin – 
blank 
Normalised 
(CDC25A/ 
Actin) 
Percentage 
of protein 
compared 
to wild type 
Wild 
Type 
573393 78875 377872 44576 1.76945 
55.81671 
(normalised 
mutant/ 
normalised 
wild type 
x100 
Mutant 516428 21910 355480 22184 0.987649 
Blank 494518 0 333296 0 0 
Table 4.3: Protein densitometry result  
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Graph to show protein stability levels
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Figure 4.7: Protein stability levels. 
Data displayed in graph form (Figure 4.7) clearly shows the reduction in stability 
between wild type and mutant CDC25A that was present in the various CRL-11421 
populations. 
4.2.3.4.2 Immunofluorescent Staining 
As for Western Blotting (see 4.2.3.2.1), CRL-11421 cells were grown on glass cover 
slips to ~80% confluency and transfected with plasmid DNA (pCMVHA+CDC25A 
and pCMHVA+CDC25A p.Thr46_Val47delinsIle and pCMVHA empty vector as a 
control) using Lipofectamine, in a ratio of 1μg DNA: 3μl Lipofectamine. These were 
left for 24 hours. Cells were washed in PBS and then 4% paraformaldehyde in PBS 
for 20 minutes, and then permeabilised in 0.1% Triton X100.The primary antibody, 
anti-HA, was diluted 1:200 in PBS-BSA. After incubation, the primary antibody was 
detected with 1:200 goat anti-mouse 488 alexia in PBS-BSA. These were then 
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incubated for two minutes with TOPRO-3 Iodide, excluding light. A drop of Pro Long 
Gold Antifade Reagent was placed on glass slides and the cover slips were inverted, 
placed on top, and this was allowed to dry, excluding light. Cells were visualised with 
a Leica Confocal Scanning Light Microscope SP2 AOBS (Leica, Germany), using 
lens 63 N/A 1.3, optical zoom 4. 
4.2.3.4.2.1 Immunofluorescent Staining Results 
Figures 4.8, 4.9 and 4.10 show randomly selected samples of CRL-11421 cells 
which were observed with the confocal microscope after immunofluorescent staining 
(4.2.3.4.2). TOPRO-3 Iodide stains nucleic acids, and is a carbocyanine with far red 
fluorescence. The alexa fluor 488 dye fluoresces green, and shows CDC25A 
localisation, due to the cross-reaction between protein, primary antibody and 
secondary antibody. 
  
Figure 4.8: Transfection of wild type CDC25A into CRL-11421 (size bar 10μm). 
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Figure 4.9:  Transfection of mutant p.Thr46_Val47delinsIle CDC25A into CRL-11421 
(size bar 10μm). 
 
  
A             B 
Figure 4.10:  A=Transfection of empty pCMVHA vector into CRL-11421.  
B= Untransfected CRL-11421 (size bars 10μm). 
 
4.2.3.4.2.2 CDC25A Localisation 
To elucidate the intracellular localisation of CDC25A, and compare differences 
between wild type and mutant p.Thr46_Val47delinsIle CDC25A, the images were 
compared (Figures 4.8 and 4.9). There is nuclear and cytoplasmic staining (with 
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some areas unstained suggesting the presence of vacuoles) in both cases. Cell 
morphology in CRL-11421 was seen to vary even within the untransfected 
population (most probably due to cell cycle stage and cell division), so morphological 
variation was expected within wild type-transfected and mutant-transfected cells, 
although there did seem to be a tendency for mutant-transfected cells to have a 
more compact shape with a more serrated appearance to their cell membrane. 
4.2.3.4.3 FACS 
FACS results indicate that there is no particular difference between mutant and wild-
type CDC25A transfectants with regard to the proportion of cells in different stages of 
the cell cycle in CRL-11421 cells (See Table 4.4 and Figures 4.11-4.14). In the 
histograms in Figures 4.12-4.15, M3 represents the proportion of dead cells, M1 the 
proportion of cells in G0/G1 phase, and M2 represents those in G2 phase. The area 
between M1 and M2 is representative of cells in S phase. The dot-plot displays 
events, or cells, and those that are dead or clumped are gated out so that they can 
be excluded from further analysis. FSC refers to forward scatter, and SSC  refers to 
side scatter. Since CDC25A stops damaged DNA from going from G1 to S phase, 
and from G2/M, the lack of difference could be due to a lack of damaged DNA. 
Cell cycle 
stage 
Wild type 
CDC25A 
Mutant 
CDC25A 
Empty 
vector  
Untransfected  
% Dead 
cells 
2.09 1.86 2.33 1.98 
% G1/G0 62.64 59.24 46.32 58.88 
% G2/M 24.14 24.50 33.98 26.14 
% S 11.13 14.40 17.37 13.00 
Table 4.4: FACS results indicating the percentage of CRL-11421 cells within cell 
cycle stages. 
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A                  B 
 
M Low, 
High 
Events % Total % Gated G Mean CV Peak, 
Value 
0 0,1023 5111 51.11 100.00 451.55 28.43 50,358 
1 277,369 1596 15.96 31.23 343.65 5.31 50,358 
2 638,749 617 6.17 12.07 674.81 3.87 17,686 
3 0,277 107 1.07 2.09 142.52 50.92 3,78 
C 
Figure 4.11: FACS results for CDC25A wild type transfected CRL-11421. A: dot-plot 
of cells; B: histogram of proportion of cells in stages of the cell cycle; C :Values 
generated as a quantitate representation of FACS results 
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A                                                                B 
 
M Low, 
High 
Events % Total % Gated G Mean CV Peak, 
Value 
0 0,1023 4905 49.05 100.00 309.41 29.93 79,246 
1 196,246 1453 14.53 29.62 232.90 4.25 79,246 
2 450,507 601 6.01 12.25 471.34 3.05 22,466 
3 0,196 91 0.91 1.86 123.23 43.31 3,196  
C 
Figure 4.12: FACS results for CDC25A mutant transfected CRL-11421. A: dot-plot 
of cells; B: histogram of proportion of cells in stages of the cell cycle; C: Values 
generated as a quantitate representation of FACS results 
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A                                                                B    
 
M Low, 
High 
Events % Total % Gated G Mean CV Peak, 
Value 
0 0,1023 5539 55.39 100.00 316.91 31.26 84,242 
1 195,241 1283 12.83 23.16 228.60 4.12 72,240 
2 440,507 941 9.41 16.99 463.85 3.34 26,462 
3 0,195 129 1.29 2.33 65.43 106.73 8,8 
C 
Figure 4.13: FACS results for CRL-11421 transfected with empty vector. . A: dot-plot 
of cells; B: histogram of proportion of cells in stages of the cell cycle; C: Values 
generated as a quantitate representation of FACS results 
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A                                                               B 
 
M Low, 
High 
Events % Total % Gated G Mean CV Peak, 
Value 
0 0,1023 6067 60.67 100.00 307.33 30.57 108,240 
1 195,239 1786 17.86 29.44 226.35 4.06 87,239 
2 440, 507 793 7.93 13.07 461.60 3.22 34,440 
3 0,195 120 1.20 1.98 107.14 65.13 7,6 
C 
Figure 4.14: FACS results for untransfected CRL-11421.  A: dot-plot of cells; B: 
histogram of proportion of cells in stages of the cell cycle; C: Values generated as a 
quantitate representation of FACS results 
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4.2.4 Discussion 
In a Turkish family, a putative deletion mutation, c.137_139del 
(p.Thr46_Val47delinsIle), was found in CDC25A which is located within a linked 
region on chromosome 3. This variant segregated with disease status. 
CDC25A, the cell division cycle 25 homolog A (S. Pombe) gene, is part of the 
CDC25 family of phosphatases and is involved in the cell cycle, being required for 
G1/S and G2/M transition during the cell cycle (Ray and Kiyokawa, 2007). In humans, 
there are two other CDC25 genes: CDC25B and CDC25C. There are four main 
stages in the cell cycle: G1 phase, S phase, G2 phase and M phase. G0 is the gap or 
resting phase where cells are in quiescence. M phase includes mitosis and 
cytokinesis. 
CDC25A is expressed in the eye, liver and spleen, brain, uterus, kidney, skin, lung 
and heart tissues, amongst others (Aceview at NCBI). 
When DNA is damaged, CDC25A is degraded, and so cells with chromosomal 
abnormalities cannot proceed through the cell cycle. During the normal course of 
events, CDC25A activates CDC2, a cyclin-dependent kinase, and this is achieved by 
removing two phosphate groups. It has been shown that ultra-violet light and ionizing 
radiation exposure in human cells causes CDC25A degradation, which is ubiquitin 
and proteasome dependent (Mailand et al, 2000). The cell cycle is arrested by 2 
hours after exposure to ultraviolet radiation. (There is another DNA damage 
checkpoint, mediated by p53/p21, which comes into play several hours later.) 
Progression to S phase was arrested due to continued inhibition of CDK2 by tyrosine 
phosphorylation and activated CHK1 protein kinase. Ultraviolet light irradiation has 
long been associated with cataractogenesis. It has been proposed that the effect is 
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exerted by the creation of highly reactive oxygen species, which cause oxidative 
stress (Varma et al, 2011). It is possible that components of an identical or a similar 
pathway are affected if this putative mutation is responsible for cataractogenesis in 
this family. When CDC25A was overexpressed, more DNA damage was evident, 
and fewer cells survived, indicating that CDC25A-mediated cell cycle arrest had 
been compromised. 
It could be expected that a gene with such a crucial role in the cell cycle would, if 
mutated, cause more devastating and widespread effects than the phenotype noted 
in this family: non-syndromic cataracts alone. This could, however, be explained by 
alternative splicing. There are eight alternative splicing patterns for CDC25A 
(according to ASTD), and exon 1, where p.Thr46_Val47delinsIle occurs, is only 
found in splice patterns 1, 4 and 5 (which corresponds to exon 2b in the Genecards 
representation in Figure 4.15), perhaps decreasing the potential impact had a similar 
mutation occurred in a more widely included section of the gene. Interestingly, 
Karagoz et al (2010) reported that an exon 3 CDC25A missense substitution 
(p.Ser88Phe) was associated with breast cancer susceptibility in humans but the 
same variant in mice was associated with embryonic lethality (in the homozygous 
state) (Bahassi et al, 2011). 
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Figure 4.15: Splicing patterns for CDC25A from Genecards. 
 
Chen et al (2011) investigated the cause of autosomal recessive congenital 
cataracts in twelve consanguineous Pakistani families, confirming linkage to 3p21-
p22 with a summed LOD score of  33.42. Mutations in FYCO1, FYVE and coiled-coil 
domain containing 1 gene (45,959,395-46,037,307), segregated with disease status, 
and nine different mutations were identified. A mutation that segregated with affected 
status was also identified in the Israeli family that was also investigated during this 
project (Pras et al, 2001). FYCO1 is a member of the PI(3)P-binding protein family, 
mediating plus-end directed vesicle transport in microtubules, being associated with 
colocalisation to the autophagosome exterior. Mutations in FYCO1 appear to be a 
significant cause of cataracts within the Pakistani population. It is interesting to note 
that FYCO1 maps within the candidate autozygous region identified in Cataract 
Family 1. However, as FYCO1 findings were published after laboratory work for this 
thesis finished, it is not known whether Cataract Family 1 harbours a FYCO1 
mutation or not. Chen‟s group did not investigate CDC25A as a candidate gene. 
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4.2.5 Conclusion 
Any future work involving elucidation of the cause of cataractogenesis in cataract 
family 1 would first need to test for a mutation in FYCO1 (Chen et al, 2011). The 
preliminary investigations undertaken to try and evaluate the significance of the 
CDC25A p.Thr46_Val47delinsIle variant illustrate the difficulty of establishing 
whether rare genetic variants are pathogenic or coincidental. Thus the variant was 
not detected in normal controls and segregated with disease status but the genetic 
information was insufficient to prove pathogenicity. Functional investigations were 
generally uninformative though there was some suggestion that the variant might 
possibly cause protein instability. If CDC25A was to be further investigated as a 
candidate gene for cataracts, it would be helpful to analyse a large number of 
recessively inherited cataract families to try to identify additional mutations. (The 
number of available families and the presence of locus heterogeneity limited the 
study.) In addition, further functional studies might be undertaken to compare the 
effects of wild-type and p.Thr46_Val47delinsIle variants on CDC25A-related 
functions. Thus the CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay 
(Promega) can be used to determine the number of viable, proliferating cells. It uses 
a tetrazolium compound (MTS), and an electron coupling reagent (phenazine 
methosulfate), and the formation of a formazan product can be measured 
colorimetrically at 490nm. There is a direct proportional relationship between the 
number of living cells and the amount of formazan formed. This could be used to 
compare differences between wild type-transfected and mutant-transfected CRL-
11421 in vitro.  
BrdU staining is another method that could be used to discover differences between 
the cell populations. 5-bromodeoxyuridine is used as a mutagen, and also as a 
4. Non-syndromic Cataract Families  145 
marker for DNA synthesis, due to the differing staining patterns that can be 
observed. It is a thymidine analogue, capable of inducing point mutations because of 
its tendency to tautomerization. It will pair with G instead of A when in the enol form. 
The protocol involves fixing cells in ethanol, resuspending in HCl with pepsin, 
centrifugation steps, incubation with primary and secondary antibodies, and 
treatment with propidium iodide.  
 
4.3 Investigation of Cataract Family 3 and Family 4 (Omani Kindreds) 
Aims: To locate shared regions of homozygosity, and to prioritise candidate 
genes for sequencing 
4.3.1 Patient DNA 
DNA was available from families in extended kindreds from Oman (Figure 4.16). 
Affected individuals presented with cataracts and exhibited no other clinical 
symptoms. The second kindred were said to be related to the first kindred as „distant 
cousins‟. Peripheral blood samples and buccal swabs were obtained, after informed 
consent, from family members, in villages in Oman by Dr Derek Lim. Blood samples 
were collected from Kindred 1 family members III:1, III:2, IV:4, IV:7, IV:8, IV:9, IV:11, 
IV:12, III:3, IV:14, IV:18, IV:19, and IV:20, and Kindred 2 family members III:3, III:4 
and IV:11. The standard phenol chloroform extraction procedure was used to obtain 
genomic DNA in the Birmingham Women‟s Hospital Diagnostic Laboratories. Buccal 
swabs were taken from Kindred 1 IV:10 and IV:13, and Kindred 2 IV:7 and IV:8. 
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A  
 
 
B  
 
Figure 4.16: A.  Cataract Family 3 - Omani Kindred 1; B. Cataract Family 4 - Omani 
Kindred 2. 
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4.3.2 Molecular Genetic Methods 
4.3.2.1 SNP Chip 
Genome-wide linkage scans were performed by Louise Tee, using the GeneChip® 
Human Mapping 250K SNP Array on DNA from Kindred 1 (IV:7, IV:8, IV:11, IV:12, 
IV:14 and IV:19). IV:19 was repeated since the call rate fell below the 93% call rate 
on the first attempt, having a call rate of 92%.  
4.3.2.2 Microsatellite Markers 
Microsatellite markers from ResGen or ABI panels or novel microsatellite markers 
were used. Details of these are provided in the Appendix (Table 6.36).  
4.3.2.3 PCR 
Forward and reverse primers were designed to flank all coding exons (and some 
non-coding exons) of the known cataract genes CRYBB2 (Table 6.21), CRYBA4 
(Table 6.22), CRYBB3 (Table 6.23), BFSP1 (Table 6.25), LIM2 (Table 6.26), GCNT2 
(Table 6.27), GJA8 (Table 6.28), CRYBB1 (Table 6.24), HSF4 (Table 6.29), CRYAA 
(Table 6.30) and GALK1 (Table 6.31). PCR was carried out with conditions 
described in the Materials and Methods chapter, unless noted otherwise in the tables 
in this chapter.  
Primers were also designed to amplify coding regions of the following candidate 
genes: LENEP (Table 6.32), CRYBG3 (Table 6.33), and HSPB6 (Table 6.34). 
CRYBG3 on chromosome 3 was chosen as a candidate gene because it is located 
from 97,595,819 to 97,663,810 and so lies in the  region (74,919,074-115,297,798) 
identified by the genome wide scan. It was an ideal candidate gene, coding for a 
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crystallin, with evidence of expression in the eye (Aceview). The in vivo function is 
unknown. 
LENEP (chromosome 1,154,966,062 to 154,966,791)  was selected as a candidate 
gene because it is in the chromosome 1 region identified by genome wide scan, 150, 
657,906-165,802,112. There is also evidence of lens expression (Aceview). 
HSPB6 was chosen as a candidate gene. According to build NCBI36/hg18 (release 
54, May 2009) this gene was located at 40,937,336-40,939,799 According to 
GRCh37/hg19, it is more accurately located on chromosome 19 from 36,245,470 to 
36,247,930, placing it outside the chromosome 19 region detected by the genome 
wide scan from 40,459,706 to 58,857,408. There is evidence of expression in the 
eye, and three of four isoforms contain Hsp20/alpha crystallin family domains 
(Aceview). HSPB6 is involved in smooth muscle relaxation modulation (Tessier et al 
2003). 
4.3.2.4 Sequencing 
Sequencing was carried out as described in the Materials and Methods chapter (see 
2.2.6). 
4.3.3 Results 
DNA concentrations from the buccal swabs taken from Kindred 1 IV:10 and IV:13, 
and Kindred 2 IV:7 and IV:8, were too low, and as such, DNA could not be amplified 
via PCR for any of the exons attempted. 
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4.3.3.1 Genome-Wide Scan 
After SNP chip analysis (based on build GRCh36/hg18), fifteen regions of 
homozygosity in Kindred 1 members IV:8 and IV:11 greater than 2Mb were 
considered possible candidate regions (Table 4.5). Two of these regions were not 
analysed with microsatellite markers since the third affected member, IV:7, was 
extremely heterozygous, and in this consanguineous family, the transmission of 
affected status was initially thought to be most likely to be autosomal recessive with 
all affected members being homozygous for the same mutation.  
Chromosome  Start End Notes 
1 105,464,488 107,660,193 Affected IV:7 is quite heterozygous 
1 150, 657,906 165,802,112 
Unaffected IV:12 and IV:14 mostly heterozygous. 
Affected IV:7 heterozygous in parts 
2 131,671,717 144,316,267 Affected IV:7 is quite heterozygous 
3 74,919,074 115,297,798 Affected IV:7 is quite heterozygous 
6 88,878,455 91,450,041 Affected IV:7 is mostly heterozygous 
6 95,956,306 100,444,677 Affected IV:7 is mostly heterozygous 
7 116,265,885 119,025,178 Affected IV:7 is mostly heterozygous 
11 31,389,403 34,497,225 Affected IV:7 is mostly heterozygous 
11 38,567,581 40,614,578 Affected IV:7 is mostly heterozygous 
14 87,629,745 94,999,444 Affected IV:7 is mostly heterozygous 
16 27,176,280 47,670,664 Unaffected have similar genotype 
19 17,270,289 37,787,896 Affected IV:7 is heterozygous 
19 40,459,706 58,857,408 
Affected IV:7 is heterozygous, but from 44.6 has 
same genotype as IV:8 and IV:11 
20 39,967,656 41,904,898 Affected IV:7 is mostly heterozygous 
22 35,860,982 41,897,898 Affected IV:7 is quite heterozygous 
Table 4.5: Regions analysed with microsatellite markers in the Omani Kindreds. 
Grey shading indicates that the regions were not selected for analysis with 
microsatellite markers. 
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4.3.3.2 Microsatellite Markers 
4.3.3.2.1 Chromosome 19 
Fine mapping analysis with microsatellite markers for the region on chromosome 19 
from 40,459, 706 to 58, 857, 408 was completed first (Figure 4.17) since the known 
cataract gene LIM2 is located in this region from 56,574,976 to 56,583,009 
(NCBI36/hg18). In the NCBI37/hg19 database release, LIM2 is located 51,883,164-
51,891,197. Twenty-nine microsatellite markers were used to investigate this region, 
from Chr19r2-16xAT (novel marker) (41,093,388) to D19S572 (58,797,162). 
D19S220 (43,123,394) showed linkage for all affected family members except 
kindred 2 family member IV:20. In kindred 1 family 1, a common homozygous 
haplotype was observed for all affected members (IV:7, IV:8 and IV;11) between 
Chr19r2-16xAT (novel marker) (41,093,388) and Chr19r2-15xGT (novel marker) 
(55,468,671), and Chr19-15xAG (novel marker) (55,215,067) and D19S571 
(57,968,784). In kindred 1 family 2, this was observed from D19S220 (43,123,394) to 
D19S421 (43,562,945), and from D19S47 (45,006,014) to Chr19r2-15xTTA (novel 
marker) (51,999,196), but only in affected individuals IV:18 and IV:19, not in affected 
individual IV:20. Homozygous regions were noted in kindred 2 IV:11 from Chr19r2-
15xAC41 (novel marker) (41,435,658) to D19S220 (43,123, 394), and from Chr19r2-
15xTAT (44,221,282) to Chr19r2-22xGT44 (novel marker) (44,669,155). 
The region was not found to be linked, so analysis of the other 12 regions, using fine 
mapping with microsatellite markers, was carried out.  
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4.3.3.2.2 Chromosome 1 
In chromosome 1 region 1 (105,464,488 to 107,660,193), linkage was excluded due 
to microsatellite marker segregation and haplotypes (Figure 4.18). Seven 
microsatellite markers were analysed across this region from D1S485 (105,069,360) 
to D1S2726 (110,896,304). 
In chromosome 1 region 2 (150, 657,906 to 165,802,112), sixteen microsatellite 
markers across the region were analysed. Two common homozygous regions were 
found in kindred 1 family 2, and in kindred 2. The regions extend between D1S498 
(148,114,568) and Chr1-26xAC (novel marker) (153,111,478), and D1S1653 
(156,199,398) and D1S1677 (161,826,325), although haplotypes were not identical, 
and the calls for Homozygosity extended as far as D1S1589 (172, 527,725) in 
kindred 2 family member IV:11. In kindred 1 family 1, unaffected individuals IV:4 and 
IV:9 shared a common homozygous region with identical haplotypes as those of 
affected individuals IV:7, IV:8 and IV:11 from Chr1-22xGT (novel marker) 
(152,009,159) to D1S2673 (163,312,611). Assuming that the same mutation is 
responsible for cataractogenesis in all affected individuals, this region was not linked 
(Figure 4.19). 
 
    
Figure 4.17: Chromosome 19 region 2 (40,459,706-58,857,408). Affected individuals are shaded black. Markers displayed in order of physical location. Boxed areas contain homozygous haplotypes.
.
Marker Location
Chr19r2-16xAAT 41,093,388 232 232 228 232
Chr19r2-15xAC41 41,435,658 243 241 243 241
Chr19r2-26xAC 42,082,888 245 243 249 243
D19S220 43,123,394 269 281 279 281
D19S421 43,562,945 186 188
Chr19r2-15xTAT 44,221,282 164 172 164 172
Chr19r2-22xGT44 44,659,155 257 247 247 247
D19S47 45,006,014 94 94 98 94
Chr19r2-17xGA 45,150,482 233 231 231 231
D19S718 46,150,100 339 343 365 343
Chr19r2-34xTC 46,287,550 204 222 214 222
Chr19r2-19xAG 47,378,235 213 215 211 215
D19S420 48,500,639 107 99 107 99
D19S900 48,859,098 163 169 169 169
D19S559 50,022,063 185 185 181 185
Chr19r2-20xCAG 50,965,303 213 213 213 213
Chr19r2-15xTTA 51,999,196 222 226 226 226
D19S902 53,023,869 241 243 251 243
Chr19r2-23xCA 53,983,566 177 179 177 179
Chr19r2-15xAC 54,898,140 215 217 215 217
D19S904 55,468,605 213 213 207 213
Chr19r2-15xGT 55,468,671 236 236 230 236
D19S246 55,647,457 243 243 251 243
Chr19-19xAG 56,215,067 229 243 247 243
Chr19-22xGT 56,411,092 246 242 242 242
Chr19-20xGT 56,655,961 251 247 237 247
Chr19-15xAC 56,664,850 235 237 243 237
D19S571 57,988,784 311 287 287 287
D19S572 58,797,162 119 119 131 119
Marker Location
Chr19r2-16xAAT 41,093,388 232 228 232 232 232 232 232 228 232 232 232 232
Chr19r2-15xAC41 41,435,658 243 243 241 241 241 241 243 243 241 241 243 241
Chr19r2-26xAC 42,082,888 245 249 243 243 243 243 245 249 243 243 245 243
D19S220 43,123,394 269 279 281 281 281 281 269 279 281 281 269 281
D19S421 43,562,945 186 186 188 188 188 188 186 186 188 188 186 188
Chr19r2-15xTAT 44,221,282 164 164 172 172 172 172 164 164 172 172 164 172
Chr19r2-22xGT44 44,659,155 257 247 247 247 247 247 257 247 247 247 257 247
D19S47 45,006,014 94 98 94 94 94 94 94 98 94 94 94 94
Chr19r2-17xGA 45,150,482 233 231 231 231 231 231 233 231 231 231 233 231
D19S718 46,150,100 339 365 343 343 343 343 339 365 343 343 339 343
Chr19r2-34xTC 46,287,550 204 214 222 222 222 222 222 214 222 222 204 222
Chr19r2-19xAG 47,378,235 213 211 215 215 215 215 213 211 215 215 213 215
D19S420 48,500,639 107 107 99 99 99 99 107 107 99 99 107 99
D19S900 48,859,098 163 169 169 169 169 169 163 169 169 169 163 169
D19S559 50,022,063 185 181 185 185 185 185 185 181 185 185 185 185
Chr19r2-20xCAG 50,965,303 213 213 213 213 213 213 213 213 213 213 213 213
Chr19r2-15xTTA 51,999,196 222 226 226 226 226 226 222 226 226 226 222 226
D19S902 53,023,869 241 251 243 243 243 243 241 251 243 243 241 243
Chr19r2-23xCA 53,983,566 177 177 179 179 179 179 177 177 179 179 177 179
Chr19r2-15xAC 54,898,140 215 215 217 217 217 217 217 217 215 217
D19S904 55,468,605 213 207 213 213 213 213 213 207 213 213 213 213
Chr19r2-15xGT 55,468,671 236 230 236 236 236 236 236 230 236 236 236 236
D19S246 55,647,457 243 251 243 251 243 243 243 251 243 251 243 243
Chr19-19xAG 56,215,067 229 247 243 243 243 243 229 247 243 243 229 243
Chr19-22xGT 56,411,092 246 242 242 242 242 242 246 242 242 242 246 242
Chr19-20xGT 56,655,961 251 237 247 247 247 247 251 237 247 247 251 247
Chr19-15xAC 56,664,850 235 243 237 237 237 237 235 243 237 237 235 237
D19S571 57,988,784 311 287 287 287 287 287 311 287 287 287 311 287
D19S572 58,797,162 119 131 119 131 119 119 119 131 119 119 119 119
IV:12IV:4 IV:7 IV:8 IV:9 IV:11
Kindred 1
III:1 III:2
228 228
243 241
249 243
279 281
186 188
164 172
247 247
98 94
231 231
365 343
214 222
211 215
107 99
169 169
181 185
213 213
226 226
251 243
177 179
215 217
207 213
230 236
221 243
249 243
242 242
237 247
243 237
287 287
131 119
236 228 232 228 232 228
243 243 241 243 241 243 243 241
241 249 243 243 241 243 249 243
281 279 281 281 281 281 279 281
188 186 188 188 188 188 186 188
164 164 172 172 164 172 164 172
255 247 247 247 255 247 247 247
86 98 94 94 94 94 100 94
231 231 231 231 231 231 231 231
353 365 343 343 343 343 365 343
222 214 222 222 222 222 214 222
213 211 215 215 215 215 211 215
105 107 99 99 99 99 107 99
167 169 169 169 169 169 169 169
169 181 185 185 185 185 181 185
213 213 213 213 213 213 213 213
222 226 222 226 226 226 226 226
251 251 251 243 243 243 251 243
181 177 181 179 179 179 177 179
215 215 215 217 217 217 215 217
213 207 215 213 213 213 207 213
238 230 238 236 236 236 230 236
247 221 243 243 251 243 243 243
241 249 241 243 243 243 243 249
246 242 246 242 246 242 246 242
237 237 237 247 249 247 249 237
247 243 247 237 247 237 247 243
311 287 311 287 287 287 287 287
115 131 115 119 115 119 115 131
IV:14 IV:18 IV:19 IV:20
Kindred 1
III:3 III:4
232 232 226 232
241 243 241 243
239 243 239 243
285 279 285 279
188 188 214 188
164 164 164 164
247 257 247 257
86 94 94 94
227 233 227 233
361 365 365 365
212 216 212 216
215 215 213 215
111 109 95 109
173 163 159 163
181 173 177 173
213 213 213 213
228 222 216 222
241 249 249 249
177 185 175 175
219 217 209 209
207 215 215 215
230 230 238 238
221 243 243 221
241 263 251 251
246 242 246 242
247 251 237 237
235 247 235 235
289 311 311 311
127 129 127 127
232 226
241 241
239 239
285 285
188 214
164 164
247 247
86 94
227 227
361 365
212 212
215 213
111 95
173 159
181 177
213 213
228 216
241 249
177 175
219 209
207 215
230 238
221 243
241 251
246 246
247 237
235 235
127 127
IV:11
Kindred 2
III:3 III:4
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Figure 4.18: Chromosome 1 region 1 (105,464,488 to 107,660,193). Affected 
individuals are shaded in black. Markers are displayed in order of physical location. 
Marker Location
D1S485 105,069,360 155 155 175 155
D1S429 105,494,413 221 221 223 221
GATA133A08 106,083,035 123 123 119 123
D1S239 106,640,929 243 243 257 243
ATA42G12 106,877,151 187 187 187 187
D1S248 106,956,443 213 213 213 213
D1S2726 110,896,304 285 283 283 283
Marker Location
D1S485 105,069,360 155 175 155 175 155 155 155 175 155 155 155 175
D1S429 105,494,413 221 223 221 223 221 221 221 223 221 221 221 223
GATA133A08 106,083,035 123 119 123 119 123 123 123 119 123 123 123 119
D1S239 106,640,929 243 257 243 257 243 243 243 243 243 243 243 257
ATA42G12 106,877,151 187 187 187 187 187 187 187 187 187 187 187 187
D1S248 106,956,443 213 213 213 213 213 213 213 213 213 213 213 213
D1S2726 110,896,304 283 283 283 283 283 283 283 283 285 283 285 283
Marker Location
D1S485 105,069,360 175 155 155 175 169 175
D1S429 105,494,413 219 221 225 217 205 219
GATA133A08 106,083,035 119 123 115 123 119 119
D1S239 106,640,929 257 243 249 241 241 243
ATA42G12 106,877,151 179 187 185 181 181 185
D1S248 106,956,443 213 213 213 213 213 213
D1S2726 110,896,304 279 277 283 287 287 285
Marker Location
D1S485 105,069,360 155 175 155 175 155 155 155 175 175 175
D1S429 105,494,413 221 219 227 219 227 221 227 219 217 219
GATA133A08 106,083,035 123 119 123 123 123 123 123 123 123 119
D1S239 106,640,929 243 257 243 257 243 243 243 257 241 243
ATA42G12 106,877,151 187 179 181 179 181 187 181 179 181 185
D1S248 106,956,443 213 213 213 213 213 213 213 213 213 213
D1S2726 110,896,304 277 279 277 279 277 277 277 277 287 285
III:3
Kindred 2
Kindred 1
Kindred 1
IV:11 IV:12
IV:20IV:19IV:18IV:14
III:4III:3
IV:11
III:4
III:1 III:2
IV:4 IV:7 IV:8 IV:9
   
Figure 4.19: Chromosome 1 region 2 (150, 657,906 to 165,802,112). Affected individuals are shaded in black. Markers are displayed in order of 
physical location. Black boxes around haplotypes indicate a common homozygous region, with identical haplotypes within the same family. 
 
Marker Location
D1S498 148,114,568 198 196 200 196
D1S498Manju 149,568,188 191 189 193 189
Chr1-25xTG 150,948,915 191 223 191 223
Chr1-22xGT 152,009,159 251 247 247 247
Chr1-26xAC 153,111,478 251 241 245 241
D1S394 154,132,484 297 297 285 297
D1S1653 154,745,743 106 98 102 98
Chr1-25xAC 155,158,129 246 252 246 252
D1S1653 156,199,398 105 97 101 97
D1S484 157,580,383 273 283 277 283
D1S1679 160,628,539 147 147 155 147
D1S1677 161,826,325 200 204 200 204
D1S2878 162,135,023 169 169 169 169
D1S2673 163,312,611 97 101 105 101
D1S196 164,335,785 321 321 331 321
D1S1589 172,527,725 199 215 205 201
Marker Location
D1S498 148,114,568 196 200 196 196 196 200 196 196 196 196 198 196
D1S498Manju 149,568,188 189 193 189 189 189 193 189 189 189 189 191 189
Chr1-25xTG 150,948,915 223 191 223 223 223 223 223 223 223 223 191 223
Chr1-22xGT 152,009,159 247 247 247 247 247 247 247 247 247 247 251 247
Chr1-26xAC 153,111,478 241 241 241 241 241 241 241 241 241 241 251 241
D1S394 154,132,484 297 297 297 297 297 297 297 297 297 297 297 297
D1S1653 154,745,743 98 98 98 98 98 98 98 98 98 98 106 98
Chr1-25xAC 155,158,129 252 252 252 252 252 252 252 252 252 252 246 252
D1S1653 156,199,398 97 97 97 97 97 97 97 97 97 97 105 97
D1S484 157,580,383 283 283 283 283 283 283 283 283 283 283 273 277
D1S1679 160,628,539 147 147 147 147 147 147 147 147 147 147 147 155
D1S1677 161,826,325 204 204 204 204 204 204 204 204 204 204 200 200
D1S2878 162,135,023 169 169 169 169 169 169 169 169 169 169 169 169
D1S2673 163,312,611 101 101 101 101 101 101 101 101 101 101 97 105
D1S196 164,335,785 321 321 321 321 321 321 321 321 321 331 321 331
D1S1589 172,527,725 215 201 215 201 215 201 215 205 215 205 199 205
IV:11 IV:12
Kindred 1
III:1 III:2
IV:4 IV:7 IV:8 IV:9
200 196
193 189
191 223
247 247
245 241
285 297
102 98
246 252
101 97
283 283
151 147
200 204
169 169
101 101
321 321
201 201
196 200 196 196 196 196 196 196
189 193 189 189 189 189 189 189
223 191 223 223 223 223 223 223
247 247 247 247 247 247 247 247
241 245 241 241 241 241 241 241
297 285 297 297 285 297 297 297
98 102 98 98 98 98 98 98
250 246 250 252 250 252 250 252
97 101 97 97 97 97 97 97
283 283 283 283 283 283 283 283
147 151 147 147 147 147 147 147
204 200 204 204 204 204 204 204
169 169 169 169 169 169 169 169
101 101 101 101 101 101 101 101
321 321 321 321 321 321 321 321
215 201 215 201 215 201 215 201
IV:14 IV:18 IV:19 IV:20
Kindred 1
III:3 III:4
200 194 200 194
191 187 193 187
197 191 221 191
252 216 246 216
249 247 241 247
289 287 301 287
106 98 102 98
246 234 242 234
105 97 101 97
277 281 277 281
147 159 155 159
196 212 200 212
157 163 159 163
93 99 101 99
321 333 321 333
201 215 201 215
194 194
187 187
191 191
216 216
247 247
187 187
98 98
234 234
97 97
281 281
159 159
212 212
163 163
99 99
333 333
215 215
IV:11
Kindred 2
III:3 III:4
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4.3.3.2.3 Chromosome 2 
For the region on chromosome 2 (131,671,717 to 144,316,267), eleven microsatellite 
markers were analyzed. This region was not linked in kindred 1, but in kindred 2, 
IV:11, homozygosity was identified from D2S112 (132,925,167) to D2S132 
(144,683,977) (Figure 4.20). 
4.3.3.2.4 Chromosome 3 
For the region on chromosome 3 (74,919,074 to 115,297,798), 26 microsatellite 
markers were analysed (Figure 4.21). In kindred 1 family 1, a common homozygous 
haplotype was found in all three affected family members, IV:7, IV:8 and IV:11. This 
was identified from Chr3-16xTTA (novel marker) (75,301,460) to Chr3-16xTC (novel 
marker) (114,880,547). In kindred 2, IV:11 had a homozygous region from D3S3045 
(108,472,546) to Chr3-16xTC (novel marker) (114,880,547). 
4.3.3.2.5 Chromosome 6 
Chromosome 6 region 1 extends from 88,878,455 to 91,450,041 (Figure 4.22). Four 
microsatellite markers were analysed from Chr6r1-15xATA (novel marker) 
(88.893,581) to Chr6-26xCA (novel marker) (91,342,860). No linkage was found. 
Affected individuals IV:8 and IV:11 in kindred 1 family 1 share a common 
homozygous haplotype across this region, but the other affected individual IV:7 is 
heterozygous, having inherited two different alleles. This region was excluded. 
Chromosome 6 region 2 is between 95,956,306 and 100,444,677 (Figure 4.23). Five 
microsatellite markers were analysed, from Chr6-30xTA (novel marker) (95,957,151) 
to Chr6-22xTG (novel marker) (99,826, 744), but no linkage was detected. Affected 
individuals IV:8 and IV:11 in kindred 1 family 1 again share a common homozygous 
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haplotype across this region, but again, the other affected individual IV:7 is 
heterozygous, having inherited two different alleles. This region was excluded. 
4.3.3.2.6 Chromosome 7 
The region on chromosome 7 extended from 116,265,885 to 119,025,178 (Figure 
4.24). Three microsatellite markers were analysed across this region from 17xATT 
(novel marker) (117,254,117) to 29xTA (novel marker) (118,671,349) but no 
common homozygous haplotype was found. A region of homozygosity for kindred 2 
family member IV:11 was detected from 17xATT to 23xAT (novel marker) 
(117,998,458). 
4.3.3.2.7 Chromosome 11 
Chromosome 11 region 1 (31,389,403 to 34,497,225) (Figure 4.25) was investigated 
with four microsatellite markers from Chr11r1-20xAC (novel marker) (31,577,606) to 
Chr11r1-18xAC (novel marker) (34,192,263). No common homozygous haplotypes 
were detected across all three families, but Chr11r1-20xAC was linked for kindred 1 
family 1.  
Chromosome 11 region 2 (38,567,581 to 40,614,578) (Figure 4.26) was investigated 
with three microsatellite markers from Chr11r2-29xGT (novel marker) (38,838, 292) 
to Chr11r2-18xTG (novel marker) but no common homozygous haplotypes were 
found. 
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Figure 4.20: Chromosome 2 (131,671,717 to 144,316,267) Affected individuals are 
shaded in black. Markers are displayed in order of physical location. The black box 
around haplotypes in IV:11 indicates a region of homozygosity. 
Marker Location
D2S112 132,925,167 143 143 143 137
D2S368 134,893,430 237 227 227 235
D2S2385 137,478,083 138 140 140 122
Chr2-24xCA 138,662,644 250 240 240 244
Chr2-24xTA 139,470,722 370 382 382 382
Chr2-19xCA 140,864,808 284 286 286 286
Chr2-22xAC 141,769,786 228 230 228 208
Chr2-22xTG 142,772,995 273 279 279 275
Chr2-22xTCT 143,627,817 273 275 275 273
D2S132 144,683,977 203 203 199 203
D2S1399 147,926,579 137 145 141 149
Marker Location
D2S112 132,925,167 143 137 143 137 143 143 143 137 143 143 143 137
D2S368 134,893,430 237 235 237 235 227 227 227 235 227 227 227 235
D2S2385 137,478,083 138 122 138 140 140 140 140 122 140 140 140 122
Chr2-24xCA 138,662,644 250 244 250 240 240 240 240 244 240 240 240 244
Chr2-24xTA 139,470,722 370 382 370 382 382 382 382 382 382 382 382 382
Chr2-19xCA 140,864,808 284 286 284 286 286 286 286 286 286 286 286 286
Chr2-22xAC 141,769,786 228 208 228 228 230 228 230 208 230 228 228 208
Chr2-22xTG 142,772,995 273 275 273 279 279 279 279 275 279 279 279 275
Chr2-22xTCT 143,627,817 273 273 275 275 275 275 275 273 275 275 275 273
D2S132 144,683,977 203 203 203 199 203 199 203 203 203 199 203 203
D2S1399 147,926,579 137 149 137 141 145 141 145 149 145 141 145 149
Marker Location
D2S112 132,925,167 135 137 141 131 131 131
D2S368 134,893,430 225 235 235 235 225 235
D2S2385 137,478,083 132 122 140 134 138 134
Chr2-24xCA 138,662,644 248 244 252 246 246 246
Chr2-24xTA 139,470,722 380 382 372 380 378 380
Chr2-19xCA 140,864,808 286 286 282 286 286 286
Chr2-22xAC 141,769,786 208 220 226 206 224 206
Chr2-22xTG 142,772,995 275 275 275 261 277 261
Chr2-22xTCT 143,627,817 269 273 257 257 257 257
D2S132 144,683,977 195 203 203 201 199 201
D2S1399 147,926,579 141 149 137 137 141 145
Marker Location
D2S112 132,925,167 143 135 143 137 143 137 131 131
D2S368 134,893,430 227 225 225 225 227 235 227 235 235 235
D2S2385 137,478,083 140 132 132 132 140 122 140 122 134 134
Chr2-24xCA 138,662,644 240 248 248 248 240 244 240 244 246 246
Chr2-24xTA 139,470,722 382 380 372 380 382 382 382 382 380 380
Chr2-19xCA 140,864,808 286 286 286 286 286 286 286 286 286 286
Chr2-22xAC 141,769,786 228 220 228 208 228 208 220 220 206 206
Chr2-22xTG 142,772,995 279 275 275 275 279 275 279 275 261 261
Chr2-22xTCT 143,627,817 275 273 273 269 275 273 257 257
D2S132 144,683,977 199 195 205 195 199 203 199 203 201 201
D2S1399 147,926,579 141 141 141 141 141 149 141 149 137 145
IV:14 IV:18 IV:19 IV:20 IV:11
Kindred 1 Kindred 2
III:3 III:4 III:3 III:4
IV:4 IV:7 IV:8 IV:9 IV:11 IV:12
Kindred 1
III:1 III:2
    
Figure 4.21: Chromosome 3 (74,919,074 to 115,297,798). Affected individuals are shaded in black. Markers are displayed in order of physical 
location. Black boxes around haplotypes indicate homozygous linked regions. 
Marker Location
Chr3-16xTTA 75,301,460 248 270 262 270
Chr3-22xGT 77,535,415 236 236 236 236
D3S3681 79,894,319 155 155 139 155
Chr3-18xTG 80,874,605 195 195 205 195
Chr3-29xGT 81,833,944 244 250 244 250
Chr3-21xAT 83,215,618 328 328 330 328
Chr3-28xAC 84,520,624 206 206 206 206
Chr3-28xTA 86,901,482 222 228 216 228
Chr3-16xATT87 87,963,171 280 270 272 270
Chr3-26xAT 90,235,425 182 198 208 198
Chr3-22xCA 95,173,162 181 183 187 183
D3S2462 97,601,374 238 234 238 234
Chr3-33xAT 98,564,706 236 240 228 240
Chr3-15xTCA 99,228,137 239 251 239 251
Chr3-28xTG 100,485,902 213 213 215 213
Chr3-16xATT10101,159,738 230 226 226 226
D3S1271 102,217,419 156 154 154 154
D3S3045 108,472,546 178 190 190 190
Chr3-24xGT 109,375,535 246 244 240 244
Chr3-22xCT 110,021,256 369 369 359 369
Chr3-16xGT 111,566,561 189 193 195 193
Chr3-25xGT 112,400,226 236 234 222 234
D3S4018 113,136,904 299 299 295 299
D3S3683 114,744,360 162 170 156 170
Chr3-16xTC 114,880,547 241 241 241 241
D3S3585 115,156,830 266 268 278 266
Marker Location
Chr3-16xTTA 75,301,460 270 262 270 270 270 270 248 270 270 270 248 270
Chr3-22xGT 77,535,415 236 236 236 236 236 236 236 236 236 236 236 236
D3S3681 79,894,319 155 139 155 155 155 155 155 155 155 155 155 155
Chr3-18xTG 80,874,605 195 205 195 195 195 195 195 195 195 195 195 195
Chr3-29xGT 81,833,944 244 250 250 250 250 250 244 250 250 250 244 250
Chr3-21xAT 83,215,618 328 330 328 328 328 328 328 328 328 328 328 328
Chr3-28xAC 84,520,624 206 206 206 206 206 206 206 206 206 206 206 206
Chr3-28xTA 86,901,482 228 216 228 228 228 228 222 228 228 228 222 228
Chr3-16xATT87 87,963,171 270 272 270 270 270 270 280 270 270 270 280 270
Chr3-26xAT 90,235,425 198 208 198 198 198 198 182 198 198 198 182 198
Chr3-22xCA 95,173,162 183 187 183 183 183 183 181 183 183 183 181 183
D3S2462 97,601,374 234 238 234 234 234 234 238 234 234 234 238 234
Chr3-33xAT 98,564,706 240 228 240 240 240 240 236 240 240 240 236 240
Chr3-15xTCA 99,228,137 251 239 251 251 251 251 239 251 251 251 239 251
Chr3-28xTG 100,485,902 213 215 213 213 213 213 213 213 213 213 213 213
Chr3-16xATT10101,159,738 226 226 226 226 226 226 230 226 226 226 230 226
D3S1271 102,217,419 154 154 154 154 154 154 156 154 154 154 156 154
D3S3045 108,472,546 190 190 190 190 190 190 178 190 190 190 178 190
Chr3-24xGT 109,375,535 244 240 244 244 244 244 246 240 244 244 246 244
Chr3-22xCT 110,021,256 369 359 369 369 369 369 369 359 369 369 369 369
Chr3-16xGT 111,566,561 193 195 193 193 193 193 189 195 193 193 189 193
Chr3-25xGT 112,400,226 234 222 234 234 234 234 236 222 234 234 236 234
D3S4018 113,136,904 299 295 299 299 299 299 299 295 299 299 299 299
D3S3683 114,744,360 170 156 170 170 170 170 162 156 170 170 162 170
Chr3-16xTC 114,880,547 241 241 241 241 241 241 241 241 241 241 241 241
D3S3585 115,156,830 268 278 268 266 268 266 266 278 268 266 266 266
IV:4 IV:7 IV:8 IV:9 IV:11 IV:12
Kindred 1
III:1 III:2
262 262
224 236
143 155
195 193 
238 244
328 328
206 206
216 216
270 270
198 200
189 191
246 238
234 242
259 251
211 213
226 230
148 154
190 190
246 240
367 359
193 195
236 222
299 295
162 156
241 241
266 278
266 262 266 262 266 262 266 262
236 236 236 236 224 236 224 236
141 143 141 155 139 155 141 143
195 195 195 193 207 193 195 195
244 238 244 244 234 244 244 238
330 328 330 328 330 328 330 328
206 206 206 206 206 206 206 206
222 216 222 216 216 216 222 216
282 270 282 270 278 270 282 270
182 198 182 200 186 200 182 198
181 189 181 191 185 191 181 189
238 246 238 238 238 238 238 246
234 234 234 242 238 242 234 234
239 259 239 251 259 251 239 259
213 211 213 213 213 213 213 211
230 226 230 230 226 230 226 230
154 148 156 154 152 154 156 148
190 190 178 190 190 190 178 190
246 246 246 240 246 240 246 246
367 367 369 359 367 359 369 367
193 193 189 195 189 195 189 193
222 236 236 222 224 222 236 236
291 299 299 295 291 295 299 299
170 162 162 156 170 156 162 162
250 241 241 241 250 241 241 241
268 266 266 278 268 278 266 266
IV:14 IV:18 IV:19 IV:20
Kindred 1
III:3 III:4
268 268 268 268
228 224 236 224
139 155 155 155
193 193 193 193
240 242 244 242
330 328 328 328
206 206 206 206
216 216 216 216
272 270 270 270
182 194 196 194
183 179 191 179
234 238 238 238
222 224 224 224
243 263 259 263
213 207 207 207
230 232 224 232
154 156 154 156
190 182 186 182
246 244 242 244
359 361 363 361
189 193 195 193
236 240 222 240
295 287 295 287
156 168 162 168
241 241 243 241
264 268 268 268
268 268
228 224
139 155
193 193
240 244
330 328
206 206
216 216
272 270
182 196
183 191
234 238
222 224
243 259
213 207
230 224
154 156
182 182
244 244
361 361
193 193
240 240
287 287
168 168
241 241
268 268
IV:11
Kindred 2
III:3 III:4
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Figure 4.22: Chromosome 6 region 1 (88,878,455 to 91,450,041). Affected 
individuals are shaded in black. Markers are displayed in order of physical location. 
 
4.3.3.2.8 Chromosome 14 
The region on chromosome 14 (87,629,745 to 94,999,444) was investigated with 
seven microsatellite markers from D14S68 (87,697,387) to D14S1434 (94,377,875) 
(Figure 4.27). No common homozygous haplotype was found, although kindred 2 
family member IV:11 was homozygous from D14S68 to D14S280 (91,252,619). 
  
Marker Location
Chr6r1-15xATA 88,893,581 208 206 208 206
Chr6r1-26xTA 89,506,164 229 223 193 223
Chr6-16xAC 90,194,544 223 219 227 219
Chr6-26xCA 91,342,860 232 230 236 230
Marker Location
Chr6r1-15xATA 88,893,581 206 208 208 208 206 206 208 206 206 206 208 206
Chr6r1-26xTA 89,506,164 223 193 229 193 223 223 229 223 223 223 229 223
Chr6-16xAC 90,194,544 219 227 223 227 219 219 223 219 219 219 223 219
Chr6-26xCA 91,342,860 230 236 232 236 230 230 232 230 230 230 232 230
Marker Location
Chr6r1-15xATA 88,893,581 196 206 196 206 196 206
Chr6r1-26xTA 89,506,164 219 223 237 237 237 237
Chr6-16xAC 90,194,544 221 219 221 223 221 223
Chr6-26xCA 91,342,860 230 230 234 234 234 234
Marker Location
Chr6r1-15xATA 88,893,581 206 196 206 196 206 196 206 196 196 206
Chr6r1-26xTA 89,506,164 223 219 223 219 223 219 223 219 237 237
Chr6-16xAC 90,194,544 223 221 223 221 223 221 223 221 221 223
Chr6-26xCA 91,342,860 230 230 230 230 230 230 230 230 234 234
IV:14 IV:18 IV:19 IV:20 IV:11
IV:11 IV:12
Kindred 1 Kindred 2
III:3 III:4 III:3 III:4
Kindred 1
III:1 III:2
IV:4 IV:7 IV:8 IV:9
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Figure 4.23: Chromosome 6 region 2 (95,956,306 and 100,444,677). Affected 
individuals are shaded in black. Markers are displayed in order of physical location. 
 
4.3.3.2.9 Chromosome 16 
The region on chromosome 16 (27,176,280 to 47,670,664) was investigated with six 
microsatellite markers, from D16S685 (30,575,220) to Chr16-23xAC (novel marker) 
(46,392,429). No common homozygous haplotype was detected amongst affected 
individuals (Figure 4.28). 
 
Marker Location
Chr6-30xTA 95,957,151 247 209 223 209
Chr6-18xAC 96818346 194 192 190 192
Chr6-21xTG 97,846,372 172 168 190 168
Chr6-17xTG 98,718,380 159 155 155 155
Chr6-22xTG 99,826,744 192 194 214 194
Marker Location
Chr6-30xTA 95,957,151 209 223 247 223 209 209 247 223 209 209 247 209
Chr6-18xAC 96818346 192 190 194 190 192 192 194 190 192 192 194 192
Chr6-21xTG 97,846,372 168 190 172 190 168 168 172 190 168 168 172 168
Chr6-17xTG 98,718,380 155 155 159 155 155 155 155 155 159 155
Chr6-22xTG 99,826,744 194 214 192 214 194 194 192 214 194 194 192 194
Marker Location
Chr6-30xTA 95,957,151 223 209 235 237 207 225
Chr6-18xAC 96818346 190 188 194 188 192 194
Chr6-21xTG 97,846,372 190 188 168 190 184 182
Chr6-17xTG 98,718,380 155 155 155 155 153 155
Chr6-22xTG 99,826,744 214 192 206 198 216 192
Marker Location
Chr6-30xTA 95,957,151 209 223 209 223 209 223 209 223 235 225
Chr6-18xAC 96818346 192 190 192 190 192 190 192 190 194 194
Chr6-21xTG 97,846,372 190 190 190 190 168 190 190 190 168 182
Chr6-17xTG 98,718,380 153 155 153 155 155 155 153 155 155 155
Chr6-22xTG 99,826,744 192 214 192 214 194 214 192 214 206 192
IV:14 IV:18 IV:19 IV:20 IV:11
IV:11 IV:12
Kindred 1 Kindred 2
III:3 III:4 III:3 III:4
Kindred 1
III:1 III:2
IV:4 IV:7 IV:8 IV:9
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Figure 4.24: Chromosome 7 (116,265,885 to 119,025,178). Affected individuals are 
shaded in black. Markers are displayed in order of physical location. 
 
4.3.3.2.10 Chromosome 22 
The region on chromosome 22 from 35,860,982 to 41,897,898 was investigated with 
seven microsatellite markers (Figure 4.29) from D22S445 (35,895,844) to D22S1151 
(41,865,323), but no common haplotype was noted in affected individuals. 
  
Marker Location
17xATT 117,254,117 211 227 211 217
23xAT 117,998,458 393 397 397 395
29xTA 118,671,349 271 261 267 261
Marker Location
17xATT 117,254,117 227 211 227 217 227 217 227 217 211 217
23xAT 117,998,458 397 397 397 397 397 395 397 397 397 395 393 395
29xTA 118,671,349 261 267 261 267 261 261 271 261 261 261 271 261
Marker Location
17xATT 117,254,117 211 217 217 217 217 217
23xAT 117,998,458 397 395 397 397 397 397
29xTA 118,671,349 267 261 277 277 253 275
Marker Location
17xATT 117,254,117 217 211 217 217 217 217 217 217 217 217
23xAT 117,998,458 393 397 393 395 393 395 393 395 397 397
29xTA 118,671,349 277 267 275 261 277 261 277 261 277 275
IV:14 IV:18 IV:19 IV:20 IV:11
IV:11 IV:12
Kindred 1 Kindred 2
III:3 III:4 III:3 III:4
Kindred 1
III:1 III:2
IV:4 IV:7 IV:8 IV:9
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Figure 4.25: Chromosome 11 region 1 (31,389,403 to 34,497,225). Affected 
individuals are shaded in black. Markers are displayed in order of physical location. 
  
Marker Location
Chr11r1-20xAC 31,577,606 207 205 195 205
Chr11r1-16xTAT 32,822,590 257 271 261 271
Chr11r1-23xAC 33,219,409 357 351 349 351
Chr11r1-18xAC 34,192,263 248 258 254 246
Marker Location
Chr11r1-20xAC 31,577,606 207 205 205 205 205 205 207 205 205 205 207 195
Chr11r1-16xTAT 32,822,590 257 271 271 271 271 271 271 271 271 271 257 261
Chr11r1-23xAC 33,219,409 357 351 351 351 351 351 351 351 351 351 357 349
Chr11r1-18xAC 34,192,263 248 246 258 246 258 246 258 246 258 246 248 254
Marker Location
Chr11r1-20xAC 31,577,606 195 205 195 209 207 207
Chr11r1-16xTAT 32,822,590 261 257 257 261 261 261
Chr11r1-23xAC 33,219,409 349 355 347 349 249 351
Chr11r1-18xAC 34,192,263 254 246 250 256 260 256
Marker Location
Chr11r1-20xAC 31,577,606 207 195 207 195 207 195 195 195 195 207
Chr11r1-16xTAT 32,822,590 257 261 257 261 257 261 261 261 257 261
Chr11r1-23xAC 33,219,409 357 349 357 349 357 349 351 349 347 351
Chr11r1-18xAC 34,192,263 248 254 248 254 248 254 248 254 250 256
IV:14 IV:18 IV:19 IV:20 IV:11
IV:12
Kindred 1 Kindred 2
III:3 III:4 III:3 III:4
IV:4 IV:7 IV:8 IV:9 IV:11
Kindred 1
III:1 III:2
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Figure 4.26: Chromosome 11 region 2 (38,567,581 to 40,614,578). Affected 
individuals are shaded in black. Markers are displayed in order of physical location. 
  
Marker Location
Chr11r2-29xGT 38,838,292 231 237 231 231
Chr11r2-20xAC 39,808,766 254 256 264 256
Chr11r2-18xTG 40,265,383 163 163 171 163
Marker Location
Chr11r2-29xGT 38,838,292 231 231 237 231 237 231 237 231 237 231 231 231
Chr11r2-20xAC 39,808,766 254 264 256 256 256 256 256 256 256 256 254 264
Chr11r2-18xTG 40,265,383 163 171 163 163 163 163 163 163 163 171 163 171
Marker Location
Chr11r2-29xGT 38,838,292 231 231 231 231 231 231
Chr11r2-20xAC 39,808,766 264 256 248 256 248 256
Chr11r2-18xTG 40,265,383 171 163 163 163 175 163
Marker Location
Chr11r2-29xGT 38,838,292 231 231 231 231 231 231 231 231 231 231
Chr11r2-20xAC 39,808,766 254 264 254 264 254 264 254 264 248 256
Chr11r2-18xTG 40,265,383 163 171 163 171 163 171 171 171 163 163
IV:14 IV:18 IV:19 IV:20 IV:11
IV:12
Kindred 1 Kindred 2
III:3 III:4 III:3 III:4
IV:4 IV:7 IV:8 IV:9 IV:11
Kindred 1
III:1 III:2
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Figure 4.27: Chromosome 14 (87,629,745 to 94,999,444). Affected individuals are 
shaded in black. Markers are displayed in order of physical location. 
  
Marker Location
D14S68 87,697,387 323 329 325 323
D14S256 88,281,213 130 142 142 142
D14S1005 88,447,761 211 211 211 211
D14S1044 89,140,145 250 256 248 256
D14S280 91,252,619 251 247 251 247
D14S302 92,432,197 185 177 185 177
D14S1434 94,377,875 210 226 210 226
Marker Location
D14S68 87,697,387 323 325 323 325 329 323 323 325 329 325 329 325
D14S256 88,281,213 130 142 130 142 142 142 142 142 142 142 142 142
D14S1005 88,447,761 211 211 211 211 211 211 211 211 211 211 211 211
D14S1044 89,140,145 250 256 250 248 256 256 250 256 256 256 256 248
D14S280 91,252,619 251 247 251 251 247 247 251 247 247 247 247 251
D14S302 92,432,197 185 177 185 185 177 177 185 177 177 177 177 185
D14S1434 94,377,875 210 226 210 210 226 226 210 226 226 226 226 210
Marker Location
D14S68 87,697,387 325 325 325 325 325 327
D14S256 88,281,213 142 150 142 152 142 152
D14S1005 88,447,761 211 211 211 211 211 227
D14S1044 89,140,145 248 256 256 256 256 248
D14S280 91,252,619 251 247 251 251 251 247
D14S302 92,432,197 185 177 177 177 181 181
D14S1434 94,377,875 210 226 222 222 226 222
Marker Location
D14S68 87,697,387 331 325 325 325 325 325 325 325 325 325
D14S256 88,281,213 130 142 130 142 130 142 142 142 142 142
D14S1005 88,447,761 223 211 209 211 209 211 209 211 211 211
D14S1044 89,140,145 248 256 248 248 248 256 248 256 256 256
D14S280 91,252,619 247 247 247 251 247 251 247 247 251 251
D14S302 92,432,197 177 177 195 185 195 185 195 177 177 181
D14S1434 94,377,875 210 226 226 210 210 210 226 226 222 226
IV:14 IV:18 IV:19 IV:20 IV:11
IV:11 IV:12
Kindred 1 Kindred 2
III:3 III:4 III:3 III:4
Kindred 1
III:1 III:2
IV:4 IV:7 IV:8 IV:9
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Figure 4.28: Chromosome 16 (27,176,280 to 47,670,664). Affected individuals are 
shaded in black. Markers are displayed in order of physical location. 
  
Marker Location
D16S685 30,575,220 122 126 114 126
Chr16-15xAAT 34,095,144 414 414 417 414
D16S746 34,715,504 290 280 280 280
D16S3105 45,349,600 184 184 186 184
Chr16-29xTG 45,836,004 364 368 366 368
Chr16-23xAC 46,392,429 352 346 354 346
Marker Location
D16S685 30,575,220 122 126 126 114 126 126 122 114 126 126 126 126
Chr16-15xAAT 34,095,144 414 414 414 417 414 414 414 417 414 417 414 414
D16S746 34,715,504 290 280 280 280 280 280 290 280 280 280 280 280
D16S3105 45,349,600 184 184 184 186 184 184 184 186 184 184 184 184
Chr16-29xTG 45,836,004 364 368 368 366 368 366 364 366 368 368 368 368
Chr16-23xAC 46,392,429 352 346 346 354 346 346 352 354 346 346 346 346
Marker Location
D16S685 30,575,220 114 126 122 116 118 118
Chr16-15xAAT 34,095,144 417 414 414 410 414 414
D16S746 34,715,504 280 280 286 280 280 280
D16S3105 45,349,600 186 184 182 182 182 182
Chr16-29xTG 45,836,004 366 368 362 368 366 366
Chr16-23xAC 46,392,429 354 346 352 346 346 346
Marker Location
D16S685 30,575,220 114 126 114 126 114 126 114 126 122 118
Chr16-15xAAT 34,095,144 417 414 414 414 417 414 414 414 414 414
D16S746 34,715,504 280 280 300 280 280 280 300 280 286 280
D16S3105 45,349,600 186 184 184 184 186 184 184 184 182 182
Chr16-29xTG 45,836,004 366 368 368 368 366 368 368 368 362 366
Chr16-23xAC 46,392,429 354 346 352 346 354 346 352 346 352 346
Kindred 1
III:1 III:2
IV:4 IV:7 IV:8 IV:9 IV:11 IV:12
Kindred 1 Kindred 2
III:3 III:4 III:3 III:4
IV:14 IV:18 IV:19 IV:20 IV:11
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Figure 4.29: Chromosome 22 (35,860,982 to 41,897,898). Affected individuals are 
shaded in black. Markers are displayed in order of physical location. 
 
4.3.3.4 Sequencing of Known Cataract Genes 
The following known cataract genes were sequenced for kindred 1 family members 
III:1, IV:7, II:3 and IV:18, and kindred 2 family members (unless otherwise noted in 
Table 4.5), using primers to amplify exons and intron/exon boundaries as detailed 
previously: CRYBB3 (Table 6.23), BFSP1 (Table 6.25), LIM2 (Table 6.26), GCNT2 
Marker Location
D22S445 35,895,844 118 110 118 110
D22S1156 36,711,717 154 148 148 148
D22S272 37,415,973 131 131 139 131
D22S428 38,284,898 143 147 147 147
D22S1197 38,749,278 167 167 163 167
D22S276 40,336,789 243 243 245 243
D22S1151 41,865,323 127 129 131 129
Marker Location
D22S445 35,895,844 110 110 110 110 110 110 110 118 110 118 118 110
D22S1156 36,711,717 148 148 148 148 148 148 148 148 148 148 154 148
D22S272 37,415,973 131 131 131 139 131 131 131 139 131 131 131 131
D22S428 38,284,898 147 147 147 147 147 147 147 147 147 147 143 147
D22S1197 38,749,278 167 167 167 163 167 167 167 163 167 167 167 167
D22S276 40,336,789 243 243 243 245 243 243 243 245 243 243 243 243
D22S1151 41,865,323 129 129 129 131 129 129 129 131 129 129 127 129
Marker Location
D22S445 35,895,844 118 118 114 118 132 118
D22S1156 36,711,717 148 156 148 154 148 148
D22S272 37,415,973 139 137 145 143 139 119
D22S428 38,284,898 147 143 143 143 143 147
D22S1197 38,749,278 167 163 163 167 163 167
D22S276 40,336,789 251 241 243 251 245 245
D22S1151 41,865,323 127 129 129 131 127 131
Marker Location
D22S445 35,895,844 126 118 126 118 126 118 126 118 114 118
D22S1156 36,711,717 148 156 148 148 148 156 148 156 148 148
D22S272 37,415,973 131 137 131 139 131 137 131 137 145 119
D22S428 38,284,898 143 143 143 147 143 143 143 143 143 147
D22S1197 38,749,278 167 163 167 167 167 163 167 163 163 167
D22S276 40,336,789 243 241 243 241 243 241 243 241 243 245
D22S1151 41,865,323 127 129 127 127 127 129 127 129 129 131
Kindred 1
III:1 III:2
IV:4 IV:7 IV:8 IV:9 IV:11 IV:12
Kindred 1 Kindred 2
III:3 III:4 III:3 III:4
IV:14 IV:18 IV:19 IV:20 IV:11
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(Table 6.27), GALK1 (Table 6.31), GJA8 (Table 6.28), CRYBB1 (Table 6.24), HSF4 
(Table 6.29), CRYAA (Table 6.30), CRYBB2 (Table 6.21), CRYBA4 (Table 6.22) and 
BFSP2 (Table 635). 
Although many known SNPs were identified, no putative pathogenic mutations were 
detected (Table 4.6). 
   Kindred 1 Family 1  Kindred 1 Family 2 Kindred 2 Family 1 
  III:2 (P) IV:8 (A) III:3 (P) IV:19 (A) III:3 (P) IV:11 (A) 
CRYBB3-1 WT  WT  WT  WT  WT  WT  
CRYBB3-2 
WT (rs 
2269672 
TT) 
WT 
(rs=TT)  
WT 
(rs=CT)  
WT 
(rs=CT)  
WT (rs=TT)  WT (rs=CT)  
CRYBB3-3 WT  WT  WT  WT  WT  WT  
CRYBB3-4 WT  WT  WT  WT  WT  WT  
CRYBB3-5 
WT (hmz 
for 
rs960378 
c.337C>G, 
p.His113 
Asp  
WT (hmz 
for 
rs960378 
c.337C>G, 
p.His113 
Asp  
WT (htz for 
rs960378 
c.337C>G, 
p.His113 
Asp  
WT (hmz 
G)  
WT (htz for rs960378 
c.337C>G, 
p.His113Asp  
WT (htz for 
rs960378 
c.337C>G, 
p.His113Asp  
CRYBB3-6 WT  WT  WT  WT  WT  WT  
BFSP1-1  WT  WT  WT  WT  *WT  WT  
BFSP1-2 WT  WT  WT  WT  *WT  WT  
BFSP1-3 WT  WT  WT  WT  *WT  WT  
BFSP1-4 WT  WT  WT  
htz c.576-
42G>A 
*htz c.576-42G>A WT  
BFSP1-5 WT  WT  WT  WT  *WT  WT  
BFSP1-6 WT  WT  WT  
htz c.776-
45A>G 
*htz c.776-45A>G 
hmz c.776-
45A>G 
BFSP1-7 WT  WT  WT  WT  *htz AG rs6080719 
hmz 
Grs6080719 
BFSP1-8A WT  WT  WT  WT  *WT  WT  
BFSP1-8B WT  WT  WT  WT  *htz AG rs6136118 
hmz G 
rs6136118 
BFSP1-8C 
hmz G 
rs6080718 
htz AG 
rs6080718 
hmz G 
rs6080718 
hmz G 
rs6080718 
*hmz G rs6080718, 
htz CT rs6080717 
hmz G 
rs6080718, 
hmz T 
rs6080717 
BFSP1-T2-1F WT WT WT WT *WT WT 
LIM2-2  WT  ***WT  WT  WT  *WT  WT  
LIM2-3  WT  ***WT  WT  WT  *WT  WT  
LIM2-4  
WT (htz CT 
int4 
rs2547318) 
***WT 
(hmz int4 T 
rs2547318) 
WT (htz 
CT int4 
rs2547318) 
WT (hmz 
int4 T 
rs2547318) 
*WT (hmz int4 T 
rs2547318) 
WT (hmz int4 
T rs2547318) 
LIM2-5 x ***WT x WT *WT WT 
4. Non-syndromic Cataract Families   168 
 
   Kindred 1 Family 1  Kindred 1 Family 2 Kindred 2 Family 1 
  III:2 (P) IV:8 (A) III:3 (P) IV:19 (A) III:3 (P) IV:11 (A) 
GCNT2-001-
1A 
**hmz C 
***htz TC 
rs2230906  
htz TC 
rs2230906  
htz TC 
rs2230906  
hmz C hmz C 
GCNT2-001-
1B 
**WT ***WT WT WT WT WT 
GCNT2-001-
1C 
**WT ***WT WT WT WT WT 
GCNT2-001-
2 
**WT ***WT WT WT WT WT 
GCNT2-001-
3 
**WT ***WT WT WT WT WT 
GCNT2-004-
1A 
**WT ***WT WT WT WT WT 
GCNT2-004-
1BF 
**WT WT WT WT WT WT 
GCNT2-004-
1C 
**hmz G 
rs539351 
***hmz G 
rs539351 
hmz G 
rs539351 
hmz G 
rs539351 
hmz G rs539351 
hmz G 
rs539351 
GCNT2-006-
3A 
**htz CT 
rs557441 
***htz CT 
rs557441, 
htz AC -26 
from start 
of ex3 
coding 
hmz T 
rs557441, 
htz AC -26 
from start 
of ex3 
coding 
hmz T 
rs557441, 
htz AC -26 
from start 
of ex3 
coding 
hmz T rs557441 
hmz T 
rs557441 
GCNT2-006-
3B 
**WT ***WT WT WT WT WT 
GCNT2-006-
3C 
**WT 
***htz 
E>K298, 
G>A892, 
unknown 
SNP 
htz 
E>K298, 
G>A892, 
unknown 
SNP 
htz 
E>K298, 
G>A892, 
unknown 
SNP 
WT-wt WT-wt 
GCNT2-010-
3 
**WT  ***WT  
htz AT 
rs6679487
4 
htz AT 
rs6679487
4 
WT  WT  
GCNT2-201-
1 
**wt: E41, 
G121 
***htz unkn 
SNP 
E/K41, 
A/G121 
htz unkn 
SNP 
E/K41, 
A/G121 
htz unkn 
SNP 
E/K41, 
A/G121 
wt: E41, G121 
wt: E41, 
G121 
GJA8-1 WT WT WT WT WT WT 
GJA8-MID-1 WT WT WT WT WT WT 
GJA8-2 WT WT WT WT WT WT 
GJA8-3F WT WT WT WT WT WT 
CRYBB1-1 WT WT WT WT WT WT 
CRYBB1-2 WT WT WT WT WT WT 
CRYBB1-3 WT WT WT WT WT WT 
CRYBB1-4 WT WT WT WT WT WT 
CRYBB1-5 WT ***WT WT WT WT WT 
CRYBB1-6 WT WT WT WT WT WT 
CRYBB1-
201-1 
WT WT WT WT WT WT 
HSF4-3 WT WT WT WT WT WT 
HSF4-4+5 WT WT WT WT WT WT 
HSF4-6 WT WT WT WT WT WT 
HSF4-7+8 WT WT WT WT WT WT 
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   Kindred 1 Family 1  Kindred 1 Family 2 Kindred 2 Family 1 
  III:2 (P) IV:8 (A) III:3 (P) IV:19 (A) III:3 (P) IV:11 (A) 
HSF4-9 WT WT WT WT WT WT 
HSF4-10+11 WT WT WT WT WT WT 
HSF4-12+13 WT WT WT WT WT WT 
HSF4-14 WT WT WT WT WT WT 
HSF4-15 WT WT WT WT WT WT 
HSF4-T2-10 WT WT WT WT WT WT 
HSF4-T2-11 WT WT WT WT WT WT 
CRYAA-1 
hmz T 
rs872331 
***htz TC 
rs872331 
hmz T 
rs872331 
hmz T 
rs872331 
*htz TC rs872331 
hmz C 
rs872331 
CRYAA-2 WT ***WT WT WT *WT WT 
CRYAA-3 WT ***WT WT WT *WT WT 
CRYAA-003-
1 
WT ***WT WT WT *WT WT 
CRYAA-004-
1 
WT ***WT WT WT *WT WT 
CRYBB2-2 WT WT WT WT WT WT 
CRYBB2-3 WT WT WT WT WT WT 
CRYBB2-4 
WT (hmz T 
int4+67) 
WT (htz 
AT) 
WT (htz 
AT) 
WT (htz 
AT) 
WT (htz AT) WT (htz AT) 
CRYBB2-5 WT 
hmz C 
rs2330991; 
hmz A 
rs233092; 
hmz C 
rs4049504 
hmz C 
rs2330991; 
hmz A 
rs233092; 
hmz C 
rs4049504; 
htz AG 
rs4049505 
int5 
htz AG 
re4049505; 
intron 5  
+34 C>T 
not on 
Ens/NCBI 
WT 
hmz C 
rs2330991; 
hmz A 
rs233092; 
hmz C 
rs4049504 
CRYBB2-6 WT WT WT WT WT 
wt-hetz GtoA 
ENSSNP119
13674/ 
rs8140949 
CRYBA4-1 WT WT WT WT WT WT 
CRYBA4-2 WT WT WT WT WT WT 
CRYBA4-3 WT WT WT WT WT WT 
CRYBA4-4 WT WT WT 
htz TC 
intron 4 
WT WT 
CRYBA4-5 WT WT WT WT WT WT 
CRYBA4-6 WT WT WT WT WT WT 
LENEP-1 F WT WT WT WT WT WT 
CRYBG3-1A WT WT WT WT WT WT 
CRYBG3-1B WT WT WT WT WT WT 
CRYBG3-1C WT WT WT WT WT WT 
CRYBG3-2+3 WT WT WT WT WT WT 
CRYBG3-4F WT WT WT WT 
WT 
 
WT 
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   Kindred 1 Family 1  Kindred 1 Family 2 Kindred 2 Family 1 
  III:2 (P) IV:8 (A) III:3 (P) IV:19 (A) III:3 (P) IV:11 (A) 
CRYBG3-5 WT WT WT WT WT WT 
CRYBG3-6 WT WT WT WT WT WT 
CRYBG3-7 WT WT WT WT WT WT 
CRYBG3-8 WT WT WT WT WT WT 
CRYBG3-9 WT WT WT WT WT WT 
CRYBG3-
10+11 
WT WT WT WT WT WT 
CRYBG3-12 WT WT WT WT WT WT 
CRYBG3-13 WT WT WT WT WT WT 
CRYBG3-14 WT WT WT WT WT WT 
CRYBG3-15 WT WT WT WT WT WT 
CRYBG3-16 WT WT WT WT WT WT 
CRYBG3-17 
hmz H926 
rs4857302 
(C,C), hmz 
G rs832089 
int17 
hmz H926 
rs4857302 
(C,C), hmz 
G 
rs832089 
int17 
htz H926, 
N926 (C,A) 
rs4857302, 
htz GA 
rs832089 
int17 
hmz N926 
rs4857302 
(A,A), hmz 
G 
rs832089 
int17 
hmz N926 rs4857302 
(A,A), hmz A 
rs832089 int17 
htz H926, 
N926 (C,A), 
htz rs832089 
int17 
CRYBG3-18 WT WT WT WT WT WT 
CRYBG3-19 WT WT WT WT WT WT 
CRYBG3-
201-1 
WT WT WT WT WT WT 
CRYBG3-
201-2 
WT WT WT WT WT WT 
CRYBG3-
004-1 
WT WT WT WT WT WT 
HSPB6-1F WT ***WT WT WT WT WT 
HSPB6-001-
2+3 
WT ***WT WT WT WT WT 
HSPB6-201-4 WT ***WT WT WT WT WT 
Table 4.6: Sequencing results for the Omani Kindreds. (Htz=heterozygous; 
Hmz=homozygous; WT=wild type; X= no result; *=DNA from kindred 2 family 1, III:4; 
**=DNA from kindred 1 family 1, III:1; ***= DNA from kindred 1 family 1,IV:7). 
4.3.3.5 Whole Exome Sequencing  
Since mapping was not able to identify a shared region of homozygosity in the 
Omani kindreds it was considered that the relevant cataract gene mutation might be 
in a small region of homozygosity (or, despite the consanguinity, one or more of the 
affected cases could be a compound heterogote). To test these hypotheses (a) 
sequencing was undertaken of known cataract genes and (b) DNA from kindred 1 
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family 1 affected individual IV:11 was sent to Dr Michael Simpson at Guy‟s Hospital 
for whole exome sequencing. 
43 novel homozygous changes were identified (Table 4.8). These consisted of 34 
missense changes, 6 synonymous changes, 1 nonsense change, 1 insertion, and 1 
UTR change. 
Investigative focus was directed on genes found in regions from SNP chip analysis. 
Primers were designed for the changes identified in CATSPERB, ARL13B, 
NUP210L, ARMC5, CRYGA, SPAG17 and ITFG, to examine segregation within the 
kindreds. Segregation of the novel ARL13B change (P866R), was detected, but only 
within kindred 1 family 1 (Table 4.7). 
  
  
Gene 
Chromosome, 
Location, Exon 
Nucleotide Protein 
K1F1 
III:1 
(Un) 
K1F1 
III:2 
(Un) 
K1F1 
IV:4 
(Un) 
K1F1 
IV:7 
(Aff) 
K1F1 
IV:12 
(Un) 
K1F1 
IV:8 
(Aff) 
K1F1 
IV:11 
(Aff) 
K1F1 
IV:9 
(Un) 
K1F2 
III:3 
(Un) 
K1F2 
IV:14 
(Un) 
K1F2 
IV:19 
(Aff) 
K1F2 
IV:18 
(Aff) 
K1F2 
IV:20 
(Aff) 
K2 
III:3 
(Un) 
K2 
III:4 
(Un) 
K2 
IV:11 
(Aff) 
CATSPERB 
14,91146577-
91146578 
(ex21) 
C2597G P866R CG CG CG 
CC 
(wt) 
CG GG GG CG CG CG 
CC 
(wt) 
CC 
(wt) 
CG 
CC 
(wt) 
CC 
(wt) 
CC 
(wt) 
ARL13B 
(005) 
3,95252408-
95252409 
(ex9) 
G1193T G398V GT GT GT TT GT TT TT GT 
GG 
(wt) 
GG 
(wt) 
GG 
(wt) 
x 
GG 
(wt) 
x 
GG 
(wt) 
GG 
(wt) 
NUP210L 
(001) 
1,152251399-
152251400 
(ex34) 
A4274G N1575S x x AG GG AG 
AA 
(wt) 
GG GG AG AG x 
AA 
(wt) 
GG  
AA 
(wt) 
AA 
(wt) 
AA 
(wt) 
ARMC5 
(201) 
16,31383364-
31383365 
(ex4) 
C1520T P507L CT TT x x x TT TT CC CT CT CT x x CC CC x 
CRYGA 
2,208736185-
208736186 
(ex2) 
G239A R80H 
GG 
(wt) 
AG AG AG AG 
GG 
(wt) 
AG AG 
GG 
(wt) 
GG 
(wt) 
GG 
(wt) 
GG 
(wt) 
GG 
(wt) 
GG 
(wt) 
GG 
(wt) 
GG 
(wt) 
SPAG17 
1,118386088-
118386089 
(ex21) 
A2914G K972E AG AG AG GG AG AG GG GG x AG GG  AG GG 
AA 
(wt) 
AA 
(wt) 
AA 
(wt) 
ITFG 
16,46020265-
46020266 
(ex6) 
G605A R202Q AG AG AG AG x AA  AA GG AG AG x x AG GG GG GG 
 
Table 4.6: Segregation of novel changes in the Omani kindreds. Un=unaffected. Aff=affected. X=no result. wt=wild type. K=kindred. F=family. 
Highlighted cells indicate segregation of the novel ARL13B change, but only within kindred 1 famiily 1. 
 
 
 
 
 
   
Ch.r Start Stop Sequence Gene Accession no. DNA/protein position Effect 
1 47676596 47676597 GCAGACTTAG C CGAGGACGAG  FOXD2 NM_004474 [c.203, p.68] missense [GCC:A GtC:V c] 
1 53514966 53514967 TCGGCCTCGT C CGATTTGTCT  LRP8 NM_001018054 [c.868, p.290] missense [GAC:D tAC:Y U] 
1 118386088 118386089 GCGTTATCCT T GCCTTTCTTT  SPAG17 NM_206996 [c.2914, p.972] missense [AAG:K gAG:E c] 
1 152251399 152251400 TACAGTTGAA T TGAGGGTATT  NUP210L NM_001159484 [c.4724, p.1575] missense [AAT:N AgT:S c] 
1 153441519 153441520 TCTCCAGCCC A TCGACCTCCG  THBS3 NM_007112 [c.498, p.166] synonymous[GAT:D GAc:D c] 
1 154832851 154832852 CAGCTCTCCA A GTCTTTGTTT  GPATCH4 NM_015590 [c.391, p.131] synonymous[TTG:L cTG:L c] 
1 156716356 156716357 TGCAGATCTT G GCAGAAAACC  OR10R2 NM_001004472 [c.66, p.22] synonymous[TTG:L TTa:L c] 
1 158123040 158123041 GTTCTTTTTG G ATCTGCTGCT  CCDC19 NM_012337 [c.651, p.217] synonymous[ATC:I ATt:I c] 
1 158917643 158917644 TGAGGCAGAC C GTGCCATTCT  CD48 NM_001778 [623-624 207-208] synonymous[ACG:T ACc:T c] 
1 159430062 159430063 CCTGAGCCAG T TGGGCAGTCC  ADAMTS4 NM_005099 [1725-1726 575-576] missense [ACT:T gCT:A c] 
1 163905171 163905172 CAGGTGTGGT C GGTTGATGAG  ALDH9A1 NM_000696 [1069-1070 356-357] missense [CGA:R CaA:Q c] 
3 47433894 47433895 GGCGAGGGAA G GGGAGCCTTT  SCAP NM_012235 [2872-2873 957-958] missense [CCT:P CaT:H c] 
3 95252408 95252409 GAGCCTCTTG G TGAAACACAT  ARL13B NM_001174150 [1192-1193 397-398] missense [GGT:G GtT:V U] 
3 95252408 95252409 GAGCCTCTTG G TGAAACACAT  ARL13B NR_033427  UTR 
3 112780633 112780634 TTACTTAAAG A TAGAGTCAAG  CD96 NM_005816 [613-614 204-205] missense [GAT:D GgT:G U] 
4 8671993 8671994 ATCCCCGCCC G GATGAAGAGG  CPZ NM_001014447 [1708-1709 569-570] missense [CGG:R CaG:Q c] 
4 20228275 20228276 CCATGCCAGG C GATCAAGTGC  SLIT2 NM_004787 [4252-4253 1417-1418] missense [GCG:A GtG:V c] 
5 139999322 139999323 AGGGCCGCCT C AGGCCCACGG  TMCO6 NM_018502 [26-27 8-9] synonymous[CTC:L CTg:L c] 
7 102503061 102503062 CGGGGCGACC G CGAGCTCGGG  ARMC10 NM_001161009 [106-107 35-36] missense [CGC:R CaC:H U] 
8 139675587 139675588 CTTCATGTAC G CCGGGGGCAT  COL22A1 NM_152888 [4468-4469 1489-1490] missense [GCG:A GtG:V c] 
9 129627905 129627906 CCACTCGAGC G TGCGGCCCAT  ENG NM_000118 [577-578 192-193] missense [ACG:T AtG:M c] 
11 60366278 60366279 TGTGGAGTTC G AGTCGAACCC  CCDC86 NM_024098 [105-106 35-36] nonsense [GAG:E tAG:* U] 
11 65070852 65070853 ACCGCGACAG G CCCCGCCCCC  LTBP3 NM_001130144 [2221-2222 740-741] missense [GCC:A GgC:G c] 
12 88268920 88268921 GGCTTGGAAC T TACTGAAGCC  DUSP6 NM_001946 [412-413 137-138] missense [AAG:K AgG:R c] 
14 52689249 52689250 GCCGCTCTCA C CCTCGCTGTA  DDHD1 NM_001160147 [316-317 105-106] missense [GGT:G GcT:A c] 
14 91146577 91146578 TTTTTTTACC G GCAAAGTTTT  CATSPERB NM_024764 [2596-2597 865-866] missense [CCG:P CgG:R U] 
16 2957438 2957439 CCGCCGGCCG C GATTGGGGGT  KREMEN2 NM_024507 [1090-1091 363-364] missense [GCG:A GtG:V c] 
16 29725562 29725563 GGCCCCCCCC T TCCCCGTGCT  MAZ NM_001042539 [39-40 13-14] missense [TTC:F gTC:V c] 
16 31383364 31383365 CAACGCACTC C GGGCCGCAGC  ARMC5 NM_001105247 [1519-1520 506-507] missense [CCG:P CtG:L U] 
16 46020265 46020266 ATGTGGAATT C GCATTTTACT  ITFG1 NM_030790 [604-605 201-202] missense [CGA:R CaA:Q c] 
17 6315207 6315208 CACTCACTGC G GGAGGCACCC  PITPNM3 NM_001165966 [1512-1513 504-505] missense [CGC:R tGC:C U] 
17 6328323 6328324 CAAGGAAACC C GGTACAGTTC  PITPNM3 NM_001165966 [178-179 59-60] missense [CGG:R CaG:Q c] 
17 7180781 7180782 GCTGAGATGA C GGTCAAGCTG  ACAP1 NM_014716 [4-5 1-2] missense [ACG:T AtG:M c] 
17 7693514 7693515 TTCTGCCCAG C CCACACCCCC  KDM6B NM_001080424 [3183-3184 1061-1062] missense [CCC:P tCC:S U] 
17 31209608 31209609 GGGGCTGAGT G CACGTGCATC  C17orf66 NM_152781 [972-973 324-325] missense [CAC:H tAC:Y c] 
17 54188482 54188482 CCGAACCCGA - ACCCGAGTCC  PPM1E NM_014906 [125-125 41-42] aa insertion [755 757] 
18 54737255 54737256 TGACACCAGC C TCCCCAGCGT  ZNF532 NM_018181 [756-757 252-253] missense [CTC:L gTC:V c] 
18 75760789 75760790 GCTGTGGGTG C GGGCAGGGCG  KCNG2 NM_012283 [1386-1387 462-463] missense [CGG:R tGG:W c] 
19 1828329 1828330 GGGCAGCGCT C GTAGAGCGCC FAM108A1 NM_001130111 [801-802 267-268] missense [GAG:E cAG:Q c] 
19 13780760 13780761 GGCGGCTACT A CGGGGCCAGC  ZSWIM4 NM_023072 [823-824 274-275] missense [TAC:Y TgC:C U] 
19 16297693 16297694 CCGCCTGCGT C CCCGCTGGAG  KLF2 NM_016270 [742-743 247-248] missense [TCC:S TaC:Y U] 
19 50779726 50779727 TCACGTTGAG C CGGCGGGAGG  OPA3 NM_001017989 [135-136 45-46] missense [GCT:A tCT:S c] 
19 55863318 55863319 GGCCGCCCCC A CCAGGGCGGC  SHANK1 NM_016148 [3709-3710 1236-1237] missense [GTG:V GgG:G U] 
Table 4.8: Novel changes identified in whole exome sequencing of Omani Kindred 1 Family 1, IV:11. 
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4.3.4 Discussion 
Despite Kindred 1 being a very large consanguineous kindred with multiple affected 
individuals, a putative mutation in a candidate cataract gene could not be identified. 
Although autozygosity mapping is a powerful approach to gene identification, it is not 
completely sensitive and under certain circumstances the responsible gene may not 
be identified. Although we suspected that the Omani kindreds might share a 
common founder mutation (as this has proven to be the case in other recessively 
inherited diseases in this population) we looked at each family individually so that we 
were not led astray by interfamilial locus heterogeneity. Usually all affected members 
of a consanguineous kindred with an autosomal recessively inherited disorder will 
harbour the same homozygous mutation. However occasionally, two mutations may 
be segregating in the same family. Thus it was possible that in these kindreds 
studied, the cataract phenotype may result from compound heterozygous mutations. 
Previously in the Maher laboratory, in a consanguineous Jordanian Arab family 
where two boys were affected with Karak Syndrome (an autosomal recessive 
disorder) (Mubaidin et al, 2003), compound heterozygous mutations in PLA2G6 were 
found in the two boys (Morgan et al, 2006). Similarly, Forshew et al (2005) found two 
TYR mutations in a large consanguineous family of Pakistani origin with 
oculocutaneous albinism.  
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4.4 Cataract Family 5  
Aims: To identify a pathogenic mutation that causes cataracts in a Pakistani 
family 
4.4.1 Patient DNA 
Cataract Family 5 are of Pakistani origin (Figure 4.30), displaying autosomal 
recessive congenital cataracts in two of the three children (II:1 and II:2). They 
underwent surgery to remove these. Clinical examination did not reveal other eye 
abnormalities or systemic problems. No cataracts were detected in I:1, I:2 or II:3. 
 
Figure 4.30: Pedigree of the Pakistani cataract family 5. 
 
4.4.2 Molecular Genetic Methods 
Experimental procedures were carried out as detailed in Chapter 2. 
Primers were designed to amplify the coding regions of the known cataract gene 
BFSP2, located on chromosome 3q32.1 (Table 6.35) and sequencing was carried 
out. 
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4.4.3 Results 
4.4.3.1 Genome-Wide Scan 
Previous work in the laboratory with a genome-wide linkage scan (Affymetrix 
Genechip Human Mapping 10K Array Version 1) on II:1, and on affected individuals 
from another family of Pakistani origin identified a 38cM homozygous region on 
chromosome 9 between D9S301 (73,802,954) and D9S910 (101,623,741) (9q13-
q22).  
Further investigation in the other Pakistani family could not be carried out due to a 
lack of available DNA. The region overlaps with the 14cM CAAR locus, located on 
9q13-q22 between markers D9S1123 (80,425,352) and D9S257 (90,290,735), which 
was identified in a family from an isolated region of Switzerland with autosomal 
recessive early-onset progressive pulverulent cataracts (ARPCs) (Héon et al, 2001), 
and previous work identified no putative mutations in the sequencing of exons and 
intron/exon boundaries of the following genes in the region: ALDH1A1, RASEF, 
GCNT1 and UBQLN1. 
Since these two Pakistani families had an overlapping region on chromosome 9, 
DNA from affected member II:1 from cataract family 5, and from one affected 
individual in the other Pakistani family was analysed on a 250k SNP array to look for 
an identical homozygous region on this chromosome. No identical homozygous 
region was identified. In Cataract Family 5, in addition to the chromosome 9 region, 
ten regions of extended homozygosity, >2Mb, were identified. 
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Chromosome Start End Size (Mb) 
1 rs1924569 (58,801,506) rs1414065 (71,073,756) 12.3 
2 rs11127467 (12,994) rs1710503 (2,520,736) 2.5 
2 rs7563021 (6,448,402) rs3747516 (18,113,508) 11.6 
3 rs1969262 (122,863,207) rs1116439 (147,599,246) 24.7 
5 rs6862891 (31,748,611) rs17552447 (73,001,379) 41.3 
8 rs7814384 (116,262,669) rs199208 (140,712,922) 24.4 
9 rs10781059 (71,219,807) rs10817865 (118,978,682) 47.8 
10 rs10047370 (2,628,101) rs12248552 (8,916,831) 6.3 
14 rs2067644 (24,142,675) rs10144249 (30,923,371) 6.8 
14 rs1286293 (91,310,904) rs3825564 (102,921,447) 11.6 
Table 4.9 :Homozygous regions detected in the genome wide scan on II:1 from 
cataract family 5. 
  4.4.3.2 Candidate Genes 
The region on chromosome 3 contains the known autosomal dominant cataract gene 
BFSP2 (Conley et al, 2000), so the coding exons and intron/exon boundaries were 
sequenced in parent I:2 and patient II:2. Sequencing of BFSP2 in I:2 and II:2 
revealed homozygosity at  rs2276737 for patient II:2, and heterozygosity for parent 
I:2. At rs2737717 and rs10563564, both I:2 and II:2 were found to be heterozygous, 
but no pathogenic changes were identified.  
4.4.4 Discussion 
No putative mutation was found. It is likely that the causative gene lies in the region 
on chromosome 9, and the same gene or mutation may be responsible for the 
cataract phenotype in the Swiss CAAR family. The region on chromosome 3 is 
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unlikely to be the correct region, in light of the finding that I:2 and II:2 were 
heterozygous for rs rs2737717 and rs10563564. The SNP chip analysis was only 
carried out on II:1, and sequencing of BFSP2  was completed for II:2, so this 
individual is likely to be heterozygous in this region, which would have been 
identified if SNP chip analysis had been carried out on II:2 DNA..  
4.5 Cataract Family 6 
Aim: To identify a pathogenic mutation that causes cataracts in a Pakistani 
family 
4.5.1 Patient DNA 
Cataract Family 6 are of Pakistani origin (Figure 4.31), displaying isolated autosomal 
recessive congenital cataracts in two of the five children (II:3 and II:4). No further 
clinical information was available. 
 
Figure 4.31: Cataract family 6. Individuals with cataracts are shaded in black. * 
indicates family members from whom DNA was available. 
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4.5.2 Molecular Genetic Methods 
An Affymetrix GeneChip Human Mapping 10K Array (version 1) was performed by 
MRC Geneservice. 
4.5.3 Results 
4.5.3.1 Genome-Wide Scan 
The genome-wide scan was performed for individuals II:3 and II:4. Three potential 
region of extended homozygosity was detected on chromosome 2, 8 and 15. The 
region on chromosome 2 from rs1079417 to rs1344063 was uninformative with 
microsatellite markers. The region on chromosome 8 from rs902619 to rs344278 
was uninformative with microsatellite markers, as was the region on chromosome 8 
from rs1172 to rs911. A region on chromosome 15 was detected between rs2042613 
and rs1875084. 
4.5.3.2 Microsatellite Markers 
Regions of interest were investigated further by Dr Esther Meyer to confirm presence 
or absence of homozygosity at various polymorphic microsatellite markers. Linkage 
to the region on chromosome 15 was confirmed and all markers for the region on 
chromosome 2 and 8 were uninformative. Microsatellite markers more closely 
defined the region on chromosome 15, indicating that it lies between D15S988 and 
D15S984, extending ~10Mb.  
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4.5.3.3 Whole Exome Sequencing 
DNA from II:3 was set to Dr Michael Simpson at Guy‟s Hospital for whole exome 
sequencing. 51 novel homozygous changes were identified, comprising of 49 
missense changes, 1 nonsense change and 1 insertion/deletion (Table 4.11). 
Due to prior SNP chip results, changes in the regions identified on chromosome 15, 
2, and 8 were selected for further analysis. Changes in C15orf39 (Arg1029Lys) and 
SNUPN (Gly137Asp) segregated with cataract phenotype (Table 4.10). Polyphen 
predicted the Arg1029Lys change in C15orf39 to be tolerated, but predicted the 
Gly137Asp change in SNUPN to be damaging. Gly137 in SNUPN is highly 
conserved across species (Figure 4.32), even in plants such as rice (O. sativa) and 
thale cress (A. thaliana) (data not shown). 
 
 
 
 
Gene 
Chromosome, 
Location 
Nucleotide Protein I:1 (Un) I:2 (Un) II:1 (Un) II:2 (Un) II:3 (Aff) II:4 (Aff) II:5 (Un) 
C15orf53 
15,36776152-
36776153, 
CGG-CaG R18Q GA GA GA AA AA AA AA 
LCMT2 
15,41409732-
41409733 
GCG-tCG A83S GT GT GT TT TT TT TT 
MAP1A 
15,41604191-
41604192 
GTC-aTC V1077I 
GA (+ GA 
rs1060939) 
GA (+ GG 
rs1060939) 
GA (+ GG 
rs1060939) 
AA (+ GG 
rs1060939) 
AA (+ GG 
rs1060939) 
AA (+ GG 
rs1060939) 
AA (+ GG 
rs1060939) 
DUOX1 
15,43231942-
43231943 
GTG-aTG V1121M 
htz 
c.G3361A 
(V1121M); 
htz  intron 
25 
NM_017434.
3:c.3194-
34G>A; htz 
GA 
rs1706804 
htz 
c.G3361A 
(V1121M); 
hmz  intron 
25 wtG; htz 
GA 
rs1706804 
htz 
c.G3361A 
(V1121M); 
hmz  intron 
25 wtG; htz 
GA 
rs1706804 
hmz 
c.A3361 
(V1121M); 
hmz  intron 
25 wtG; hmz 
A rs1706804 
hmz 
c.A3361 
(V1121M); 
hmz  intron 
25 wtG; hmz 
A rs1706804 
hmz 
c.A3361 
(V1121M); 
hmz  intron 
25 wtG; hmz 
A rs1706804 
hmz 
c.A3361 
(V1121M); 
hmz  intron 
25 wtG; hmz 
A rs1706804 
SLC30A4 
15,43564760-
43564761 
AAC-AAa N394K CA CA CA AA AA AA AA 
SECISBP2L 
15,47117119-
47117120 
ATT-gTT I55V AG AG AG GG GG GG GG 
CA12 
15,61418154-
61418155 
GAC-aAC D264N GA GA GA AA AA AA AA 
C15orf39 
15,73290451-
73290452 
AGA-AaA R1029K GA GA GA GA AA AA GA 
SNUPN 
15,73689045-
73689046 
GGT-GaT G137D GA GA GA GA AA AA GA 
KLHL25 
15,84113042-
84113043 
GCC-aCC A335T GA GA AA GA AA AA GA 
RSAD2 
2,6935604-
6935605 
GTC-aTC V75I GA AA AA GA GG GG GA 
Table 4.10 : Segregation of novel changes in Cataract Family 6. Un=unaffected. Aff=affected. X=no result. wt=wild type. 
K=kindred. F=family. Htz=heterozygous. Hmz=homozygous 
Highlighted cells indicate segregation of genotype with cataract phenotype. Lighter text indicates anomalous result. 
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Figure 4.32: Sequence alignment of Gly137Asp in SNUPN across species 
highlighted in red. (For C. elegans, F23F1.5 is a hypothetical protein). 
 
4.5.4 Discussion 
A potential causative mutation was detected in SNUPN in this Pakistani family, which 
may be responsible for the cataract phenotype. Polyphen predicts this G137D 
change to be damaging. Further work to investigate this putative mutation would 
include sequencing ethnically matched controls, and controls from other populations 
to discern whether or not this is actually just a rare SNP that happens to segregate 
within the family. Functional work could be carried out, expressing both the mutant 
and wild type sequences in the lens derived cell line CRL-11421. 
Not much is known about the implications of the specific role of SNUPN. There is 
evidence of expression in the eye, as well as in the brain, liver, uterus, kidney, colon 
and many more tissues (Aceview). There are two known transcripts. 
ENST00000308588 is a nine exon gene of 1513bp and 360 amino acids, and 
ENST00000371091 is a ten exon gene of 1913bp and 402 amino acids (Ensembl). 
The protein coded for by this gene, SPN1 is a nuclear import receptor for 
cytoplasmically assembled, m(3)G-capped spliceosomal U small nuclear riboproteins 
(snRNPs) (Monecke et al, 2009). 
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Chromosome Start Stop Codon Gene Transcript ID DNA/protein Effect 
1 170895266 170895265 ATG-AcG FASLG ENST00000340030 M101T missense 
1 184274619 184274620 GGT-GtT HMCN1 ENST00000367492 G1963V missense 
2 6935604 6935605 GTC-aTC RSAD2 ENST00000382040 V75I missense 
2 21085625 21085626 GGC-GtC APOB ENST00000233242 G2540V missense 
2 71681465 71681466 ATC-cTC DYSF ENST00000258104 I1277L missense 
2 74630168 74630169 GGG-GaG LOXL3 ENST00000264094 G176E missense 
2 95305518 95305519 GGG-aGG PROM2 ENST00000317620 G137R missense 
2 198354793 198354794 TCC-TaC BOLL ENST00000321801 S21Y missense 
2 201980409 201980410 CTC-gTC TRAK2 ENST00000332624 L83V missense 
3 180443718 3180443719 AAC-AAg KCNMB3 ENST00000314235 N169K missense 
3 180534503 180534504 AAT-AgT ZNF639 ENST00000326361 N353S missense 
3 182170731 182170732 AGT-gGT FXR1 ENST00000305586 S414G missense 
4 6354985 6354986 TCA-cCA WFS1 ENST00000226760 S855P missense 
4 75123159 75123160 AGC-AGa CXCL3 ENST00000296026 S11R missense 
4 111763062 111763063 ATG-ATa PITX2 ENST00000306732 M1I missense 
5 154190576 154190577 ATT-gTT C5orf4 ENST00000326080 I115V missense 
7 6787494 6787495 CGT-tGT RSPH10B2 ENST00000297186 R541C missense 
7 72649567 72649568 CCC-tCC MLXIPL ENST00000313375 P495S missense 
8 42350955 42350956 ATT-AcT DKK4 ENST00000220812 I165T missense 
9 15584042 15584043 GCG-GtG C9orf93 ENST00000297641 A183V missense 
9 15713729 15713730 ACT-gCT C9orf93 ENST00000297641 T493A missense 
9 18940906 18940907 AAG-tAG FAM154A ENST00000380534 K23* nonsense 
9 97678153 97678154 GCG-cCG C9orf102 ENST00000288985 A16P missense 
9 101032519 101032520 CGT-CaT SEC61B ENST00000223641 R95H missense 
9 115162686 115162687 CGG-CaG BSPRY ENST00000238359 R127Q missense 
9 129551319 129551320 TGC-TaC SH2D3C ENST00000314830 C377Y missense 
9 134770896 134770897 AAA-AcA TSC1 ENST00000298552 K630T missense 
9 108731578 108731581 indel ZNF462 ENSG00000148143 AA_DELETION indel 
10 3162055 3162056 GTG-aTG PFKP ENST00000381075 V569M missense 
12 12831388 12831389 GCC-cCC APOLD1 ENST00000326765 A126P missense 
12 46479003 46479004 GCA-GtA HDAC7 ENST00000310824 A30V missense 
12 122863982 122863983 CGC-CaC DNAH10 ENST00000339192 R855H missense 
14 64280076 64280077 CCG-CtG PLEKHG3 ENST00000247226 P1132L missense 
15 36776152 36776153 CGG-CaG C15orf53 ENST00000318792 R18Q missense 
15 41409732 41409733 GCG-tCG LCMT2 ENST00000305641 A83S missense 
15 41604191 41604192 GTC-aTC MAP1A ENST00000300231 V1077I missense 
15 43231942 43231943 GTG-aTG DUOX1 ENST00000321429 V1121M missense 
15 43564760 43564761 AAC-AAa SLC30A4 ENST00000261867 N394K missense 
15 47117119 47117120 ATT-gTT SECISBP2L ENST00000261847 I55V missense 
15 61418154 61418155 GAC-aAC CA12 ENST00000178638 D264N missense 
15 73290451 73290452 AGA-AaA C15orf39 ENST00000360639 R1029K missense 
15 73689045 73689046 GGT-GaT SNUPN ENST00000308588 G137D missense 
15 84113042 84113043 GCC-aCC KLHL25 ENST00000337975 A335T missense 
16 2061858 2061859 CCT-tCT TSC2 ENST00000219476 P674S missense 
16 20459495 20459496 CCA-CtA ACSM2 ENST00000329697 P537L missense 
16 23613897 23613898 GAG-aAG ERN2 ENST00000256797 E663K missense 
16 29949266 29949267 CAG-CcG FAM57B ENST00000380495 Q28P missense 
18 19743219 19743220 CGA-CaA LAMA3 ENST00000269217 R765Q missense 
19 7586122 7586123 CGG-gGG KIAA1543 ENST00000160298 R909G missense 
20 60327005 60327006 GGC-aGC LAMA5 ENST00000370691 G2380S missense 
22 22892769 22892770 AAA-AgA CABIN1 ENST00000263119 K1724R missense 
Table 4.11: Novel changes identified in whole exome sequencing of Pakistani 
Cataract Family 6, II:3. 
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4.6 Cataract Family 7 
Aim: To identify a pathogenic mutation that causes cataracts in a Pakistani 
family 
4.6.1 Patient DNA 
Cataract family 7 are of Pakistani origin. I:1 and I:2 are first cousins. II:2 developed 
sudden onset cataracts at three years of age (Figure 4.33). 
 
Figure 4.33: Cataract family 7. Individuals with cataracts are shaded in black. * 
indicates family members from whom DNA was available. 
 
4.6.2 Molecular Genetic Methods 
II:2 was run on 250K SNP chip, and regions of homozygosity, however small, around 
known cataract genes were identified.Primers  for many known cataract genes were 
already present in the laboratory, and time available for investigation into the cause 
of cataractogenesis in this family was limited.  
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4.6.3 Results 
4.6.3.1 Genome-Wide Scan 
Small homozygous regions around known genes were found and noted. A 
homozygous call was made for 145,846,565, and GJA8 is found across this position 
from 145,841,560-145,848.017 on chromosome 1. BFSP2 (134,601,480-
134,676,746 on chromosome 3) is contained within a homozygous region with 
homozygous calls at least from 134,598,678-134,677,146. CRYGS (187,738,926-
187,744,861 on chromosome 3) is also located in a homozygous region extending at 
least from 187,713,436-187,776,514. 
4.6.4 Discussion 
This family‟s DNA was received towards the end of the project, leaving little time for 
analysis. Since homozygosity around GJA8, BFSP2, and CRYGS was detected by 
genome wide scan, the next step would be to sequence the coding regions of these 
genes to look for pathogenic mutations. 
4.7 Cataract Family 8  
Aim: To identify a pathogenic mutation that causes cataracts in an Omani 
family 
4.7.1 Patient DNA 
Cataract family 8 are of Omani origin. Two siblings (II:2 and II:3) presented with 
cataracts. Their sister(II:1) and parents (I:1 and I:2) were unaffected (Figure 4:35).  
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Figure 4.34: Cataract family 8. Individuals with cataracts are shaded in black. * 
indicates family members from whom DNA was available. 
 
4.7.2 Molecular Genetic Methods 
A 250K genome wide scan was performed on DNA from II:2 and II:3, and common 
homozygous regions were noted. Known cataract genes were sequenced to identify 
any mutations. 
4.7.3 Results 
4.7.3.1 Genome-Wide Scan 
Seven regions of shared homozygosity were identified in II:2 and II:3 (Table 4:12). 
Chromosome Start Stop 
1 116,258,116 116,966,263 
4 116,770,717 119,842,915 
6 56,713,291 63,944,147 
7 118,424,891 120,877,689 
7 130,881,572 134,219,717 
16 31,488,031 46,754,604 
17 71,886,214 73,788,078 
Table 4:12: Regions of homozygosity shared by affected members of Cataract 
Family 8. 
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4.7.3.2 Sequencing of Known Cataract Genes 
Sequencing of known cataract genes CRYBB3, BFSP1, LIM2, GCNT2, CRYBB2, 
CRYBA4, GJA8, CRYBB1, HSF4 and CRYAA was undertaken. Although no putative 
pathogenic mutations were detected, numerous SNPs were detected. Results are 
are summarised in Table 4.13. 
 
Cataract Family 8 Cataract Family 9 
I:1 (P) II:3 (A) III:1 (P) IV:7 (A) 
CRYBB3-1 WT WT WT WT 
CRYBB3-2 WT  WT  WT  WT  
CRYBB3-3 WT WT WT WT 
CRYBB3-4 WT WT WT WT 
CRYBB3-5 
WT (htz for 
rs960378 
c.337C>G, 
p.His113Asp 
WT (htz for 
rs960378 
c.337C>G, 
p.His113Asp 
WT (hmz G) WT (hmz G) 
CRYBB3-6R WT WT WT WT 
BFSP1-1 WT WT WT WT 
BFSP1-2 WT WT WT WT 
BFSP1-3 WT WT WT WT 
BFSP1-4 
htz c.576-
42G>A 
hmz c.576-
42G>A 
htz c.576-42G>A htz c.576-42G>A 
BFSP1-5 WT WT WT WT 
BFSP1-6 
htz c.776-
45A>G 
hmz c.776-
45A>G 
htz c.776-45A>G htz c.776-45A>G 
BFSP1-7R 
htz AG 
rs6080719 
hmz G 
rs6080719 
htz AG rs6080719 htz AG rs6080719 
BFSP1-8A WT WT WT WT 
BFSP1-8BR 
htz AG 
rs6136118 
hmz G 
rs6136118 
htz AG rs6136118 hmz A rs6136118 
 
 
4. Non-syndromic Cataract Families  188 
 
 
 
Cataract Family 8 Cataract Family 9 
I:1 (P) II:3 (A) III:1 (P) IV:7 (A) 
BFSP1-8C 
hmz G 
rs6080718, 
htz CT 
rs6080717 
hmz G 
rs6080718, 
hmz 
Trs6080717 
1) htz AG rs6080718, 
P583, 
NG_012423.1:g.6963
8A>G 2) ATT>ATA on 
F and R. Still I636, not 
on Ens/NCBI 3)htz CA 
rs6105762 intronic 
hmz G rs6080718 
BFSP1-T2-1 WT WT WT WT 
LIM2-2  WT WT WT WT 
LIM2-3  WT WT WT WT 
LIM2-4 R 
WT (homz 
int4 T 
rs2547318) 
messy (homz 
int4 C 
rs2547318) 
WT (hetz CT int4 
rs2547318) 
WT (hetz CT int4 
rs2547318) 
LIM2-5  WT WT WT WT 
GCNT2-001-1A 
htz TC 
rs2230906  
htz TC 
rs2230906  
hmz C htz CT rs2230906 
GCNT2-001-1B WT WT WT WT 
GCNT2-001-1C WT WT WT WT 
GCNT2-001-2 WT WT WT WT 
GCNT2-001-3 WT WT WT WT 
GCNT2-004-1A WT WT WT WT 
GCNT2-004-1B WT WT WT WT 
GCNT2-004-1C 
hmz G 
rs539351 
hmz G 
rs539351 
hmz G rs539351 hmz G rs539351 
GCNT2-006-3A WT WT WT WT 
GCNT2-006-3B WT WT WT WT 
GCNT2-006-3C WT WT WT WT 
GCNT2-010-3 WT WT WT WT 
GCNT2-201-1 
wt: E41, 
G121 
wt: E41, 
G121 
wt: E41, G121 wt: E41, G121 
GALK1-201-1 x x x x 
GALK1-201-2 x x WT WT 
GALK1-201-3 x x WT x 
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Cataract Family 8 Cataract Family 9 
I:1 (P) II:3 (A) III:1 (P) IV:7 (A) 
GALK1-201-4 x x WT WT 
GALK1-201-5 x x WT WT 
GALK1-201-
6+7+8 
x x WT  WT  
GALK1-202-2 x x WT  x  
GALK1-202-3+4 x x WT WT 
GJA8-1 WT WT WT WT 
GJA8-MID-1 WT WT 
htz rs3766503: 
NM_005267.3:C804C
>T, 
NM_034400.4:g.9215
03C>T 
hmz for rs3766503 
GJA8-2 WT WT WT WT 
GJA8-3 WT WT WT WT 
CRYBB1-1 WT WT WT WT 
CRYBB1-2 WT WT WT WT 
CRYBB1-3 WT WT WT WT 
CRYBB1-4 WT WT WT WT 
CRYBB1-5 WT WT WT WT 
CRYBB1-6 WT WT WT WT 
CRYBB1-201-1 WT WT WT WT 
HSF4-3 WT WT WT WT 
HSF4-4+5 WT WT WT WT 
HSF4-6 WT WT WT WT 
HSF4-7+8 WT WT WT WT 
HSF4-9 WT WT WT WT 
HSF4-10+11 WT WT WT WT 
HSF4-12+13 WT WT WT WT 
HSF4-14 WT WT WT WT 
HSF4-15 WT WT WT WT 
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Cataract Family 8 Cataract Family 9 
I:1 (P) II:3 (A) III:1 (P) IV:7 (A) 
HSF4-T2-10 WT WT WT WT 
HSF4-T2-11 WT WT WT WT 
CRYAA-1 
hmz T 
rs872331 
hmz T 
rs872331 
htz TC rs872331 X 
CRYAA-2 WT WT WT WT 
CRYAA-3F WT WT WT WT 
CRYAA-003-1 WT WT WT WT 
CRYAA-004-1 WT WT WT WT 
CRYBB2-2 WT WT WT WT 
CRYBB2-3 WT WT WT WT 
CRYBB2-4 WT (htz AT) WT (htz AT) WT (htz AT) WT (htz AT) 
CRYBB2-5 
wt htz AG 
rs4049505 
wt htz AG 
rs4049505,ht
z AG int5 
rs55700037 
WT WT 
CRYBB2-6 WT WT 
wt-hetz GtoA 
ENSSNP11913674/ 
rs8140949 
wt-hetz GtoA 
ENSSNP11913674
/ rs8140949 
CRYBA4-1 WT WT 
hmz A int1 
rs16982454 
htz CA int1 
rs16982454 
CRYBA4-2 WT WT WT WT 
CRYBA4-3 WT 
htz 
c.108G>A, 
still V 
WT WT 
CRYBA4-4 WT WT WT WT 
CRYBA4-5 WT WT WT WT 
CRYBA4-6 WT WT WT WT 
Table 4.13: Sequencing results for the Omani families. (Htz=heterozygous; 
Hmz=homozygous; WT=wild type; X= no result). 
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4.7.4 Discussion 
No putative mutations were identified in Cataract Family 8. Seven homozygous 
regions were identified, in total containing hundreds of genes. It is impractical to 
investigate all of these, especially in light of no obvious candidate genes in these 
regions. It would be useful to obtain more DNA from Omani families with cataracts, 
with the aim to compare regions of homozygosity in affected individuals, identify a 
suitable candidate region and identify a small number of candidate genes for 
sequencing, based on evidence of expression in the eye, or links to known cataract 
genes. 
4.8 Cataract Family 9  
Aim: To identify a pathogenic mutation that causes cataracts in an Omani 
family 
4.8.1 Patient DNA 
Cataract family 9 are of Omani origin (Figure 4:36). III1 has retinal disease and 
cataract, which were noted at age 40 (although from the pedigree it is not clear how 
long she had been afflicted with these conditions). The affected children presented 
with cataract at age 9 (IV:5), age 7 (IV:7), age 8 (IV:11). III:2 has myopia, but no 
cataracts (no DNA available). IV:3 and IV:9 (identified at age 7 for IV:9) have 
myopia, but no cataracts were observed. 
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Figure 4.35: Cataract family 9. Individuals with cataracts are shaded in black. * 
indicates family members from whom DNA was available. 
 
4.8.2 Molecular Genetic Methods 
A 250K genome wide scan was carried out on DNA from affected individuals IV:7 
and IV:11. Sequencing of known cataract genes CRYBB3, BFSP1, LIM2, GCNT2, 
CRYBB2, CRYBA4, GJA8, CRYBB1, HSF4, GALK1 and CRYAA was carried out.  
4.8.3 Results 
4.8.3.1 Genome-Wide Scan 
The 250K genome wide scan identified 14 common homozygous regions in IV:7 and 
IV:11 (Table 4.14). 
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Chromosome Start Stop 
1 48,839,231 52,951,964 
1 112,091,506 155,434,695 
1 230,893,966 238,771,340 
6 57,021,031 63,599,624 
7 86,208,080 88,697,030 
7 119,918,519 120,410,220 
8 32,585,951 35,010,158 
8 89,055,865 105,755,886 
10 22,187,429 24,640,014 
10 78,467,676 80,612,626 
15 23,825,206 66,294,326 
16 64,964,335 66,860,911 
22 Small regions ~1-1.5Mb towards the end 
Table 4.14: Regions of homozygosity shared by affected members IV:7 and IV:11 of 
Cataract Family 9. 
 
4.8.3.2 Sequencing of Known Cataract Genes 
No putative pathogenic mutations were detected, numerous SNPs were detected. 
Results are summarised in Table 4.11. 
4.8.4 Discussion 
To narrow down the homozygous regions in this family, it would be useful to conduct 
a 250K genome wide scan on DNA from affected individual IV:5. Comparison of 
regions found in other Omani families would also aid identification of the most 
suitable candidate regions if homozygosity. 
4.9 Conclusion 
Gene identification studies with SNP arrays and exome sequencing can be 
successful. There are many published instances of genes that have been identified 
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using this approach. For example, TGM6, when mutated, was identified as a novel 
causative gene of spinocerebellar ataxia (Wang et al, 2010). 
Currently, exome sequencing does not cover all exons in equal depths, and it is not 
possible to discount the possibility of a mutation within a non-coding region. When 
genome sequencing becomes available, many more questions about the genotype 
behind certain phenotypes are sure to be answered. 
The 1000 Genome Project is a step in the right direction in elucidating sequence 
changes that can more accurately be described as mutations, Not all ethnic groups 
are included in this venture (currently, there are 28 populations being sequenced in 
phase 2 of the project), so when sequence changes are identified, their possible 
deleterious or benign nature cannot be discerned simply based on 1000 Genome 
data. 
Functional studies can be useful in confirming that sequence changes are, in fact, 
damaging mutations, but this is more useful after a single (or few) suspects are 
identified, because functional studies are arduous, time-consuming and expensive. 
In a situation similar to that of the Omani Kindreds, so many sequence changes can 
be identified. Once the dogma that there must be a single causative autosomal 
recessively segregating mutation is abandoned, and possibility that there may be 
compound heterozygotes or different genes playing a role in the same family, a very 
good candidate must be identified before embarking on functional studies. 
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Primer Sequence 
CRYBA2-1F CCTCAGCACTTTCTGTTGTC 
CRYBA2-1R TTTCCCATGTTGGCAGGTCT 
CRYBA2-2F AAGGGTTTGGGGTTGGAGAA 
CRYBA2-2R TCTTGGAGACACCCTTCTGA 
CRYBA2-3F GACAGCTTCCACAGCTTGTGA 
CRYBA2-3R CAGTCTGACTCCATCATCTC 
CRYBA2-4F GCTGCTGGTGGAGAACATAG 
CRYBA2-4R TTCGTAGCCAAGGATGCTGG 
Table 6.1: Primers used for sequencing coding regions of CRYBA2 gene. 
  
Primer Sequence Primer 
length (bp) 
Product 
size 
Annealing 
temperature 
IHH-1F CATCAGCCCACCAGGAGA 18 459 57°C 
+acetamide IHH-1R CCAGCCAGTCGAGAAAATGT 20 
IHH-2F CGCCTACACCTGCACCTC 18 400 57°C 
IHH-2R CTACTCCTCCTGCCCATGC 19 
IHH-3A F GTTGTGACCAGGAGGCTGAG 20 525 57°C 
IHH-3A R AGCAGGATGCCACCACAT 18 
IHH-3B F GACACTGGTGGTGGAGGATG 20 469 57°C 
IHH-3B R GAGAGAGGGGTCAACAACCA 20 
IHH-3C F AGTCATAGAGCTGCAAGCTGAG 22 459 57°C 
IHH-3C R CAGCAGAAGGGGGAGCTTA 19 
IHH-3D F TGTGTTCTGGCCAATGTGAC 20 324 57°C 
IHH-3D R AAGGTGAGCCAGGCCTCT 18 
Table 6.2: Primers for IHH gene. 
 
Primer Sequence Primer 
length (bp) 
Product 
size 
Annealing 
temperature 
INHA-1F GTGGGAGATAAGGCTCATGG 20 561 57°C 
INHA-1R CATGCTGTGCCTTGCTTTT 19 
INHA-2A F AGAGGAGGGGTGCCAGGT 18 594 57°C 
INHA-2A R TGCTACTCTGTGGCAGTTGG 20 
INHA-2B F CTCAACTCCCCTGATGTCCT 20 477 57°C 
INHA-2B R CTTTCCTCCCAGCTGATGAT 20 
Table 6.3: Primers for INHA gene. 
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Primer Sequence Primer 
length 
(bp) 
Product 
size 
Annealing 
temperature 
TUBA4A-1F GCAGCTAGCGCAGTTCTCA
C 
20 150 57°C 
TUBA4A-1R AGCATGCCTGGAAGAAGT
GT 
20 
TUBA4A-2F AGACTCGCAAGGTGAGG
AC 
20 352 57°C 
TUBA4A-2R T TCCAGGGAGAAGCTTTG
A 
20 
TUBA4A-3F TGAGTCCTTCCATGCATCT
G 
20 293 57°C 
TUBA4A-3R TTCCTGACCATTAGCACAG
TCT 
22 
TUBA4A-4A F ACGCTTTATGGAGCCAGG
T 
20 593 57°C 
TUBA4A-4A R AAAGCAGGCATTGGTGATC
T 
20 
TUBA4A-4B F CGCCTCATTAGCCAAATTG
T 
20 599 57°C 
TUBA4A-4B R CTTCTCCCTCATCCTCGT
C 
20 
TUBA4A-4C F TCAACTACCAGCCTCCCAC
T 
20 395 57°C 
TUBA4A-4C R GAAGGCAGCAGAAGCTCA
AG 
20 
Table 6.4: Primers for TUBA4A gene. 
 
Primer Sequence Primer 
length 
(bp) 
Product 
size 
Annealing 
temperature 
WNT10A-1F AGTCCCACTGGGCTGTGA 18 249 57°C 
WNT10A-1R TCTACCCCAGCAAGAGCATC 20 
WNT10A-2F TGTTAGATGGGGCTCTCCTG 20 380 57°C 
WNT10A-2R CTGAGGTGGAGATGCTGGA 19 
WNT10A-3F CTGGAGAATGGGGTGTCAAG 20 493 57°C 
WNT10A-3R GGGTAGGCCCTAGGCAAAG 19 
WNT10A-4A 
F 
GGAGTGGGTTTCAGAAGCAG 20 494 57°C 
WNT10A-4A 
R 
GTCTGGCGCAGGATGTTGT 19 
WNT10A-4B 
F 
CGCCGACCTGGTCTACTTC 19 329 57°C 
WNT10A-4B 
R 
CCAAGACCGTAAGCCTCAGA 20 
Table 6.5: Primers for WNT10A gene. 
 
Primer Sequence 
Primer 
length (bp) 
Product 
size(bp) 
Annealing 
temperature 
CYP27A1-1A F CCCTCCAGGGATCAGATG
AC 
20 
480 57°C 
CYP27A1-1A R CTTTGGGTCGAGTGCTGA
GT 
20 
CYP27A1-1B F CCCTCTCCTGCAGCTC 18 
500 57°C 
CYP27A1-1BR TCACCTCTAGCCTCTCTGT
TCC 
22 
CYP27A1-2F C TCACCTCATCTCCTGTC
C 
20 
392 57°C 
CYP27A1-2R AGACCATCAGGCTCAGAG
GA 
20 
CYP27A1-3F GTGGACTTCAGGGTGAG
AA 
20 
387 57°C 
CYP27A1-3R GGAGGCAGAACCAGGACA
TA 
20 
CYP27A1-4F GTCAGGGAGAGGTTGTGC
TC 
20 
388 57°C 
CYP27A1-4R GGTAGCATGAGGGAAAA
GG 
20 
CYP27A1-5F TCCTTGGAGATCATGACTT
TTG 
22 290 57°C 
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CYP27A1-5R AGGGAACTGGTTCAGGTT
GG 
20 
CYP27A1-6F CCCATTACTGGCCTCTTTC
C 
20 
281 57°C 
CYP27A1-6R GATTCCCTCCCCACAAAGA 19 
CYP27A1-7F ATGGGAGAGGTAGGGGAG
AA 
20 
240 57°C 
CYP27A1-7R G AGATTGGGCAGCATGA
AT 
20 
CYP27A1-8newF  TGCCCAGGAGTGCCCT
AT 
20 
397 57°C 
CYP27A1-8newR  T GTGTGTTTGCCATCCAC
T 
20 
CYP27A1-9F CACAGGGTAGGAGTGTGC
AG 
20 
499 57°C 
CYP27A1-9R T ACTCACTGGAGGAGAG
GA 
20 
Table 6.6: Primers for CYP27A1 gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.7: Primers for SIL1 gene 
Primer Sequence 
Annealing 
Temperature 
(°C) 
Annealing  
Time 
(seconds) 
SIL1-1F  GCAGGCGTGAAGCTATCTCT 
64 60 
SIL1-1R  AGGAGGAGGCCCGGAAG 
SIL1-2F  GTTAGTAGGGATGCGGCAGT 
57 30 
SIL1-2R  AGGAGAACATTCATTGGTGA 
SIL1-3F  GGGAACCAAGCATTAGCTTTT 
59 60 
SIL1-3R ACAACAGCCCTGGTGACAG 
SIL1-4F  GAAAAGAACGTGCCACCCTA 
57 30 
SIL1-4R  GGGACAAAGGACATATGAGT 
SIL1-5F  CGACGACCTTCCAAAGACCT 
57 30 
SIL1-5R  CATGAATTTGGGTAACATTTTAAGT 
SIL1-6F  ACTGTGAGCCACCAAGCCTA 
57 30 
SIL1-6R  CCATTCTCGCAAAGACAACA 
SIL1-7F  TGTGAGTCTTGGAGCAGCAG 
57 30 
SIL1-7R  GCTTAGGGAAGGGGGATTTTA 
SIL1-8F  AACAGCTTTCTGTCCCTGA 
57 30 
SIL1-8R  CAAGTGTACCCTTCTTCCAAGC 
SIL1-9F  GGCTCAGTTCCCTGACCAT 
58.4 30 
SIL1-9R  AGGAACCCTTTCCTTTCAGG 
SIL1-10F  GGACTAATTTGGGGCACCTC 
57 30 
SIL1-10R  AAACAAGTGACGTCCGCAGT 
SIL1-11A F  GCTCCCTGTGTGTTCTCTCC 
57 30 
SIL1-11A F  AGAGGATGGCCTTCAGGTTT 
SIL1-11B F  AGCTTGCTGAAGGAGCTGAG 
59 60 
SIL1-11B R  CGATAGAGGGGCAGTGAAT 
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Primer Sequence 
Primer 
length (bp) 
Product 
size 
Annealing 
temperature 
C17orf42- 1F 
 
GCTTGGACAACAACCTTTCC 20 
200 
57°C 
C17orf42- 1R GCCTCTAGGGTCAGAGGCTAA 
 
21 
C17orf42- 2F GCTTGCAACTAACCCCAAAG 
 
20 
600 
57°C 
C17orf42- 2R CAATGCCCAGAAGAGTGCTT 
 
20 
C17orf42- 3F CCCAGAAGGTGGAGCTTGTA 
 
20 
359 
57°C 
C17orf42- 3R TCCTTTTGGGACCAGAAGATT 
 
21 
C17orf42- 4A F GACAGAGAGGGGACCAAACA 
 
20 
491 
57°C 
C17orf42- 4A R CACTGCTAATTCATAGAAGGCAAT 
 
24 
C17orf42- 4B F GGGGAAGCATTTTGAACTGA 
 
20 
499 
57°C 
C17orf42- 4B R GCTGGGATTATCGGCATAAG 
 
20 
Table 6.8: Primers for C17orf42 gene. 
 
Primer Sequence 
Primer 
length (bp) 
Product 
size 
Annealing  
temperature 
OMG- 1F TTGTCCATTTTGTTGCGTGT 
 
20 298 57°C 
OMG- 1R AAAAGAAAAAGGAAAAAGATTCCA 
 
24 
OMG- 2A F ACCCATGCAGATGCCTAAAC 
 
20 489 57°C 
OMG- 2A R GAGGACAACCTTTTCCAGCA 
 
20 
OMG- 2B F CCTCGGTCTCTGTGGAACAT 
 
20 488 57°C 
OMG- 2B R GATGATATTTGGGTAGAACATGGA 
 
24 
OMG- 2C F TTTGACCAACTCTTTCAGTTGC 
 
22 500 57°C 
OMG- 2C R GGTGTTGGGGATGATTTTGT 
 
20 
OMG- 2D F TCCACAGAGACTATCAATTCACAT 
 
24 500 57°C 
OMG- 2D R AGCAAGTACCAAGACATTGTGC 
 
22 
OMG- 2E F GAAAGCACTCCTCCCTGATG 
 
20 395 57°C 
OMG- 2E R GGTGAGGTCATTTTGATTCTGC 
 
22 
Table 6.9: Primers for OMG gene. 
 
Primer Sequence 
Primer 
length(bp) 
Product 
size 
Annealing 
temperature 
EVI2A- 1F ATGCCAGTGGCCAACTAGAG 
 
20 328 62°C 
EVI2A- 1R TTTGATAGCATTTCCTCGAACA 
 
22 
EVI2A- 2F TTTTGTTTGCATAACTCAACGTA 
 
23 298 56°C 
EVI2A- 2R TTGCCTGGTTAAGAACCCTA 
 
20 
EVI2A- 3A F AGGCATAAGCTTGTAGTTTACTTGT 
 
25 600 57°C 
EVI2A- 3A R AACCACAGTTGATAGAAATAGAAAGG 
 
26 
EVI2A- 3B F CACAAGCAAAAGTCATGGTGA 
 
21 492 57°C 
EVI2A- 3B R TGCAAGGTCTACCATGTCAAA 
 
21 
Table 6.10: Primers for  EVI2A gene.  
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Primer Sequence 
Primer 
length(bp) 
Product 
size 
Annealing 
temperature 
EVI2B- 1F CTTCCGGAACCAGCTATTGA 
 
20 300 57°C 
EVI2B- 1R AACCACAAAAACCTGTTATAGACATC 
 
26 
EVI2B- 2A F TGCCAGGAATCATAATGAAAA 
 
21 577 57°C 
EVI2B- 2A R AGGGATCTGGACAGATGATGA 
 
21 
EVI2B- 2B F CCAATAGCCAACACCTCCTC 
 
20 584 57°C 
EVI2B- 2B R TTGGGGTTGTTGGAGTCTTC 
 
20 
EVI2B- 2C F CTGATGGAGAAACCCCTGAC 
 
20 594 57°C 
EVI2B- 2C R GAGGTGGCAGGGATTCATTA 
 
20 
EVI2B- 2D F AATCATTTCCACCGCTTGAC 
 
20 732 57°C 
EVI2B- 2D R CCCAACCCTTCAGTTGATGT 
 
20 
Table 6.11:  Primers for EVI2B gene. 
 
Primer Sequence 
Primer 
length (bp) 
Product 
size 
Annealing 
temperature 
RNF135- 1A F GTCTTTCCAGCTGGGCACT 
 
19 
441 
51°C 
+acetamide RNF135- 1A R AGGTCCTGCAGTAGCGTGTT 
 
20 
RNF135- 1B F GACCTCGGCTGCATCATC 
 
18 
391 
56°C 
RNF135- 1B R CCACATGGGAAAGGGTCA 
 
18 
RNF135- 2F GTGGTTCCTGGGTCCAGTTT 
 
20 
254 
57°C 
RNF135- 2R GCAATCCCTAGCCCTATTCC 
 
20 
RNF135- 3F TTAAAAACTTGCTGGGAATTAAA 
 
23 
367 
56°C 
RNF135- 3R CCCCAGAGAACAAAGCCATA 
 
20 
RNF135- 4F TGCCTTGACCATGATGTTTG 
 
20 
233 
51°C 
RNF135- 4R ATATTCTCGAAGCCCGCTCT 
 
20 
RNF135- 5A F TGGACCATCAAAAGATGACC 
 
20 
646 
57°C 
RNF135- 5A R CCTGATTGATGACAGGGAGA 
 
20 
RNF135- 5B F CTTTGTACCCTGCCTTCTGG 
 
20 
500 
58.4°C 
RNF135- 5B R CTTGCAAGGTCAAGCTGATACT 
 
22 
RNF135- 5C F TGAACCCTGGACATTCCAAA 
 
20 
491 
57°C 
RNF135- 5C R CTGCCCTCAGGTTCAGTGAT 
 
20 
Table 6.12: Primers for RNF135 gene. 
Primer Sequence 
Product 
Size bp 
Annealing 
Temp. °C 
RHOA- 1F CGGCTGCAATGATTGGTTA 
485 57 
RHOA -1R GAGTCAGGTCAAGGGTCAGG 
RHOA- 2F CCAAAGCATGTGTCATCCTG 
295 57 
RHOA- 2R CATGCTCCATAAATATTCTAACATGG 
RHOA- 3F TCAATGGTCTGCCATTTCAA 
296 57 
RHOA- 3R ACTTGATGCCCAGAAACCAG 
RHOA- 4F TGCAATTTCACTGAGGTTCTTG 300 57 
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RHOA- 4R CCTGTGAAGGTTCCTGCTG 
RHOA- 5AF ACCGACGAGCAAAACTGTCT 
474 57 
RHOA -5AR ACGGGTTGGACATCGTTAAT 
RHOA- 5BF TGCTACCAGTATTTAGAAGCCAAC 
537 57 
RHOA- 5BR CCAATACACTTTCTTTGAGGATGA 
RHOA- 5CF TGCCACTTAATGTATGTTACCAAAA 
600 57 
RHOA- 5CR CTCTCCAGGGTGAGCTAGGC 
Table 6.13: RHOA Primers. 
Primer Sequence 
Product 
Size bp 
Annealing 
Temp. °C 
LAMB2-1F TTGGGGGCACAATAAAGATT 
494  57 
LAMB2-1R AAGGGCAACTACCAGGACCTA 
LAMB2-2F AGGTGGAGCCACTGGATAG 
300  57 
LAMB2-2R GGGATTAGAATCAGTGCCTCAG 
LAMB2-3F CTGGGGACAGGGTGTGAC 
292  57 
LAMB2-3R GGACAGGAATCGGAAGTCAA 
LAMB2-4F GTGGGGCAAAAGTGAGCAG 
239  57 
LAMB2-4R ATGCTCAAGGAGGCTGTGTT 
LAMB2-5F CAGTCACCCCCACTCTCTGT 
400  57 
LAMB2-5R TGGAGAAGCAGGGAGTTCAT 
LAMB2-6F TGGAAGCTGGGGATGATG 
192  57 
LAMB2-6R GAGGCCCCAAATAGTCCCTA 
LAMB2-7F CGGGTGGCAGTGTATAGGAG 
394  57 
LAMB2-7R GGCAGGTAGGTTGTCAGCAC 
LAMB2-8F GCTTCAGACGGTTGGGATAG 
292  57 
LAMB2-8R TAGGGGCTTGACCAACTAGC 
LAMB2-9F AGCCCCTACCCACAAATTCT 
395  57 
LAMB2-9R CTAACCCCAATTTCCTGCAA 
LAMB2-10F GGACTGGCAGTGAGCTAGTTG 
298  57 
LAMB2-10R AGGAGTAAGAGGACAGGGGTTA 
LAMB2-11F GAACATGAGCACTGCCACAG 
227  57 
LAMB2-11R CAGCCCTGTGCTCTAAGGA 
LAMB2-12F GTGGTTGGGATTTCCTGCT 
248  57 
LAMB2-12R CTGGAGGGAACTCTGTGGTT 
LAMB2-13F GGATGGGGAAAGATCCTGAG 
300  57 
LAMB2-13R ATCACCCCTATCCCCTCAAC 
LAMB2-14F CTGTGGCAGAAGAGGCAAAG 
287  57 
LAMB2-14R AACGGGATGATGGAGGAGAT 
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LAMB2-15F ATCTGGGGCTGAACCTCTG 
280  57 
LAMB2-15R GAATGAGCTGTGGGGTCTTC 
LAMB2-16F GGAGGCCCAGATGATTTGTA 
274  57 
LAMB2-16R ACCCCTGCTATCCCTCAAGT 
LAMB2-17F AGTGCTCTGGCAATGCCTAC 
323  57 
LAMB2-17R AGGGTTGGGCCAAGTCAG 
LAMB2-18F TCTGTGATGTGGGTTGATGG 
292  57 
LAMB2-18R AGCAGGTCCAGAAGGAGGAG 
LAMB2-19F TCCTGACCTTCCCACCTAGA 
427  57 
LAMB2-19R GCAGGGAGGAGGAAGAAGAA 
LAMB2-20F ATGAGTGGGTTGGTTGGTG 
300  57 
LAMB2-20R TTAAGAGGAAGCTGTGAGTGCT 
LAMB2-21F CGTGGGATCAGGGTGAGTT 
348  57 
LAMB2-21R GTCAAGAGGAGGCCAAGAAG 
LAMB2-22F CTGAATTGGGGTTCTGCTTC 
353  57 
LAMB2-22R AAGAGGCTAAGCCCTGGAGA 
LAMB2-23F GCAGATCCCTGGTTAGATGG 
249  57 
LAMB2-23R GTCACTGTGGGGCATTCTG 
LAMB2-24F GCCAGGGTAGATGGAGGACT 
500  57 
LAMB2-24R CTGGTCCACTGGGCCTCT 
LAMB2-25F GCGGAAGGGCCTAAGAATAC 
352  57 
LAMB2-25R CTAAATTGGGCAGAGGCAGA 
LAMB2-26F TAGCCAACTAGGCAGGTGGA 
381  57 
LAMB2-26R CAGGCACAGAACAAGTCAGG 
LAMB2-27F GGCAGGTGGGTGTAGATGTT 
469  57 
LAMB2-27R ATACAGACACCGGGAGTTGC 
LAMB2-28F CCTGAGTCCATACCCCAAAA 
362  57 
LAMB2-28R GGAGAAGGGGGAATCAGAAC 
LAMB2-29F CCTATCCCTGACACCTGGTT 
275  57 
LAMB2-29R GGGTGAGCCAAAGGTTACAC 
LAMB2-30F AGGACATCAGTGGGACAAGG 
293  57 
LAMB2-30R CCATCTTCCACCCCTACCT 
LAMB2-31F GGAGAAGGTAGGGGTGGAAG 
299  57 
LAMB2-31R CTAGGAAGGGCAGGTGTCAG 
LAMB2-32F TAAGAAATGGGGCACCAGAG 
374  57 
LAMB2-32R CGAGGTTCCCCTGGAGACT 
Table 6.14: LAMB2 primers. 
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Primer Sequence 
Product 
Size bp 
Annealing 
Temp. °C 
TREX1-2AF ATGTGCTGGTCCCACTAAGG 
485  57 
TREX1-2AR TGCTCAGACCTGTGATCTCG 
TREX1-2BF ACCTCCCACAGTTCCTCCA 
567  57 
TREX1-2BR TTGGTCCTAGCAGAGGCTGT 
TREX1-2CF CAGCCTAGGCAGCATCTACA 
484  57 
TREX1-2CR AGGAGCCAATTGACCACTCA 
Table 6.15: TREX1 primers. 
Primer Sequence 
Product 
Size bp 
Annealing 
Temp. °C 
CSPG5-1F AGCGAGGGGTCTGTCTGTT 
497  57 
CSPG5-1R CTCACAGCTCCACCTGTCC 
CSPG5-2AF CTGGGTTGACCAGGTCTAGG 
588  57 
CSPG5-2AR TAAGTCAGCTCTGGCCCTTG 
CSPG5-2BF CAGCTTCTGAACTCCCCAAG 
577  57 
CSPG5-2BR TTTTCACTGGAGGCCAAGTC 
CSPG5-2CF CACTGGGAAGCCTGGTCTG 
345  57 
CSPG5-2CR TTGAGTCGGCCTCACATACA 
CSPG5-3F CTAGATGGCCTTCGGAACAG 
393  57 
CSPG5-3R AAGTCCCTGGATCAGTTGGA 
CSPG5-4F ATTGTCATGTTTTGCCGTGA 
295  57 
CSPG5-4R TTCTGAAATAGACATCAGACATGG 
CSPG5-5F CGCTGATATTATTATTTGGTTGC 
289  57 
CSPG5-5R GATAATGTTTCTTCCCCTACCC 
Table 6.16: CSPG5 primers. 
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Primer Sequence 
Product 
Size bp 
Annealing 
Temp. °C 
CCDC12-1F CCGCGAGACATTTATCCACT 
250  57 
CCDC12-1R CCCTTTGCTCTCCTCAAGC 
CCDC12-2F CCACGTGGACTGGAAGTAGG 
277  57 
CCDC12-2R CAGGGCAGACACTGAACAGA 
CCDC12-3F AATTCACGGGCTATGCAAAT 
246  57 
CCDC12-3R AGAGAGCAAAGCCTGCTGAG 
CCDC12-4AND5F CAGTGTCCCTGCAGAGTGG 
464  57 
CCDC12-4AND5R CATGCTGGCACCAAGAGTC 
CCDC12-6AND7F ACCCAATGCCACATCAGG 
371  57 
CCDC12-6AND7F AAGACCATCCTCTGCAGGAC 
Table 6.17: CCDC12 primers. 
Primer Sequence 
Product 
Size bp 
Annealing 
Temp. °C 
TMIE-1F ATGATGCTCGCTGACTACCC 
291  57 
TMIE-1R AAAAAGGCGTCCCCTCTC 
TMIE-2F GGCCCTTCTCAGCTGGTT 
240  57 
TMIE-2R GGGTGCTGTGTTCCCACT 
TMIE-3F CCATTCCTTGGGTCTCTGAA 
289  57 
TMIE-3R GAGCAGAGGAACAGGGTGAC 
TMIE-4F GTCAGACCCCAGGACCTTGT 
249  57 
TMIE-4R GAGCTCAGAGTCCAACATGC 
Table 6.18: TMIE primers. 
Primer Sequence 
Product Size 
bp 
Annealing 
Temp. °C 
CDC25A-1A F AAGAGGTGTAGGTCGGCTTG 
400  57 
CDC25A-1A R AGCTCCCGCTCCCTCTTC 
CDC25A-1B F GCGGAGGCAGAGGAAGAG 
295  57 
CDC25A-1B R GTTTCCTGGCCTGATCTCTC 
CDC25A-2 F GCCTGGCTGCTTCTTAATCT 
286  57 
CDC25A-2 R TTTATCACCCAATGCCATGA 
CDC25A-3 F AAAGACCCAGGTACTTTGTTTAGTG 
245  57 
CDC25A-3 R GGTAAATCCAGGGCTCCAGT 
CDC25A-4 F CTGTACCCCCAAGCTACAGG 
211  57 
CDC25A-4 R TCCTATCAAGGTCATGCTGGT 
CDC25A-5 F TTGAGAACTGAATTTTCCACTGA 229  57 
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CDC25A-5 R ACTGACAGCCTGTGGGTTTC 
CDC25A-6 F CTGAGGCCTGAGTTGGTTTT 
249  57 
CDC25A-6 R CAATTCTGGATGAAAGAAGGTG 
CDC25A-7 F GTGACCCATTCAAGGAAATG 
270  57 
CDC25A-7 R CACATGCCTTCTCCAGAGGT 
CDC25A-8 F TTGTTCAGGGAGAAACACACC 
217  57 
CDC25A-8 R ACTCTGTCCAGTGCCCCAAT 
CDC25A-9 F AATCGGCAGTGTCTGTTGG 
399  57 
CDC25A-9 R AGCAAAGAAAATAAATGAACCACT 
CDC25A-10 F CGAGACATGCTCCAAGTGAA 
250  57 
CDC25A-10 R GACAGGCTGAGTGGGATTCT 
CDC25A-11and12 F GCCAGACAAAACAGTATAAGTGTGA 
400  57 
CDC25A-11and12 R TCCTCCCCACTTTAAAACCA 
CDC25A-13 F GCTGAATCATTACTTCATGTGTGA 
250  57 
CDC25A-13 R GTCCCACAAAAGCATCATGG 
Primer Sequence 
Product Size 
bp 
Annealing 
Temp. °C 
CDC25A-14 F CTTGTTGCTGTGCTGGAAAA 
243  57 
CDC25A-14 R ATGACCACCAGACAGATCCA 
CDC25A-15A F GAGAGGAAACCAGGTTGTGG 
593  57 
CDC25A-15A R CTTTGCTATTTGGCCAGCAG 
CDC25A-15B F GAGAAGTTACACAGAAATGCTGCT 
529  57 
CDC25A-15B R ATGCTGCCTCAAGTGCTTTC 
CDC25A-15C F GTTCCATGACATTGGCTGGT 
539  57 
CDC25A-15C R TCTCTCTAGAATCAATGAAGTCTGC 
CDC25A-15D F TTCAAAAGAACACCTCATCCAA 
560  57 
CDC25A-15D R TGGCCATCCCAAACACTAAT 
Table 6.19: CDC25A primers. 
 
Primer Sequence Length 
Product 
Size bp 
CDC25A-P1F ATGGAACTGGGCCCGGAGCCCCCGC 25 
634 
CDC25A-P1R ACAAAGTGGCTGTCACAGGTGACTG 25 
CDC25A-P2F GGACTCCAGGAGGGTAAAGATCTCT 25 
633 
CDC25A-P2R GGCAAACTTGCCATTCAAAACAGATGCC 28 
CDC25A-P3F CCATTGAGAACATTTTGGACAATGACCC 28 
602 
CDC25A-P3R TCAGAGCTTCTTCAGACGACTGTAC 25 
Table 6.20: Plasmid Primers. 
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Primer Sequence 
Product 
Size bp 
Annealing 
Temp. °C 
CRYBB2-2F GTCTCAAGGCCCCACAGAG 
214 64 
CRYBB2-2R AGAAGGGCAACTAAGTCTGGG 
CRYBB2-3F CCACGTCTACCACCCAGTTC 
276 64 
CRYBB2-3R CACAACTTGATCACCTCACCC 
CRYBB2-4F GCTTTGGGCACAGCGATGTTCTG 
750 64 
CRYBB2-4R GGCCCCTTCCTGGTCCCCA 
CRYBB2-5F AGTGGTCATAGACACGTAGTGGGTGCAC 
700 64 
CRYBB2-5R CTGTTCCCAAACTTAGGGACACACGC 
CRYBB2-6F GGCTTCACCCTTCCTAGTGG 
526 64 
CRYBB2-6R CTGTTGCCCTACTCCTAGCAC 
Table 6.21: CRYBB2 primers. 
Primer Sequence 
Product 
Size bp 
Annealing 
Temp. °C 
CRYBA4-1F CTTGCCATTGGCTCTTCAGC 
253 57 
CRYBA4-1R CACAGTGACATCCCTAGGAC 
CRYBA4-2F TGGATCCTGACCAGGTCCAA 
206 64 
CRYBA4-2R GGATTCATGGGGACCTGAAC 
CRYBA4-3F TGCGGATCTCCACCTTTTT 
250 56 
CRYBA4-3R GGGAGAGGGGACCTAGAATATC 
CRYBA4-4F CTGTGACCGTTCTAGACCCA 
290 57 
CRYBA4-4R TTCCGAAGTGCCCACATGAG 
CRYBA4-5F GGAAGGCTGATTTGGGAGAC 
307 57 
CRYBA4-5R TACACCTACCCCTCCCAGTA 
CRYBA4-6F TGTGTTGATCACCATGCTGG 
570 
64+ 
acetamide CRYBA4-6R AATGACCCAGAAGTCTGCCT 
Table 6.22: CRYBA4 primers. 
Primer Sequence 
Product 
Size bp 
Annealing 
Temp. °C 
CRYBB3-1F AGTGAAGTGGCCTGGATGGA 
248 62.9 
CRYBB3-1R ATGCGCGTCCCACAGAAACT 
CRYBB3-2F GCAAGGCTCTGTAGCTCATC 
255 57+ DMSO 
CRYBB3-2R TTGGCTGGGAAGATGACCCT 
CRYBB3-3F GATGCAGAAAGCAGAGGGTA 
305 64 
CRYBB3-3R CAGATCTAGAGCTCAGACTG 
CRYBB3-4F GGTTCAAGGTCAGCAGCTCT 305 62.9 
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CRYBB3-4R AATGAGCTGCCTGACCAGCT 
CRYBB3-5F ATCTGGAGCCTCCTTGACCT 
275 64 
CRYBB3-5R CTGTTTGGAGCCAGAGGCAT 
CRYBB3-6F CAGAGTGCATGGTCAGATGC 
495 64 
CRYBB3-6R CTGGGAGTCTCAGAACACTC 
Table 6.23: CRYBB3 primers. 
Primer Sequence 
Product 
Size bp 
Annealing 
Temp. °C 
CRYBB1-1F TGCTGCTGTCTGCAGTGATC 
303 57 
CRYBB1-1R CATGGCACTGCTATCTCTGC 
CRYBB1-2F AAACGAGCTCCAAGGAGGCT 
405 57 
CRYBB1-2R TGCGGAGGAGTAAGAGGTGA 
CRYBB1-3F ATGTGACTCCTGCACTGCTG 
286 
62.9+ 
acetamide CRYBB1-3R GCAGCTACTGTTGTGTGGTC 
CRYBB1-4F TTGCCAGGGGAGAGAGAAAG 
288 62.9 
CRYBB1-4R CTCAGACTTACACCTGCCCT 
CRYBB1-5F TCATCTCTCTCGCTCCACAC 
300 62.9 
CRYBB1-5R AGCCTCTGATTCTGCCTGTG 
CRYBB1-6F TCAATGAAGGACAGGCTGGT 
438 62.9 
CRYBB1-6R GAGGAAGTCACATCCCAGTA 
CRYBB1-201-1F GTTGTGGAGGGTTGGATTTG 
194 57 
CRYBB1-201-1R TCACTGCTGTTTTGCTTTGG 
Table 6.24: CRYBB1 primers. 
 
Primer Sequence 
Product Size 
bp 
Annealing Temp. 
°C 
BFSP1-1F ACTGCTGATCGGCTCTGG 
600 60.4+ GCrich 
BFSP1-1R ACCCCTGCATGGTAGCAG 
BFSP1-2F AAAGGAGAGGGCATCGTACC 
238 64 
BFSP1-2R AACCTGCACTTCCACCATTC 
BFSP1-3F TATACCCGGCCAGCTTTACC 
232 57 
BFSP1-3R CCTCGGCTTACCTGATCAAA 
BFSP1-4F TGTCCATTCCTGTTCTCATCT 
250 57 
BFSP1-4R GCCCTTCCCTGGGAGTCT 
BFSP1-5F GCACCTTCTCTGCCCTTTTC 
235 57 
BFSP1-5R GCGTAACACCTCCATGAAAC 
BFSP1-6F CAGGTTCCTTTTCCTGGTGA 400 57 
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BFSP1-6R CACATGCCCACTGCCTATAA 
BFSP1-7F CATTTTTGCTCAACATTAACGA 
230 57 
BFSP1-7R GAAGAGAGCCGCTTGGTTT 
BFSP1-8AF ATAGGCGTTTGTTTCCGAGA 
499 57 
BFSP1-8AR GTAATTGGCATCCCCTGTGA 
BFSP1-8BF AGTCCCCTGACACAAGAAGG 
459 57 
BFSP1-8BR GGGTCTCCTGGACTCTTCGT 
Table 6.25: BFSP1 primers. 
Primer Sequence Product Size bp Annealing Temp. °C 
LIM2-2F CCCAGTTCCTCCCTTCAAGT 
480 57 
LIM2-2R GTCAGGAAATGCCACCTCTC 
LIM2-3F GAAAGGGGCAAGGCATTT 
296 57 
LIM2-3R TTGGGGTTTGAGATGAGAGC 
LIM2-4F CCACCTCCAAAATCACACC 
250 57 
LIM2-4R TGTGGGACACCCTGTCATC 
LIM2-5F GGGATACCCAGGGAGAAAGA 
221 64+DMSO 
LIM2-5R CTCCTCTTCAGTGGCCTCAC 
Table 6.26: LIM2 primers. 
Primer Sequence 
Product 
Size bp 
Annealing 
Temp. °C 
GCNT2-001-1AF GGGCAGGAGTGAGTGGAGTA 
500 57 
GCNT2-001-1AR TTTTTCATCCACATGAACACAG 
GCNT2-001-1BF GCAAGGAATACTTGACCCAGA 
491 64 
GCNT2-001-1BR CAGGTGCTCTTGGTGGACAT 
GCNT2-001-1CF TTTCTGCCTTCGAGGTCTCA 
500 57 
GCNT2-001-1CR TTCCAGTTTTCATCTTCTACTTCC 
GCNT2-001-2F CTGGAGGAAACAGAAGATGG 
399 62.9 
GCNT2-001-2R AAGCCTCTGGCTTCTCCAAT 
GCNT2-001-3F ACCATTGGCACAGTTGTAGTT 
383 57 
GCNT2-001-3R CGAAGGCAAAAGTCTCTCACA 
GCNT2-004-1AF CAAGACTGGCAAGAGAAGCA 
486 51+DMSO 
GCNT2-004-1AR TTTCTCATCCACGTGAACACA 
GCNT2-004-1BF ATCACCTTTGCGAAGTGTCC 
487 57 
GCNT2-004-1BR TCGCTTAATTGCATGGTCAG 
GCNT2-004-1CF GACTCCAGGCTGACCTGAAC 
565 57 
GCNT2-004-1CR TTGCTACAAGCAACCAAACTAA 
GCNT2-006-3AF CACGAGGATGATTTCGGAAC 
499 57 
GCNT2-006-3AR GTCGCCTTCTGATCCAGGT 
GCNT2-006-3BF CATGGTTCGAAGCCACTATG 486 57 
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GCNT2-006-3BR TGGTTTAACAGTTCTTGGTGGA 
GCNT2-006-3CF CTTGTGGCCTCTGAAGTTCC 
481 57 
GCNT2-006-3CR TTTTCCACTCTTTTCAAAGCAA 
GCNT2-010-3F TCATTCCCTATTTAATTTGTCCTTT 
250 57 
GCNT2-010-3R GGTCATCTCATTCATCACACCA 
GCNT2-201-1F CGCTGTTGGACGGACTAAAT 
360 57 
GCNT2-201-1R CCGTAAAGAAGTTTGTCCCATT 
Table 6.27: GCNT2 primers. 
Primer Sequence Product Size bp 
Annealing Temp. 
°C 
GJA8-1F ATATCTGCTCAGTCGTGCAG 
320 62.9 
GJA8-1R GAGGGTTTTCAGAGTTGGAG 
GJA8-MID-1F GGCAGCAAAGGCACTAAGAA 
574 57 
GJA8-MID-1R GAGCGTAGGAAGGCAGTGTC 
GJA8-2F CGTTCTGGCAACTTGGAAAG 
791 57 
GJA8-2R CAACTCCATCACGTTGAGGA 
GJA8-3F CAAGAGACACTGCCTTCCTA 
834 57 
GJA8-3R GAGGACAGGAGACAGAAGAT 
Table 6.28: GJA8 primers. 
Primer Sequence 
Product Size 
bp 
Annealing 
Temp. °C 
HSF4-3F GCAAACGCAGCACTTTCC 
270  57  
HSF4-3R GGCATGGGTGTTCACTGAC 
HSF4-4+5F CTGGACCCAAGAGTGAGCAT 
494  64  
HSF4-4+5R AGTCCCAGCACCCCTCCT 
HSF4-6F GGAATGAGCAAAGAGGAGGA 
298  64  
HSF4-6R AAGGGGCTGCCCAGAACT 
HSF4-7+8F CAGCCTCGCCATTCTGTG 
474  64  
HSF4-7+8R CGGTGAAGGAGTTTCCAGAG 
HSF4-9F GGAGGGAGGGAAGTGCAG 
249  64  
HSF4-9R GGGAGAAGGAACAGGCTCTC 
HSF4-10+11F TCCTCCCTCAAACCTTCTCC 
647  57  
HSF4-10+11R AAGCTTTGTGGGCTGGTAAG 
HSF4-12+13F TTGATGCATCTGGGTTCCTT 
430  57  
HSF4-12+13R GGCTTTGGCTCACAGAGAAC 
HSF4-14F CAGTGATTTCCCAGCTGTCC 
244  57  
HSF4-14R AACTCAGGATTTCCCTGCAA 
HSF4-15F GCTCTCCTTCCCTGAAGAAA 
354  62.9  
HSF4-15R AGGGATAGTCGGGGTAGTGG 
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HSF4-T2-10F TCAAACCTTCTCCCTTAGACCT 
300  57  
HSF4-T2-10R CTCTACCCCTACAGCCATCTG 
HSF4-T2-11F CTGGCACTGCTCAAAGAAGA 
285  
60.4+DMSO 
  HSF4-T2-11R GAAGCTTTGTGGGCTGGTAA 
Table 6.29: HSF4 primers. 
Primer Sequence Product Size bp 
Annealing 
Temp. °C 
CRYAA-1F CCTTAATGCCTCCATTCTGC 
395  56  
CRYAA-1R CAGAGTCCATCGCTCTCCAC 
CRYAA-2F AGGTGACCGAAGCATCTCTG 
334  64  
CRYAA-2R AAGGCATGGTGCAGGTGT 
CRYAA-3F GCAGCTTCTCTGGCATGG 
376  64  
CRYAA-3R GGGAAGCAAAGGAAGACAGA 
CRYAA-003-1F GGTTCCTCTGGTCTCCTGAGT 
298  64  
CRYAA-003-1R CTGGGGAGGACCCTGTTTAT 
CRYAA-004-1F TGACCATAGCCAAACAACCA 
495  64  
CRYAA-004-1R AAGGCATGGTGCAGGTGT 
Table 6.30: CRYAA primers. 
Primer Sequence 
Product 
Size bp 
Annealing 
Temp. °C 
GALK1-201-1F GAACCGGCTGAGGTCTGG 
491  64 +GCrich 
GALK1-201-1R CTTCCAACGTGGGGAACAG 
GALK1-201-2F ACTGTGGAGGCATCAGAACC 
394  57 
GALK1-201-2R CTCTACAAGCCTTCCCCACA 
GALK1-201-3F GGTTGGTGGCTTCTGACAAT 
350  57 
GALK1-201-3R ACCCCCTCCATAAGGCATAG 
GALK1-201-4F CAGGTGGTCCCAGCTTCTAC 
385  57 
GALK1-201-4R CTGGGGTGGAGTTACAATGG 
GALK1-201-5F CTCCTGGGTGGGAGTGTG 
394  
64 
+acetamide GALK1-201-5R TTGAAGGGACTGGGGAGAG 
GALK1-201-6+7+8F CCACCCTTCACCGTCCAG 
685  
64 
+acetamide GALK1-201-6+7+8R ACCCTCACCGTGTGCTGT 
GALK1-202-2F CTGGTGCTGCCTATGGTGA 
566  57 
GALK1-202-2R TGTGCACTCCCCAAGCTG 
GALK1-202-3+4F CCTAGAGAGGCCCAGTGAAC 
378  57 
GALK1-202-3+4R GCCTCCACAGTCATCAGGTT 
6. Appendix   228 
  
 
 
Table 6.31: GALK1 primers. 
Primer Sequence Product Size bp 
Annealing 
Temp. °C 
LENEP-1 F GGCCTAGAACCTTCCCTTTG 
390 
57 
LENEP-1 R TACTCTACCCTGCCCACCTG 
Table 6.32: LENEP primers. 
Primer Sequence 
Product 
Size bp 
Annealing 
Temp. °C 
CRYBG3-1aF TGCTGAAGGGAGTGTTGAAG 540 
  
57 
  CRYBG3-1aR TTGTACCTTTTGGCCTCCAC 
CRYBG3-1bF TACGAAGAGCCCCTTCAAGA 572 
  
57 
  CRYBG3-1bR GAAATTCCAACGCTCTCCTG 
CRYBG3-1cF GGAGGAGGAGGCAGCAGTAT 490 
  
57 
  CRYBG3-1cR GCTTGGCCAAAACATTGACT 
CRYBG3-2+3F TGGATACAAGACTGCTAAGAAAATG 
600  57  
CRYBG3-2+3R TCGAAAAGTAGAGGAAGGAGAA 
CRYBG3-4F TGGAAGATATCCCAGCTTAAAAA 
367  57  
CRYBG3-4R AACAGCACAAAAATTAGCAATGA 
CRYBG3-5F TCCAGGACATTGAGAAGACTG 
335  57  
CRYBG3-5R CTGCAGTCTTTCTTGGGTGA 
CRYBG3-6F TGTGATGGAGGATTTTGTTTT 
300  57  
CRYBG3-6R GCATGAGCAAACATCATGG 
CRYBG3-7F TCTTGCCCCATCTACATTGA 
471 57  
CRYBG3-7R CCTCCATCTTTGCAGACTGA 
CRYBG3-8F TCCCTGTACATTTTGTGGTCTTT 
294  57  
CRYBG3-8R TGCTTTGCTTAGCACATTTTTG 
CRYBG3-9F TGGAGATGAACCACTATGAGCTT 
300  57  
CRYBG3-9R CAGGAGTCATGTCCAATTTTTG 
CRYBG3-10+11F CCCATCAGTATGTGATATTTTGC 
570  57  
CRYBG3-10+11R TGACATCATTCAACAACTCCACT 
CRYBG3-12F TACCCCAGCCTGGATAACAG 
250  57  
CRYBG3-12R GAGAAAGATTTGAGAGAAAGGGTA 
CRYBG3-13F AAAGGTTTTTATTTGCTCGTGA 
299  57  
CRYBG3-13R TGCCTGTTGAAGATAAATTTTAAGG 
CRYBG3-14F CCTACCCCAATTCCCACAG 
294  57  
CRYBG3-14R CCAACTTCACATTATCATTGGTG 
CRYBG3-15F CCTGTGTTCAGACTGGGATG 
281  57  
CRYBG3-15R TGGTTTGCAACTCTGCAACT 
CRYBG3-16F CCCTATAAGGCAAAGTGCAGA 
284  57  
CRYBG3-16R TCAGATGCTGTGGTTTATGACA 
CRYBG3-17F AGCTTTCCTCCTCTGGAAGG 
316  57  
CRYBG3-17R TGCCAGTTGATTTGACAGGA 
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CRYBG3-18F CCTAAGATAAAAGGGACCTAATTCA 
309  57  
CRYBG3-18R CCCAAAATGAGGAGATTTGG 
CRYBG3-19F TGAACAGAAGCTTGTGAAAATTG 
250  57  
CRYBG3-19R TTTCCACGTCCACAAGACAA 
CRYBG3-201-1F TTCCCCAGACACAAGGATAGA 
 173  57 
CRYBG3-201-1R ATGCACAAGAATGGTGGTGA 
CRYBG3-201-2F TGATTTGGAATCATGGGTCTC 
228  57  
CRYBG3-201-2R TGACATCCCAGTCTGAACACA 
CRYBG3-004-1F CAAGCTAAATGTGAAAAGCAAAC 
226  57  
CRYBG3-004-1R TTCTGACTTGTGGAACTGCAA 
Table 6.33: CRYBG3 primers 
.Primer Sequence 
Product 
Size bp 
Annealing 
Temp. °C 
HSPB6-1F GCACAGGGCGCACTATAAAT 
359  57  
HSPB6-1R CAAGGCCAACGAACATTCTC 
HSPB6-001-2+3F CTCCGGAGGCCAGAGTGA 
594  
66 
+acetamide  HSPB6-001-2+3R GACAGTCCTTGGCGCACT 
HSPB6-201-4F GAGGGCGTCCTGTCCATC 
349  64  
HSPB6-201-4R GACTGTCGGCTGAGGGTTAG 
Table 6.34: HSPB6 primers. 
Primer Sequence Size Temperature °C 
BFSP2-1A F CACATGACCCTGCATCAAAG 
575  57  
BFSP2-1A R CCCTAGGTCCTCAACAGCAC 
BFSP2-1B F AGGACCAATGCCATGAGTG 
450  64  
BFSP2-1B R GCCTCAGCCTACTCACAACC 
BFSP2-2 F TGTGCCTAACACAAGTCATGG 
247  57  
BFSP2-2 R CAGGCTCCAGAACAGCATTA 
BFSP2-3 F TCACATAATTGGCCTGTTGG 
358  57  
BFSP2-3 R CGCAATGTGGAGAGTCAGAA 
BFSP2-4 F TCTGTGAAGCCTGTGTCTGG 
383  57  
BFSP2-4 R TTTCTTCGTCTGCACATTGACT 
BFSP2-5 F GAGGCAGTGGAGTGGTGATT 
323  57  
BFSP2-5 R GGGAATCCCCTGGAAACTAA 
BFSP2-6 F TGCCACTGCTCTGCACAC 
389  57  
BFSP2-6 R TTAAATACTTCTACAGTGTTTGGAAAA 
BFSP2-7 F TTGTTCCAAAGGCCAGATTC 
452  57  
BFSP2-7 R TTCCAGAAGCCTTCAAGCAT 
Table 6.35: BFSP2 primers. 
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Marker Chr. Start Stop Size Tag 
D1S485 1 105,069,360 105,069,668 157-181 FAM 
D1S429 1 105,494,413 105,494,742 213-225 TET 
GATA133A08 1 106,083,035 - 114-134 HEX 
D1S239 1 106,640,929 106,641,320 242-258 TET 
ATA42G12 1 106,877,151 - 178-196 FAM 
D1S248 1 106,956,443 106,956,768 191-211 TET 
D1S2726 1 110,896,304 - 280-294 NED 
D1S498 1 148,114,568 - 187-209 NED 
D1S498Manju 1 149,568,188 149,568,378 183-205 FAM 
*Chr1-25xTG 1 150,948,915 150,949,365 223 FAM 
*Chr1-22xGT 1 152,009,159 152,009,203 246 FAM 
*Chr1-26xAC 1 153,111,478 153,111,529 250 FAM 
D1S394 1 154,132,484 154,132,911 289 FAM 
D1S1653 1 154,745,743 154,746,066 104 FAM 
*Chr1-25xAC 1 155,158,129 155,158,179 247 FAM 
D1S1655 1 156,199,398 - 96-120 HEX 
D1S484 1 157,580,383 - 272-286 VIC 
D1S1679 1 160,628,539 - 144-176 FAM 
D1S1677 1 161,826,325 - 184-212 FAM 
D1S2878 1 162,135,023 - 148-176 NED 
D1S2673 1 163,312,611 - 148-176 NED 
D1S196 1 164,335,785 - 321-337 VIC 
D1S1589 1 172,527,725 - 199-220 HEX 
D2S112 2 132,925,167 132,925,417 136-150 TET 
D2S368 2 134,893,430 134,893,756 218-244 TET 
D2S2385 2 137,478,083 137,478,431 128-150 FAM 
*Chr2-24xCA 2 138,662,644 138,662,692 249 FAM 
*Chr2-24xTA 2 139,470,722 139,470,770 390 FAM 
*Chr2-19xCA 2 140,864,808 140,864,845 289 FAM 
*Chr2-22xAC 2 141,769,786 141,769,786 212 FAM 
*Chr2-22xTG 2 142,772,995 142,773,039 242 FAM 
*Chr2-22xTCT 2 143,627,817 143,627,884 273 FAM 
D2S132 2 144,683,977 144,684,275 189-213 FAM 
D2S1399 2 147,926,579 - 266-310 FAM 
*Chr3-16xTTA 3 75,301,460 75,301, 509 270 FAM 
*Chr3-22xGT 3 77,535,415 77,535,458 231 FAM 
D3S3681 3 79,894,319 - 121-161 VIC 
*Chr3-18xTG 3 80,874,605 80,874,641 199 FAM 
*Chr3-29xGT 3 81,833,944 81,834,001 250 FAM 
*Chr3-21xAT 3 83,215,618 83,215,659 345 FAM 
*Chr3-28xAC 3 84,520,624 84,520,680 207 FAM 
*Chr3-28xTA 3 86,901,482 86,901,538 225 FAM 
*Chr3-16xATT87 3 87,963,171 87,963,218 281 FAM 
*Chr3-26xAT 3 90,235,425 90,235,476 208 FAM 
*Chr3-22xCA 3 95,173,162 95,173,205 186 FAM 
D3S2462 3 97,601,374 97,601,614 232-254 FAM 
*Chr3-33xAT 3 98,564,706 98,564,772 248 FAM 
*Chr3-15xTCA 3 99,228,137 99,228,183 241 FAM 
*Chr3-28xTG 3 100,485,902 100,485,958 228 FAM 
*Chr3-16xATT101 3 101,159,738 101,159,785 228 FAM 
D3S1271 3 102,217,419 - 84-104 VIC 
D3S3045 3 108,472,546 - 172-208 FAM 
*Chr3-24xGT 3 109,375,535 109,375,582 241 FAM 
*Chr3-22xCT 3 110,021,256 110,021,299 375 FAM 
*Chr3-16xGT 3 111,566,561 111,566,592 199 FAM 
*Chr3-25xGT 3 112,400,226 112,400,275 233 FAM 
D3S4018 3 113,136,904 113,137,228 282-302 FAM 
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D3S3683 3 114,744,360 114,744,531 160-174 FAM 
*Chr3-16xTC 3 114,880,547 114,880,578 239 FAM 
D3S3585 3 115,156,830 115,157,098 227-271 FAM 
*Chr6r1-15xATA 6 88,893,581 88,893,626 209 FAM 
*Chr6r1-26xTA 6 89,506,164 89,506,216 218 FAM 
*Chr6-16xAC 6 90,194,544 90,194,576 227 FAM 
*Chr6-26xCA 6 91,342,860 91,342,911 238 FAM 
*Chr6-30xTA 6 95,957,151 95,987,211 247 FAM 
*Chr6-18xAC 6 96,818,346 96,818,781 193 FAM 
*Chr6-21xTG 6 97,846,372 97,846,614 181 FAM 
*Chr6-17xTG 6 98,718,380 98,718,413 159 FAM 
*Chr6-22xTG 6 99,826,744 99,826,788 201 FAM 
*Chr7-17xATT 7 117,254,117 - 223 FAM 
*Chr7-23xAT 7 117,998,458 - 397 FAM 
*Chr7-29xTA 7 118,671,349 - 270 FAM 
*Chr11r1-20xAC 11 31,577,606 31,577,646 215 FAM 
*Chr11r1-16xTAT 11 32,822,590 32,822,638 271 FAM 
*Chr11r1-23xAC 11 33,219,409 33,219,454 356 FAM 
*Chr11r1-18xAC 11 34,192,263 34,192,299 247 FAM 
*Chr11r2-29xGT 11 38,838,292 38,838,349 239 FAM 
*Chr11r2-20xAC 11 39,808,766 39,808,806 250 FAM 
*Chr11r2-18xTG 11 40,265,383 40,265,419 164 FAM 
D14S68 14 87,697,387 - 318-346 NED 
D14S256 14 88,281,213 88,281,346 133-156 FAM 
D14S1005 14 88,447,761 88,447,972 204-230 FAM 
D14S1044 14 89,140,145 89,140,529 219-261 FAM 
D14S280 14 91,252,619 - 238-258 FAM 
D14S302 14 92,432,197 92,432,521 178-196 FAM 
D14S1434 14 94,377,875 - 212-232 HEX 
D16S685 16 30,575,220 30,575,577 123 FAM 
*Chr16-15xAAT 16 34,095,144 34,095,188 419 FAM 
D16S746 16 34,715,504 34,715,996 285 FAM 
D16S3105 16 45,349,600 45,349,998 185-195 FAM 
*Chr16-29xTG 16 45,836,004 45,836,062 373 FAM 
*Chr16-23xAC 16 46,392,429 46,392,475 357 FAM 
*Chr19r2-16xAAT 19 41,093,388 41,093,437 231 FAM 
*Chr19r2-15xAC41 19 41,435,658 41,435,687 244 FAM 
*Chr19r2-26Xac 19 42,082,888 42,082,940 249 FAM 
D19S220 19 43,123,394 - 267-291 FAM 
*Chr19r2-15xTAT 19 44,221,282 44,221,328 186 FAM 
*Chr19r2-22xGT44 19 44,659,155 44,659,198 250 FAM 
D19S47 19 45,006,014 45,006,185  FAM 
*Chr19r2-17xGA 19 45,150,482 45,150,515 231 FAM 
*Chr19r2-34xTC 19 46,287,550 46,287,617 228 FAM 
*Chr19r2-19xAG 19 47,378,235 47,378,273 210 FAM 
D19S420 19 48,500,639 - 95-117 NED 
D19S900 19 48,859,098 28,859,425 157-177 FAM 
D19S559 19 50,022,063 - 162-198 HEX 
*Chr19r2-20xCAG 19 50,965,303 50,965,364 228 FAM 
*Chr19r2-15xTTA 19 51,999,196 51,99,242 218 FAM 
D19S902 19 53,023,869 - 237-273 FAM 
*Chr19r2-23xCA 19 53,983,566 53,983,611 182 FAM 
*Chr19r2-15xAC 19 54,898,140 54,898,169 233 FAM 
D19S904 19 55,468,605 55,458,843 210-224 FAM 
*Chr19r2-15xGT 19 55,468,671 55,468,701 233 FAM 
D19S246 19 55,647,457 55,647,733 185-229 FAM 
*Chr19-19xAG 19 56,215,067 47,378,273 210 FAM 
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*Chr19-22xGT 19 56,411,092 56,411,535 239 FAM 
*Chr19-20xGT 19 56,655,961 56,656,401 243 FAM 
*Chr19-15xAC 19 56,664,850 56,665,279 234 FAM 
D19S571 19 57,988,784 - 287-319 NED 
D22S445 22 35,895,844 35,896,190 110-130 FAM 
D22S1156 22 36,711,717 36,711,872 130-162 FAM 
D22S272 22 37,415,973 37,415,973 132-150 FAM 
D22S428 22 38,284,898 38,285,044 147-155 FAM 
D22S1197 22 38,749,278 38,749,445 168 FAM 
D22S276 22 40,336,789 40,337,164 241-263 FAM 
D22S1151 22 41,865,323 41,865,641 129-137 FAM 
Table 6.36: Microsatellite markers.
  
 
 
 
 
 
 
 
Chapter 7 
Publications 
 
 
 
Bourkiza, R., Joyce, S., Patel, H. et al. (2009) Cerebrotendinous xanthomatosis 
(CTX): an association of pulverulent cataracts and pseudo-dominant 
developmental delay in a family with a splice site mutation in CYP27A1- a 
case report. Ophthal Genet. 31 (2): 73-76  
Joyce, S., Tee, L., Abid, A. et al. (2010) Locus heterogeneity and Knobloch             
syndrome. Am J Med Genet. A. 152A (11): 2880-2881  
  
 
